Development and application of fast fuzzy pharmacophore-based virtual screening methods for scaffold hopping by Renner, Steffen
 
 
Development and application of fast fuzzy 
pharmacophore-based virtual screening methods 
for scaffold hopping 
 
 
 
Dissertation 
zur Erlangung des Doktorgrades 
der Naturwissenschaften 
 
 
 
vorgelegt beim Fachbereich  
Biochemie, Chemie und Pharmazie  
der Johann Wolfgang Goethe–Universität 
in Frankfurt am Main 
 
 
von 
Steffen Renner 
aus Freiburg im Breisgau 
 
 
Frankfurt 2006 
(DF1) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vom Fachbereich Biochemie, Chemie und Pharmazie der 
Johann Wolfgang Goethe–Universität als Dissertation angenommen. 
 
 
 
 
 
 
 
 
 
 
 
Dekan:       Prof. Dr. Harald Schwalbe 
erster Gutachter:     Prof. Dr. Gisbert Schneider 
zweiter Gutachter:   Prof. Dr. Ernst Egert 
Datum der Disputation:   4. Mai 2006   Danksagung 
 
Ich möchte mich an dieser Stelle herzlich bei Prof. Dr. Gisbert Schneider bedanken, für eine 
sehr  schöne,  interessante  und  lehrreiche  Zeit,  die  ich  in  seiner  Arbeitsgruppe  verbringen 
durfte.  
 
Weiterer  Dank  gilt  der  Merz  Pharmaceuticals  GmbH  für  die  Vergabe  eines  Stipendiums, 
besonders meiner dortigen Betreuerin Dr. Tanja Weil für eine sehr angenehme und fruchtbare 
Zusammenarbeit.  
 
Der  Arbeitsgruppe  danke  ich  für  die  schöne  Zeit  in  Frankfurt,  viel  Hilfe  und  manchen 
Programmcode. Vielen Dank vor allem an Uli Fechner, Michael Schmucker, Lutz Franke, 
Evgeny Byvatov, Tobias Noeske, Alexander Böcker, Andreas Schüller, Michael Meissner, 
Tina  Grabowski,  Manuel  Nietert,  Swetlana  Derksen,  Petra  Schneider,  Norbert  Dichter, 
Alireza Givehchi und Brigitte Scheidemantel-Geiß. Vielen Dank auch an Obdulia Rabal und 
Yusuf Tanrikulu für die Fortführung meiner Arbeit an SQUID. An dieser Stelle geht auch 
Dank  an  das  Beilstein-Institut  zur  Förderung  der  Chemischen  Wissenschaften,  das  die 
„Beilstein Stiftungsprofessur“ erst ermöglicht hat.  
 
Bei Tobias Noeske, Dr. Mirko Hechenberger und Dr. Chris Parsons möchte ich mich für die 
experimentellen  Messungen  im  mGluR  Projekt  bedanken.  Dank  gilt  in  diesem 
Zusammenhang  auch  Dr.  Gabriele  Costantio  für  die  angenehme  Zusammenarbeit  bei  der 
Homologie-Modellierung  der  mGluRs,  auch  wenn  es  dieses  Projekt  leider  nicht  mehr 
rechtzeitig in die Doktorarbeit geschafft hat.  
 
Für die gemeinsame Arbeit an den Inhibitoren der TAR-RNA möchte ich Prof. Dr. Michael 
Göbel, Verena Ludwig, Oliver Boden und Dr. Ute Scheffer danken.  
 
Prof. Dr. Rolf Marschalek und Jens Rabenstein möchte ich für die Zusammenarbeit an den 
Taspase1 Liganden danken. 
 
Prof.  Dr.  Johnny  Gasteiger  und  Dr.  Christof  Schwab  danke  ich  für  die  interessante 
Zusammenarbeit in der Untersuchung der Konformations-Abhängigkeit meiner Deskriptoren. 
  
Besonders möchte ich mich noch bei meiner Frau Katharina, bei meinen Eltern und meinen 
Schwiegereltern  bedanken,  die  mit  ihrer  großen  Unterstützung  einen  großen  Anteil  am 
Gelingen dieser Arbeit hatten. Der größte Dank geht aber an meine Tochter Lena Maria, die 
noch  gar  nicht  weiß,  was  eine  Doktorarbeit  ist  und  so  viel  zur  effizienten  Fertigstellung 
derselben beigetragen hat, wenn mal Zeit dafür war.  
  
Publications resulting from this thesis: 
 
Contributions to scientific journals and books: 
 
(1) Fechner, U., Franke, L., Renner, S., Schneider, P., and Schneider, G. (2003) Comparison 
of correlation vector methods for ligand-based similarity searching. J. Comput. Aided Mol. 
Des. 17, 687-698. 
(2) Paetz, J., Fechner, U., Franke, L., Renner, S., Schneider, P., and Schneider, G. (2004) 
Pharmacophore feature selection with a neuro-fuzzy system. In: Proceedings of the 4th 
Europ. Symp. on Intelligent Technologies, Hybrid Systems and their Implementation on 
Smart  Adaptive  Systems  (EUNITE  2004),  (Ed.  Elite-Foundation),  Aachen,  Mainz 
Wissenschaftsverlag, pp. 179-184. 
(3) Renner,  S.,  and  Schneider,  G.  (2004)  Fuzzy  pharmacophore  models  from  molecular 
alignments for correlation-vector based virtual screening. J. Med. Chem. 47, 4653-4664. 
(4) Renner, S., Noeske, T., Parsons, C. P., Schneider, P., Weil, T., and Schneider, G. (2005) 
New  allosteric  modulators  of  metabotropic  glutamate  receptor  5  (mGluR5)  found  by 
ligand-based virtual screening. ChemBioChem, 6, 620-625. 
(5) Renner, S., Ludwig, V., Boden, O., Scheffer, U., Göbel, M., and Schneider, G. (2005) 
New inhibitors of the Tat-TAR RNA interaction found with a “fuzzy” pharmacophore 
model, ChemBioChem, 6, 1119-1125. 
(6) Schneider, G., Renner, S., and Fechner, U. (2005) Navigation in chemical space based on 
correlation-vector representations of molecules. Proceedings of the Beilstein-Workshop 
2004 (Kettner, K., Hicks, M.; Eds.), Logos Verlag, Berlin. 
(7) Renner, S., Fechner, U., and Schneider, G. (2006) Alignment-free pharmacophore patterns 
–  A  correlation-vector  approach.  In:  Pharmacophores  and  Pharmacophore  Searches 
(Langer, T. and Hoffmann, E.; Eds), Wiley-VCH, Weinheim, 49-79. 
(8) Renner,  S.,  and  Schneider,  G.  (2006)  Scaffold-hopping  potential  of  ligand-based 
similarity concepts, ChemMedChem, 1, 181-185. 
(9) Schüller, A.P., Fechner, U., Renner, S., Franke, L., Weber, L., and Schneider, G. (2006) A 
pseudo-ligand approach to virtual screening, Comb. Chem. High-Throughput Screen , 9, 
359-364. 
(10)  Renner,  S.,  Schwab,  C.,  Gasteiger,  J.,  and  Schneider,  G.  (2006)  Impact  of 
conformational  flexibility  on  three-dimensional  similarity  searching  using  correlation 
vectors, J. Chem. Inf. Model., 46, 2324-2332.  
 
Talks: 
 
(1) Renner,  S.  (2003)  Enhancing  MOE‘s  Pharmacophore  Capabilities,  MOE  Usergroup 
Meeting, Frankfurt am Main. 
(2) Renner,  S.  (2003)  Fuzzy  Pharmacophore  Models  for  Rapid  Virtual  Screening,  Bayer 
Workshop „Computational Chemistry“, Wuppertal.  
(3) Renner, S., (2005) Successful Virtual Screening for Tat-TAR Interaction Inhibitors with a 
Fuzzy  Pharmacophore  Model,  7
th  International  Conference  on  Chemical  Structures, 
Noordwijkerhout, Niederlande. 
 
 
Posters: 
 
(1) Renner, S., Fechner, U., and Schneider, G. (2004) Correlation Vector  Approaches for 
Ligand-Based Similarity Searching. 3
rd Joint Sheffield Conference on Cheminformatics, 
Sheffield. 
(2) Parsons, C.G., Noeske, T., Bauer, T., Renner, S., Schneider, G., and Weil, T. (2004) Non-
competitive  antagonists  of  mGluR5  –  Assay  development  and  molecular  modeling 
investigations, Neuroscience, San Diego. 
(3) Renner,  S.,  and  Schneider,  G.  (2005)  Correlation  vector-based  virtual  screening 
approaches for scaffold hopping, MGMS Annual International Meeting, Dublin. 
(4) Renner,  S.,  Noeske,  T.,  Böcker,  A.,  Weil,  T.,  and  Schneider,  G.  (2005)  Combining 
supervised and unsupervised neural networks for the identification of novel scaffolds of 
metabotropic  glutamate  receptor  5  (mGluR5)  modulators,  1
st  German  Conference  on 
Chemoinformatics, Goslar. 
(5) Hechenberger, M., Renner, S., Baude, A., Schneider, G., Parsons, C. G., and Weil, T. 
(2005) Characterization of the MPEP-binding site by computer modeling and functional 
expression of mGluR5 mutants, Neuroscience, Washington. 
 
 
 
  
Abbreviations 
 
2D    Two-dimensional 
3D    Three-dimensional 
ACE    Angiotensin converting enzyme 
ACHE   Acetylcholinesterase 
ADMET   Absorption, distribution, metabolism, excretion, toxicity 
ANN    Artificial neural network 
ATS    Autocorrelation of a topological structure 
BACE   Beta-amyloid converting enzyme 
BLAST  Basic local alignment search tool 
CAII    Carbonic anhydrase II 
CATS   Chemically advanced template search 
CATS3D  Chemically advanced template search 3D 
cc    Matthews correlation coefficient 
COBRA  Collection of bioactive reference analogues 
COX2   Cyclooxygenase 2 
CRD    Cystein-rich domain 
CRF    Corticotropin releasing factor 
CV    Correlation-vector 
D1    Manhattan distance  
D2    Euclidean distance 
DNA    Desoxyribonucleic acid 
DPP    Dipeptidyl-peptidase  
ef    Enrichment factor 
ELA    Elastase 
ES    Evolutionary strategy 
FEPOPS   Feature point pharmacophores 
FMN    Flavin mononucleotide 
FRET    Fluorescence resonance energy transfer 
FXA    Factor Xa 
GPCR    G-protein coupled receptor 
GRIND  Grid independent descriptors 
HE    Heptahelical domain 
HIV    Human imunodeficiency virus 
HIVP    Human imunodeficiency virus protease 
HTS    High-throughput screening 
IC50    Concentration of a drug that is required for 50 % inhibition 
IUPAC  International Union of Pure and Applied Chemistry 
Ki    Binding constant 
LFD    Local feature density 
M5vsCO  mGluR5 vs. COBRA 
M5vsCOpca  Principle components of M5vsCO 
M5vsM1  mGluR5 vs. mGluR1 
M5vsM1pca  Principle components of M5vsM1 
MACCS  Molecular access system 
Meqi    Molecular equivalence indices 
mGluR  Metabotropic glutamate receptor  
MLL    Mixed lineage leukemia 
MMP    Matrix metalloprotease  
MOE    Molecular operating environment 
MSE    Mean square error 
NEU    Nauraminidase 
NIPALS  Nonlinear iterative partial least squares 
NK    Neurokinine receptors 
NMR    Nuclear magnetic resonance 
NUC    Nuclear receptors 
PCA    Principle component analysis 
PDB    Protein data bank 
PLS    Projection to latent structures or partial least squares 
PPAR    Peroxisome proliferators-activated receptor 
PPP    Potential pharmacophore point 
PSA    Polar surface area 
PTK-CSRC  Protein tyrosine kinase c-src 
PTP1B   Protein tyrosine phosphatase 1b 
QSAR   Quantitative structure activity relationship 
QSPR    Quantitative structure property relationship 
ReSc    Reduced scaffold 
RNA    Ribonucleic acid 
RMSD   Root mean square deviation 
SAR    Structure activity relationship 
Sc    Scaffold 
SE    Shannon entropy 
SOM    Self-organizing map 
sSE    Scaled shannon entropy 
SURFCATS  Surface CATS 
SQUID   Sophisticated quantification of interaction distributions 
STRO1  Stromelysin 1 
SVL    Scientific vector language 
TAR    Transactivation response element 
THR    Thrombin 
TPP    Thiamine pyrophosphate 
UTPA   Urokinase type plasminogen activator 
VFTM   Venus flytrap module 
w    Conservation weight 
 
 Contents 
 
1  INTRODUCTION  1 
1.1  Scope of the thesis  1 
1.2  The drug discovery process  3 
1.3  Chemoinformatics in the drug discovery process  3 
1.4  Virtual screening  4 
1.5  Molecular similarity  6 
1.6  Scaffold hopping  7 
1.7  The pharmacophore concept  8 
1.8  Representation of molecules  9 
1.9  Autocorrelation descriptors  11 
1.10  Retrospective and prospective screening  12 
1.11  Artificial neural networks in virtual screening – machine learning based on molecular 
representations  13 
1.12  Incorporating receptor structure information into virtual screening  14 
1.13  The metabotropic glutamate receptor 5 (mGluR5)  15 
1.14  RNA drug design and the Tat-TAR RNA interaction  18 
1.15  Taspase1  20 
2  COMPUTATIONAL METHODS  22 
2.1  Correlation-vector based descriptors  22 
2.1.1  CATS  22 
2.1.2  CATS3D  24 
2.1.3  SURFCATS  25 
2.2  Descriptor vector based virtual screening  26 
2.2.1  Retrospective screening evaluation  27 
2.3  SQUID  28 
2.3.1  Calculation of the SQUID pharmacophore model  29 
2.3.2  Virtual Screening  32 
2.4  Methods of Section 4.1: Influence of similarity metrics and descriptor vector scaling on CATS3D 
retrospective screening  33 
2.5  Methods of Section 4.2: Impact of conformational flexibility on CATS3D virtual screening  34 
2.6  Methods of Section 4.3: Virtual screening and scaffold hopping efficiency of alignment-free 
pharmacophore pair descriptors  37  
2.7  Methods of Section 4.4: Prospective screening for mGlurR5 allosteric modulators with CATS3D
  38 
2.8  Methods of Section 4.5: Prospective screening for mGluR5 allosteric modulators with an artificial 
neural network approach based on CATS3D representations  39 
2.9  Methods of Section 4.6: Retrospective evaluation of SQUID fuzzy pharmacophore models  46 
2.10  Methods of Section 4.7: Prospective screening for inhibitors of the Tat-TAR RNA interaction 
with a SQUID fuzzy pharmacophore model and CATS3D  47 
2.11  Methods of Section 4.8: Prospective screening for taspase1 inhibitors with a receptor-derived 
pharmacophore model  49 
3  EXPERIMENTAL SECTION  52 
3.1  Determination of IC50 values for mGluR  52 
3.2  Determination of IC50 values for TAR-RNA  55 
4  MAIN SECTION  57 
4.1  Influence of similarity metrics and descriptor vector scaling on CATS3D retrospective screening
  58 
4.1.1  Conclusion  60 
4.2  Impact of conformational flexibility on CATS3D virtual screening  62 
4.2.1  Calculation of conformations for the PDBbind dataset and the COBRA database  64 
4.2.2  Reproducing the crystal-structure conformations of reference ligands  66 
4.2.3  Retrospective screening  68 
4.2.4  Conclusion  71 
4.3  Virtual screening and scaffold hopping efficiency of alignment-free pharmacophore pair 
descriptors  73 
4.3.1  Conclusion  82 
4.4  Prospective screening for mGlurR5 allosteric modulators with CATS3D  83 
4.4.1  Conclusion  90 
4.5  Prospective screening for mGluR5 allosteric modulators with an artificial neural network 
approach based on CATS3D representations  91 
4.5.1  Training of feedforward ANNs  93 
4.5.2  Prediction of allosteric mGluR5 modulators  99 
4.5.3  Selection of a representative subset by SOMs  100 
4.5.4  Binding assay results  104 
4.5.5  Conclusions  107 
4.6  Retrospective evaluation of SQUID fuzzy pharmacophore models  108 
4.6.1  Pharmacophore model of COX-2 ligands  110 
4.6.2  Retrospective screening for COX-2 inhibitors  112 
4.6.3  Pharmacophore model of thrombin ligands  117 
4.6.4  Retrospective screening for thrombin inhibitors  119 
4.6.5  Method performance  121 
4.6.6  Conclusion  124 
4.7  Prospective screening for inhibitors of the Tat-TAR RNA interaction with a SQUID fuzzy 
pharmacophore model and CATS3D  126 
4.7.1  Calculation of an alignment of reference compounds  128 
4.7.2  Calculation of pharmacophores and virtual screening  130 
4.7.3  FRET determination of the inhibition constants  131  
4.7.4  Conclusions  133 
4.8  Prospective screening for Taspase1 inhibitors with a receptor-derived pharmacophore model  135 
4.8.1  Conclusions  144 
5  SUMMARY  146 
5.1  Summary  146 
5.2  Zusammenfassung  151 
6  APPENDIX  157 
6.1  Enrichment factors of activity classes from Section 4.3  157 
6.2  Protein report from MOE for the taspase1 homology model from Section 4.8  161 
7  REFERENCES  163 
 
 
 1 Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1 Scope of the thesis 
Rationalization of the drug discovery process is crucial to be prepared for future challenges in 
human health care [Tollman et al., 2001]. Technological developments like combinatorial 
synthesis and high-throughput screening (HTS)  had a large impact on the drug discovery 
process: hundreds of thousands up to millions of molecules can be tested today for a single 
target [Bajorath, 2002]. Despite this large increase in assay capacities such techniques have 
not led to an increased number of approved new chemical entities per year [Xu & Agrafiotis, 
2002]. One reason for this failure might be grounded in the focus on large numbers of tested 
molecules  instead  of  high  quality  experiments,  i.e.  testing  the  right  molecules.  Computer 
based  methods  might  provide  a  means  to  rationalize  these  experiments  incorporating  the 
challenges provided by the high-throughput experiments [Agrafiotis et al., 2002; Bleicher et 
al., 2003; Bajorath, 2002]. 
Computational methods for the compilation of molecule-libraries for pharmacological 
screening  are  called  virtual  screening  methods  [Böhme  &  Schneider,  2000].  Using  such 
methods one can restrict pharmacological screening to molecules with a high probability of 
being active instead of testing all molecules accessible. Within the scope of this thesis virtual Chapter 1  2 
screening methods were developed, evaluated and applied with the aim to contribute to the 
rationalization of the drug discovery process.  
Virtual screening can either be applied by knowledge of the receptor structure or of 
active ligands [Böhm & Schneider, 2000]. The focus of this work was on ligand-based virtual 
screening  methods  for  “scaffold  hopping”  [Schneider  et  al.,  1999]:  the  ability  to  retrieve 
molecules that have a different topology compared to known active molecules. In other words 
we were interested in methods that were able to retrieve the non-obvious hits from the vast 
chemical space.  
The  CATS  method  is  such  an  approach  based  on  an  alignment-free  topological 
pharmacophore pair description of molecules [Schneider et al., 1999]. Molecules with similar 
CATS descriptors are likely to evoke similar biological responses. Since the binding of a 
ligand to a receptor is a three-dimensional interaction, a three-dimensional extension of such 
descriptors is an attractive approach and might improve the ability of the descriptor to find 
isofunctional molecules. 
The  first  goal  of  this  thesis  was  to  develop  and  evaluate  novel  alignment-free 
pharmacophore pair based descriptors for virtual screening, based on the three-dimensional 
conformation  of  a  molecule.  Therefore  the  CATS  approach  was  extended  to  a  three-
dimensional  pharmacophore  pair  descriptor  (CATS3D)  and  a  molecular  surface-based 
descriptor  (SURFCATS).  These  methods  were  evaluated  and  optimized  by  the  following 
retrospective screening experiments: 
·  Comparison of different similarity metrics and scaling methods 
·  Dependence on the correct “receptor bound” conformation 
·  Comparison of the enrichment performance and “scaffold hopping” capability with 
CATS and MACCS substructure keys  
·  Combination of CATS3D with artificial neural networks 
The second goal of the thesis was to develop and evaluate a three-dimensional “fuzzy” 
pharmacophore  model  method  for  virtual  screening.  The  fuzzy  description  of  molecules 
should result in a more general pharmacophore representation which might be favorable to 
retrieve isofunctional molecules with new scaffolds. The resulting approach was compared to 
existing virtual screening methods. 
The last goal was to apply the developed virtual screening methods prospectively to 
retrieve  novel  inhibitors  for  the  TAR  RNA,  the  metabotropic  glutamate  receptor  5  and 
taspase1. In quest of this goal the methods developed in this thesis were employed for a 
prospective evaluation. Taspase1 could not serve as test case for the ligand-based methods Introduction  3 
since no inhibitors were known. For this project a homology model derived pharmacophore 
hypothesis  was  used  for  virtual  screening,  complementing  the  methods  developed  in  this 
thesis. 
 
 
1.2 The drug discovery process 
The drug discovery and -development process can be illustrated by a value chain (Figure 1.1) 
[Bleicher et al., 2003]. The initial step in this process is to identify a target (mostly a protein) 
that is associated with a disease state under consideration and which can be modulated to alter 
this state. Having identified a target, first hits have to be found, i.e. molecules which possess a 
minimum biological activity. This can be achieved by high-throughput screening (HTS) of 
large  libraries  of  molecules  or  by  modification  of  endogenous  or  competitor’s  ligands 
available from literature or patents. The next step is the lead generation where the initial hits 
are refined into leads or lead series, variants of prototypical molecules with a unique core 
structure, showing high in-vitro activity, selectivity and initial structure activity relationships 
(SAR). Lead optimization includes further optimization of activity, selectivity and of ADME 
(absorption,  distribution,  metabolism  and  excretion)  and  toxicity  properties  to  obtain 
molecules appropriate for the clinical trials. 
 
 
 
Figure 1.1 Drug discovery value chain.  
 
 
1.3 Chemoinformatics in the drug discovery process 
The name “chemoinformatics” was introduced in 1998 for computational methods used for 
improved decision making in the drug discovery process [Brown, 1998]. According to the 
book  “Chemoinformatics”  by  Gillet  and  Leach  [Leach  &  Gillet,  2003]  chemoinformatics 
methods include the handling of chemical libraries, calculating the similarity and diversity of 
compounds, clustering, predictions of properties and structure activity relationships. From the 
viewpoint  of  drug  design,  computational  techniques  like  docking  [Kitchen  et  al.,  2004], 
homology-modeling [Hillisch et al., 2004], molecular mechanics [Karplus & McCammon, 
2002], quantum chemistry calculations [Clark, 2003] or sequence alignment [Durbin et al., Chapter 1  4 
1998]  are  of  relevance,  too.  These  latter  techniques  are  mostly  assigned  to  the  fields  of 
computational chemistry or bioinformatics.  
Applications  of  computational  approaches  were  reported  for  each  step  in  the  drug 
discovery  process.  Designing  libraries  for  HTS  can  be  rationalized  by  chemoinformatics 
methods  [Schneider,  2002;  Bajorath,  2002]  incorporating  “chemogenomics”  strategies 
[Schuffenhauer et al., 2003] or ADME and “drug-likeness” considerations [Lipinski et al., 
1997;  Ajay et  al.,  1998].  In  lead  optimization  incorporation  of  computational  models  for 
quantitative  structure  activity  relationships  (QSAR)  or  the  incorporation  of  the  receptor 
structure facilitates the rational improvement of ligands [Kubinyi, 1993; Hansch et al., 1995; 
Kitchen et al., 2004]. 
 
 
1.4 Virtual screening 
The  number  of  chemically  feasible  molecules  which  could  be  in  principle  used  as  drug 
candidates has been estimated to be 10
100 [Walters et al., 1998], which is larger than the 
number of atoms in the universe. This number has two main consequences: first, it should be 
possible to find a ligand with appropriate characteristics for each biological macromolecule. 
Second, it is absolutely impossible to test all these ligands experimentally.  
Virtual screening provides a means to enlarge the number of molecules which can be 
tested for some desired property by several orders of magnitude [Xu & Agrafiotis, 2002]. 
Even though computational prediction of properties will probably never replace biochemical 
measurements, it is much faster. In this way large amounts of molecules can be excluded prior 
to pharmacological experiments to avoid a waste of resources for molecules which have a 
high probability of not being active.  
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Figure 1.2 Hierarchical virtual screening. Virtual screening campaigns are often organized 
hierarchically. First simple and computationally fast filters are applied to remove undesired 
molecules. Subsequent methods are increasingly accurate, more problem specific and often 
computationally slower.  
 
 
In virtual screening campaigns a hierarchical sequence of increasingly complex and 
specific methods is often applied [Bleicher et al., 2003; Böhm & Schneider, 2000] (Figure 
1.2).  Starting  from  a  database  of  molecules  (real  or  virtual  molecules)  the  first  step  of a 
hierarchical virtual screening is to eliminate all molecules which have undesired properties. 
These properties could be reactive or toxic groups or a violation of the Lipinski “rule of five” 
[Lipinski et al., 1997] which was suggested as a rule of thumb assessing the potential oral 
bioavailability of a molecule. Another possible approach is to predict the “drug-likeness” or 
the  “lead-likeness”  of  molecules  to  consider  only  molecules  which  possess  some  general 
properties derived from the analysis of known drugs or lead molecules [Ayay et al., 1998; 
Sadowski & Kubinyi, 1998; Byvatov et al., 2003; Teague et al., 1999]. Subsequently with 
smaller libraries increasingly more target specific and computational demanding approaches 
can be applied. These methods range from similarity searching [Willett et al., 1998] based on 
topological  or  three-dimensional  descriptions  of  molecules  to  three-dimensional Chapter 1  6 
pharmacophore  searching  [Güner,  2000]  and  docking  methods  which  also  incorporate 
receptor information [Kitchen et al., 2004].  
 
 
1.5 Molecular similarity 
Many  virtual  screening  methods  search  for  molecules  which  are  similar  to  a  reference 
molecule of known activity. This approach is called “similarity searching” [Willett et al., 
1998].  Given  a  suitable  definition  of  similarity  it  has  been  demonstrated  that  similar 
molecules have a higher chance of exhibiting a similar biological  activity than dissimilar 
molecules [Brown & Martin, 1996; Martin et al., 2002]. A quality criterion for a similarity 
searching  method  is  the  “neighborhood  behavior”  [Patterson  et  al.,  1996].  A  similarity 
measure satisfies the neighborhood behavior criterion if modifications of a molecule, which 
lead to small changes in the molecular descriptor result in small changes in the activity and 
modifications which lead to large changes in the descriptor result in larger changes in the 
activity.  
No  single  method  is  best-suited  for  all  targets  and  all  small  molecules.  Molecular 
similarity is dependent on the context of the ligands chemotypes and the receptor [Schneider 
& So, 2003; Bender & Glen, 2004]. Different representations of molecules focus on different 
aspects  of  molecules  and  for  different  ligand-receptor  complexes  there  are  different 
interactions  which  are  important  for  ligand-binding.  Employing  a  variety  of  different 
descriptors increases the probability to have an appropriate molecular encoding suitable for a 
problem under consideration [Sheridan & Kearsley, 2002].  
One difficulty for molecular similarity considerations is that the “fitness-landscape” of 
molecules in drug discovery projects is often found to be multimodal, i.e. there are multiple 
local  optima  found  [Schneider  &  So,  2003].  The  “fitness-landscape”  is  the  relation  of  a 
molecular descriptor (the landscape) with a desired property (the fitness), which can be e.g. 
the binding affinity, selectivity or metabolic stability. An ideal “fitness-landscape” would be 
smooth with respect to the neighborhood of molecules. In such a “fitness-landscape” similar 
molecules would exhibit similar properties. “Fitness-landscapes” representing the QSAR of 
molecules  in  drug  discovery  projects  are  believed  to  be  jagged  [Maggiora  et  al.,  2004]. 
Maggiora compared ideal fitness-landscapes with the hills of Kansas and realistic fitness-
landscapes with the Bryce Canyon (Figure 1.3) [Maggiora et al., 2004]. 
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Figure 1.3 Fitness-landscapes in drug discovery projects. Ideal fitness-landscapes are smooth 
and  show  few  local  optima.  This  would  support  the  rational  optimization  of  molecules. 
Realistic fitness-landscapes are assumed to be jagged and filled with local optima, which can 
render the rational optimization of ligands impossible.  
 
 
1.6 Scaffold hopping  
A naïve approach for similarity searching is to compare the molecular connection tables to 
assess the similarity between two molecules. Such approaches were reported for searching the 
maximum common substructure between two molecules [Raymond & Willett, 2002]. If a 
structural element is known to be associated with activity, other molecules containing this 
substructure can be retrieved and tested for activity [Barnard, 1993]. A drawback of such 
methods is the lack of the ability to retrieve molecules with largely different topologies. This 
ability is called “Scaffold hopping” [Schneider et al., 1999]. Two molecules are considered to 
have different scaffolds if they have different topologies [Böhm et al., 2004]. This idea is 
based on the concept that drug-like molecules are built up from a scaffold (framework) and 
side-chains (Figure 1.4) [Bemis & Murcko, 1996]. 
 
 
 
Figure  1.4.  The  atoms  of  a  molecule  can  be  separated  into  scaffold  and  sidechains.  The 
scaffold determines the pharmacological properties, which can be obtained by variation of the 
sidechains.  Chapter 1  8 
 
Scaffold  hopping  is  one  of  the  most  challenging  goals  in  virtual  screening.  Ideal 
virtual  screening  methods  would  not  only  find  a  maximum  number  but  also  a  maximum 
diverse set of active compounds from a given chemical subspace. There are several reasons 
for seeking a set of diverse structures. Diverse structures offer the medicinal chemist a choice 
in  terms  of  chemical  accessibility  and  prospects  for  lead  optimization.  Multiple  leads 
(“backup”  leads)  lower  the  chance  of  drug  development  attrition  in  case  of  undesirable 
ADMET properties [Jenkins et al., 2004]. Furthermore, the creation of intellectual property is 
facilitated.  
Different virtual screening concepts have been proposed for scaffold-hopping [Böhm 
et al., 2004]. These include three-dimensional pharmacophore models [Good & Mason, 1996; 
DeEsch et al., 2001], pseudoreceptors [Lloyd et al., 2004], protein structure-based de novo 
design [Schneider & Fechner, 2005; Stahl et al., 2002], and ligand-based similarity searching 
[Willett et al., 1998]. In contrast to the former methods similarity searching is based on the 
comparison of descriptor vectors rather than on the alignment of molecules to a reference and 
can thus be applied efficiently for large datasets [Willett et al., 1998].  
From the viewpoint of a “fitness-landscape” the scaffold defines the region of the 
landscape that is accessible using different sidechains. Different scaffolds might have some 
overlapping regions in the “fitness-landscape”, but also some regions which might not be 
accessible by other scaffolds. This behavior is especially attractive if multiobjective “fitness-
landscapes” are considered [Gillett et al., 2002]. Drugs have to satisfy many objectives like 
tight  binding,  selectivity  or  acceptable  ADMET  properties.  Different  scaffolds  provide  a 
higher  chance  of  finding  molecules  that  can  access  acceptable  regions  in  the  “fitness-
landscape” for all these objectives. 
 
 
1.7 The pharmacophore concept 
It  has  long  been  recognized  that  some  fragments  of  chemical  molecules  can  be mutually 
exchanged  without  much  affecting  the  biological  activity.  Such  fragments  are  called 
bioisosteric groups [Patani & LaVoie, 1996]. Bioisosteric groups mediate identical or similar 
interactions with the receptor.  
Ligand  receptor  interactions  can  be  clustered  into  three  general  groups: 
“hydrophobic”, “polar positive” and “polar negative” [Horvath et al., 2004]. These groups can 
be  further  broken  down  into  “hydrophobic-alkyl”,  “aromatic”,  “hydrogen-bond  donor”, Introduction  9 
“cation”, “hydrogen-bond acceptor” and “anion”. Various definitions and combinations of 
these groups have been reported as pharmacophore atom-types in literature [Güner, 2000; 
Bush & Sheridan, 1993; Pickett, 2003]. An object with an associated pharmacophoric type is 
called a potential pharmacophore point (PPP). PPPs can represent atoms or larger fragments 
of a molecule. 
Based on the spatial arrangement of PPPs of a ligand, a pharmacophore hypothesis can 
be derived. According to the IUPAC definition a pharmacophore is the “ensemble of steric 
and electronic features that is necessary to ensure the optimal supramolecular interactions 
with a specific biological target structure and to trigger (or to block) its biological response” 
[Wermuth et al., 1998]. Accordingly to define a pharmacophore, prior knowledge about the 
importance  of  the  PPPs  of  a  molecule  is  needed.  A  pharmacophore  can  be derived  from 
structure-activity  data  or  from  conserved  features  within  a  set  of  ligands.  Receptor-based 
pharmacophores have also been reported [Pickett, 2003]. 
The most widely used application of pharmacophores is to search for new molecules 
comprising the pharmacophore. These molecules are expected to have a similar biological 
effect.  If  the  relevant  pharmacophore  pattern  is  not  known,  one  can  also  utilize  the 
distribution  of  PPPs  of  molecules  for  similarity  searching:  Molecules  that  have  similar 
distributions of PPPs are likely to have a similar activity (neighborhood principle).  
The  description  of  a  ligand-receptor  interaction  by  pharmacophores  is  a  crude 
simplification which does not consider effects like entropy or solvatation. Also some groups 
like fluorine, which can interact like hydrophobic groups and as hydrogen-bond acceptors 
[Böhm et al., 2004] are hard to model correctly by pharmacophore types. 
 
 
1.8 Representation of molecules 
The  way  the  structure  of  a  molecule  is  encoded  has  a  major  influence  on  the  way  how 
molecules can be compared. Molecules can be represented either by a full connection table or 
by sets of substructures that are present or absent in the molecule. The first representation is 
more detailed, but to establish a similarity calculation, molecules have to be aligned or a 
maximum common sub-graph between to molecules has to be calculated [Labute et al., 2001; 
Willett  et  al.,  1998].  This  can  be  a  time-consuming  procedure,  especially  for  the  three-
dimensional alignment of flexible molecules. The comparison of the presence and absence of 
substructures  can  be  computed  more  efficient.  Such  methods  are  called  “alignment-free”. 
Substructure similarity can be calculated on the basis of predefined substructure dictionaries Chapter 1  10 
(e.g. the MACCS keys [MDL Information Systems]) or on the basis of molecule-specific 
generated  substructures  (e.g.  Daylight  fingerprints  [Daylight  Chemical  Information 
Systems]).  Substructures  can  be  defined  as  exact  chemical  fragments  (e.g.  MACCS),  or 
loosely defined like pairs, triplets or quartets of PPPs [Schneider et al., 1999; Good & Kuntz, 
1995; Mason et al., 1999]. Substructure descriptions like the MACCS keys contain only local 
descriptions neglecting the overall topology of the molecule.  
Both kinds of molecular encodings are found  combined with two-dimensional and 
three-dimensional representation of molecules. Two-dimensional topological representations 
of molecules have the advantage that the time-consuming calculation of three-dimensional 
conformations for the molecules can be avoided. The stereochemistry of molecules can also 
be left aside. On the other hand the binding event is a three-dimensional interaction between 
ligand and receptor. So it should be advantageous to include such information. The naïve 
assumption about the three-dimensional conformation of a molecule in the binding-pocket 
would be that the conformation of the molecule with the lowest internal energy would be the 
most likely to be found in the  receptor. However it has been shown that the  “bioactive” 
conformation, i.e. the conformation of a molecule bound to the receptor, does not necessarily 
correspond either to the global torsion-angle energy minimum or to a torsion-angle energy 
minimum at all  [Nicklaus et al., 1995; Boström et al., 1998; Perola & Charifson, 2004]. In 
practice, this renders the task of finding the “bioactive” conformation of a molecule to the 
computational demanding task of presenting a large number of low-energy conformations. 
While it is clear that methods, which are based on the explicit three-dimensional alignment of 
molecules, strictly rely on the presence of a fitting conformation, alignment-free descriptors 
have produced reasonable results using only a small set of conformations or even a single 
conformation [Sheridan et al., 1996; Brown & Martin, 1996].  
A step further away from the atomic representation of molecules is the description of 
molecules based on their molecular surface. Since the interaction between ligand and receptor 
is mediated by the molecular surfaces, surface-based descriptions are thought to be more 
general than atom based descriptions [Wagener et al., 1995; Zamora et al., 2003, Stiefl & 
Baumann, 2003; Clark, 2004]. Field-based methods are another way to circumvent an atom-
based description of a molecule [Cramer et al., 1988; Klebe et al.; 1994; Pastor et al., 2000]. 
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1.9 Autocorrelation descriptors 
Spatial autocorrelation is a quantitative measure for the probability to find objects of defined 
properties within a distance of interest [Wagener et al., 1995; Todeschini & Consonni, 2000]. 
The idea of a molecular descriptor based on the autocorrelation concept was first introduced 
into the field of cheminformatics by Morau and Broto in 1980 [Moreau & Broto, 1980] with 
the ATS (Autocorrelation of a Topological Structure) descriptor. For this approach the atoms 
of a molecule were represented by properties like atomic mass or partial charge. The distance 
between  atoms  was  measured  as  the  number  of  bonds  between  the  respective  atoms 
(topological distance). 
The ATS descriptor for a given topological distance d is calculated by: 
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where w is the atomic property, A is the number of atoms in the molecule, δij,d (Kronecker 
delta) evaluates to 1 for all pairs of atoms with distance d. 
To obtain the full descriptor the ATS autocorrelation is calculated over all defined 
distances  and  concatenated  to  a  vector  {ATS0,  ATS1,  ATS2,  …  ,  ATSD},  where  D  is  the 
maximum distance considered. Moreau, Broto and Vandycke were also the first who applied 
this approach to the three-dimensional conformation of a molecule [Moreau et al., 1984]. For 
the three-dimensional approach the topological distance was replaced by the spatial Euclidean 
distance between two atoms. Pairs of atoms were clustered into groups with distances falling 
into predefined distance ranges (bins). All atom pairs within one bin were treated as having 
the  same  distance.  Gasteiger  extended  this  approach  to  the  spatial  autocorrelation  of  the 
partial  charges  calculated  for  surface  points  [Wagener  et  al.,  1995].  The  resulting  vector 
values were normalized by dividing the raw counts by the number of atom pairs in each 
distance range.  
In  2000  Pastor  and  coworkers  [Pastor  et  al.,  2000]  presented  GRIND  (Grid-
Independent Descriptors), an approach very similar to the autocorrelation descriptors. The 
GRIND  descriptor  is  calculated  from  force  field-based  interaction  energies  calculated  for 
GRID [Goodford, 1985] points surrounding a molecule. Instead of summing up all products 
of  interaction  energies  for  pairs  of  GRID  points  within  a  distance  range,  only  the  most 
favorable energy contribution is stored for each distance range. Given a descriptor vector, 
pairs of grid points can be identified that are responsible for each descriptor value. Such a Chapter 1  12 
trace back from the descriptor to the underlying pairs of grid points is not amenable to other 
autocorrelation approaches. 
In 1985 Carhart [Carhart et al., 1985] introduced a topological atom pair descriptor 
using atom-types instead of atom property values. Each atom is assigned to one atom-type 
class instead of an atom property value. Atom-types are defined by their element, the number 
of neighboring non-hydrogen atoms and their number of π-electrons. The employment of 
these  atom-types  led  to  a  further  distinction  of  chemical  elements  according  to  the  atom 
environment. Binary values are assigned to each atom, i.e. an atom does or does not have a 
specific atom-type. Consequently and in contrast to the Moreau-Broto approach, the resulting 
autocorrelation vector for an atom-type is equivalent to a histogram counting the frequencies 
of  the  atom  pairs  of  the  considered  atom-type  over  the  different  atom-atom  distances. 
Calculation of the autocorrelation between pairs of atoms of different atom-types is called 
crosscorrelation. The final Carhart descriptor vector consists of the autocorrelation vectors for 
all atom-types and the crosscorrelation vectors of all pairs of different atom-types. 
In  1996  Sheridan  and  coworkers  [Sheridan  et  al.,  1996]  were  the  first  to  use 
pharmacophoric  atom-types  for  an  autocorrelation  approach.  This  technique  provides  a 
description presumably most relevant to characterize ligand-receptor interactions in a general 
way, allowing for more different but equally interacting molecules to be identified as similar. 
In this work Sheridan and coworkers also extended the topological Carhart approach to the 
three-dimensional  conformation  of  molecules.  This  approach  was  soon  followed  up  by  a 
binary  representation  of  such  a  descriptor  [Brown  &  Martin,  1996].  In  2003  Stiefl  and 
Baumann [Stief & Baumann, 2003] reported an autocorrelation approach using surface points 
representing pharmacophoric features. 
The work of Schneider and coworkers [Schneider et al., 1999] first focused on the 
applicability of the autocorrelation descriptors, in this case topological pharmacophores, for 
scaffold hopping. The general description of the atoms with pharmacophore atom-types in 
combination with the decomposition of molecules into atom-pairs was shown to be especially 
successful to find new molecules with significant different molecular scaffold, maintaining 
the desired biological effect. 
 
 
1.10 Retrospective and prospective screening 
The effectiveness of a virtual screening method can be assessed in two ways: retrospective 
and  prospective  screening.  Given  a  reference  molecule  with  known  biological  effect, Introduction  13 
retrospective screening quantifies the ability of a method to retrieve molecules with the same 
biological activity from a database containing molecules with various biological activities 
[Willett et al., 1998; Hert et al., 2004a; Hert et al., 2004b; Xu & Agrafiotis, 2002]. Several or 
all molecules of selected classes of biological activities are mutually taken as reference for the 
screening. For each individual virtual screening experiment, the molecules remaining in the 
database are ranked according to the similarity or distance to the reference molecule.  
A method is considered successful if molecules with the same annotated activity (the 
“active”  molecules)  as  the  reference  are  statistically  better  scored  than  molecules  with 
different annotated activities (“inactive” molecules). A shortcoming of retrospective screening 
is that it is mostly not known if molecules which are considered inactive for one receptor are 
true  inactives  or  molecules  for  which  the  respective  activity  has  not  been  tested 
experimentally. It is likely that the latter situation represents the majority of cases.  
The most rigorous test for a virtual screening method is prospective screening. Only in 
this way it is possible test the ability of a method to find novel active molecules. On the other 
hand, prospective screening requires much more effort in time and costs and consequently in 
most cases only a smaller number of experiments can be performed, resulting in a less reliable 
statistical assessment of the results. In the worst case this could lead to a poor rating of a 
method  which  was  able  to  find  similar  molecules  which  were  inactive  due  to  small 
unfavorable  interactions  to  the  receptor,  like  a  steric  clash  from  a  methyl  group  of  the 
molecule. Consequently it is best to probe a method by both retrospective and prospective 
screening to obtain a realistic assessment of its performance. 
 
 
1.11 Artificial  neural  networks  in  virtual  screening  – 
machine learning based on molecular representations 
Artificial neural networks (ANN) had a large impact on recent drug discovery projects [Zupan 
& Gasteiger, 1999; Schneider, 2000; Terflot & Gasteiger, 2001; Livingstone & Manallack, 
2003].  Applications  of  ANNs  are  found  for  classification,  prediction,  visualization,  and 
clustering. One can distinguish between supervised methods like feedforward networks and 
unsupervised  networks  like  self-organizing  maps  (SOM)  [Kohonen,  1982].  Supervised 
methods  establish  a  relationship  between  a  representation  of  an  object  of  interest  (e.g.  a 
molecular descriptor) and an observed response (e.g. a binding affinity or a class affiliation). 
Unsupervised  methods  cluster  the  data  based  on  their  representation.  One  particular 
implementation (SOM) projects a data distribution from a high-dimensional space (i.e. the Chapter 1  14 
molecular  representation)  to  a  lower  dimensional  space  (e.g.  two-dimensional  for 
visualization) [Kohonen, 1982]. 
In chemoinformatics, supervised ANNs are mainly applied in the  establishment of 
quantitative  structure  activity  relationships  (QSAR),  quantitative  structure  property 
relationships (QSPR) or binary classification tasks [Schneider, 2000]. ANNs provide a means 
to establish in principle any linear or non-linear relationship between descriptor and observed 
data [Zupan  &  Gasteiger, 1999]. As a drawback, an ANN behaves like a black box: the 
modeled  relationship  between  the  input  variables  is  difficult  to  extract  [Livingstone  & 
Manallack, 2003]. Applications of supervised neural networks range from general predictions 
like drug-likeness [Sadowski & Kubinyi, 1998; Ajay et al., 1998] or the identification of 
frequent hitters [Roche et al., 2002a] to more specific tasks like the prediction of binding to 
the hERG K
+ channel [Roche et al., 2002b] or to cytochrome P450 [Molnar & Keseru, 2002].  
Unsupervised SOMs can be used for the projection of data into lower dimensional 
space  for  visualization.  This  can  be  utilized  for  example  to  evaluate  different  descriptor-
representation of molecules for their suitability to distinguish between different classes of 
activities [Teckentrup et al., 2004]. Comparison of diversity and coverage of chemical space 
of chemical databases or combinatorial libraries were also reported for SOMs [Schneider & 
Schneider, 2003; Anzali et al., 1998]. A trained SOM can also be used for the prediction of 
class affiliation for new molecules [Schneider et al., 2003; Teckentrup et al., 2004].  
 
 
1.12 Incorporating  receptor  structure  information  into 
virtual screening  
The binding-event is an interaction between ligand and receptor. Using the receptor for virtual 
screening should enhance the capability for scaffold hopping in comparison to ligand-based 
methods [Xu & Agrafiotis, 2002; Böhm et al., 2004]. The latter methods are intrinsically 
biased  towards  the  chemotypes  of  the  reference  molecules.  Receptor-based  ranking  of 
molecules  is  independent  of  reference  molecules.  Structure-based  approaches  provide  a 
rational  basis  for  the  establishment  of  new  interactions  between  ligand  and  receptor,  not 
realized in known ligands before. Using ligand-based approaches new interactions can only 
be found by trial and error. Structure-based virtual screening can suffer from the difficulty in 
scoring  ligand-receptor  complexes  correctly  [Halperin  et  al.,  2002;  Schneider  &  Böhm, 
2002],  the  flexibility  of  the  receptor  upon  ligand  binding  [Teague,  2003]  and  from 
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Receptor  information  can  also  be  exploited  for  the  derivation  of  pharmacophore 
models [Pickett, 2003]: 
￿  the alignment of ligands can be calculated on the basis of the receptor [Grüneberg, 
2005]. 
￿  promising  potential  pharmacophore  points  derived  from  the  receptor  can  be 
incorporated into or solely used for a pharmacophore model [Wolber & Langer, 
2005, Pirard et al., 2005]. 
￿  receptor information can be used to disregard molecules, that were regarded as 
active by other methods, that overlap with receptor atoms [Pickett, 2003]. 
Following  this  idea,  multiple  receptor  conformations  obtained  from  molecular  dynamics 
simulations were used to establish a receptor-based dynamic pharmacophore model, which 
was successfully applied for the prediction of new HIV-1 integrase inhibitors [Carlson et al., 
2000].  
If no receptor information is available, homology modeling of the receptor structure 
provides  an  approach  for  virtual  screening  [Hillisch  et  al.,  2004;  Bissantz  et  al.,  2003; 
Grüneberg, 2005; Evers et al., 2003; Evers & Klabunde, 2005]. Homology modeling is based 
on the fact that the sequence of proteins is less conserved than the structure [Chothia & Lesk, 
1986, Andreeva et al., 2004]. Consequently the structure of a protein can be predicted based 
on the structure of a closely  related protein. The quality of the  resulting model critically 
depends on the sequence similarity of the modeled protein to the template structure [Hillisch 
et al., 2004].  
 
 
1.13 The metabotropic glutamate receptor 5 (mGluR5) 
Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system 
[Conn & Pin, 1997]. The effect of glutamate is mediated by ionotropic and metabotropic 
glutamate receptors, via pre- and postsynaptic mechanisms. The long term modulating effect 
of glutamate is mediated by the metabotropic glutamate receptors [Conn & Pin, 1997]. The 
family of metabotropic glutamate receptors comprises a set of at least eight subtypes. These 
can be further clustered into three groups on the basis of sequence similarity, pharmacology 
and the respective signal transduction mechanism. Group I (mGluR1 and -5) are coupled to 
the activation of phospholipase C, group II (mGluR2 and -3) and group III (mGluR4, -6, -7, 
and -8) are negatively coupled to cAMP production [Hermans & Challiss, 2001]. Chapter 1  16 
The  mGluRs  belong  to  family  3  of  the  G-protein-coupled  receptors  (GPCRs) 
[Bockaert & Pin, 1999; Fredriksson et al., 2003]. Other members of family 3 are the GABAB, 
Ca
2+-sensing, vomeronasal, pheromone and putative taste receptors [Pin et al., 2003]. GPCRs 
are characterized by  a  general topology  of seven transmembrane helices. Class 3  GPCRs 
differ from the other GPCR classes by the presence of an additional N-terminal extracellular 
ligand  binding  domain,  the  venus-flytrap  module  (VFTM),  connected  to  the  heptahelical 
domain (HD) via a cystein rich region (Figure 1.5). Other classes of GPCRs contain ligand 
binding regions directly within the seven-transmembrane domain. Family 3 GPCRs are found 
as homodimers or heterodimers [Pin et al., 2003]. Receptor dimerization does also include 
dimerization of the venus-flytrap modules [Kunishima et al., 2000]. 
 
 
 
Figure 1.5 Topology of the metabotropic glutamate receptors. The receptor consist of an 
extracellular  venus-flytrap  module  (PDB  code:  1etw)  for  glutamate  binding,  and  a 
heptahelical transmembrane domain (PDB code from the bovine rhodopsin structure: 1f88), 
which  are  connected  by  a  Cystein-rich  domain.  Allosteric  modulators  bind  in  the 
transmembrane domain.  
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The activation mechanism of mGluRs involves several steps. Upon glutamate binding 
the venus-flytrap domain undergoes a large conformational change resulting in a closure of 
the venus-flytrap [Kunishima et al., 2000]. This leads to a modified relative orientation of the 
two  VFTMs  of  a  dimer.  The  activated  dimer  complex  of the  two  VFTMs  is  assumed  to 
stabilize the active conformation of the heptahelical domains [Pin et al., 2004].  
Like  with  many  GPCRs,  a  basal  “constitutive  activity”  can  be  measured  without 
ligand binding [Pin et al., 2004]. Agonists like the natural substrate glutamate stabilize the 
active  state  via  the  VFTM.  The  “constitutive  activity”  is  not  inhibited  by  competitive 
antagonists that prevent the VFTM closure [Prezeau et al., 1996]. Consequently neither the 
active nor the inactive state of the heptahelical domain is predominantly stable. 
Recently  molecules  were  reported  that  bind  to  an  allosteric  binding  site  in  the 
heptahelical domain of mGluR5 [Gasparini et al., 1999; O’Brien et al., 2003], i.e. in the 
region where the ligand binding site is found in the other classes of GPCRs. These molecules 
are called “allosteric modulators”. Allosteric antagonists which stabilize the inactive state of 
the  heptahelical  domain  are  called  “inverse  agonists”.  Such  modulators  were  able  to 
completely inhibit the “constitutive activity” and the effect of agonist binding in the VFTM 
[Gasparini et al., 1999]. Allosteric modulators which are able to stabilize the active state of 
the receptor are “positive allosteric modulators”. These molecules cannot activate the receptor 
by themselves, but have a potentiating effect on agonist binding. This effect is assumed to be 
caused in a stabilizing effect of the opened VFTM on the inactive state of the heptahelical 
domain [Pin et al., 2004]. If the VFTM is pruned from the heptahelical domain of mGluR5, 
positive allosteric modulators behave as conventional agonists while inverse agonists shown 
antagonistic behavior [Goudet et al., 2004]. 
Group I mGluRs provide a great prospect for pharmaceutical applications. Molecules 
antagonizing the function of mGluR5 have a potential in prevention of pain and anxiety, and 
in the treatment of Parkinson’s disease [Spooren & Gasparini, 2001; Swanson et al., 2005]. A 
potential role in the treatment of drug dependence has also been reported [Chiamulera et al., 
2001]. Activators or potentiators of group I mGluRs were proposed to be useful in the therapy 
of schizophrenia and Alzheimer’s disease [Pin et al., 2004]. 
For  GPCRs  only  the  crystal  structure  of  rhodopsin  in  the  inactive  state  has  been 
resolved, so far [Palczewski et al., 2000]. Homology models based on this structure were 
shown to provide a basis for structure-based virtual screening for GPCR ligands [Evers & 
Klebe, 2004; Evers & Klabunde, 2005]. Successful applications of homology-model based Chapter 1  18 
virtual screening for family 3 GPCRs have not been reported until now, despite the fact that 
such  models  have  been  published  [Pagano  et  al.,  2000;  Malherbe  et  al.,  2003].  Many 
allosteric modulators of mGluR1 and mGluR5 were reported in literature. This also renders 
mGluR5 a target for ligand-based virtual screening and library design. 
 
 
1.14 RNA drug design and the Tat-TAR RNA interaction 
In recent years it has become clear that RNA is an active multifunctional player of the cell 
instead of just a passive vehicle for sequence information [Special journal issues on RNA as 
drug target]. RNA was found to have enzymatic functionality, e.g. the self-splicing intron of 
the Tetrahymena pre-rRNA [Kruger et al., 1982] or within the ribosome [Noller et al., 1992]. 
Gene regulatory elements on the mRNA can have an effect on the transcriptional and on 
translational  level.  This  effect  can  be  mediated  by  specific  RNA-protein  interactions  and 
directly  by  RNA-small  molecule  interactions  [Mandal  &  Breaker,  2004].  Such  small 
molecules  can  be  the  metabolites  of  the  genes  under  control,  e.g.  TPP  (thiamine 
pyrophosphate)  [Winkler  et  al.,  2002a]  or  FMN  (flavin  mononucleotide)  [Winkler  et  al., 
2002b].  With  the  RNAi  mechanism,  RNA  was  also  found  to  participate  in  anti-infective 
responses [Dykxhoorn et al., 2003].  
Together with these functionalities it was found that RNA can fold into complex and 
well  defined  three-dimensional  structures.  Like  within  proteins,  these  complex  structures 
provide  interfaces  for  specific  intermolecular  protein-RNA  and  small  molecule-RNA 
interactions. These findings have led to a constantly increasing interest in RNA as a potential 
drug target with a plethora of potential applications [Zaman et al., 2003; Drysdale et al., 2002; 
Gallego & Varani, 2001; Sucheck & Wong, 2000], and several natural and synthetic small 
molecules have been reported to interact specifically with RNA [Hermann, 2003]. 
In principle it is possible to employ the same approaches for RNA drug discovery as 
for molecules targeting proteins [Hermann, 2000]. One difference can be found in the relative 
importance of ligand-protein interactions and ligand-RNA interactions. The latter is biased 
towards electrostatic and stacking interactions in comparison to protein-ligand interactions 
[Hermann, 2000]. This might raise complications with unspecific binding of small molecules 
that comprise a large number of positive charges. In addition, very polar or charged ligands 
bear the danger of low oral bioavailability [Lipinski et al., 1997; Mayer & James, 2004]. 
Other problems might arise from unspecific stacking of molecules which can lead to toxic 
effects from DNA-intercalation [Snyder et al., 2004]. Another difference between protein and Introduction  19 
RNA targets is the comparably high flexibility of RNA, especially of structures with low 
structural complexity like stem-loop RNAs [Schroeder et al., 2004]. For these structures it has 
been found that different ligands result in ligand-receptor complexes with largely different 
conformations of the RNA structure. A recent publication even reported an RNA sequence 
which was able to fold into two completely different tertiary structures with two different 
enzymatic activities [Schultes & Bartel, 2000]. 
Beside these complications a structure-based automated docking approach including a 
scoring function optimized for RNA was shown to be useful for finding small and enriched 
sets of molecules inhibiting the Tat-TAR interaction [Filikov et al., 2000; Lind et al., 2002]. 
Other  studies  indicated  that  the  inherent  flexibility  of  RNA  structures  might  limit  the 
applicability of entirely structure-based approaches [Williamson, 2000; Gallego & Varani, 
2001; Leulliot & Varani, 2001]. 
One of the best characterized RNA-based regulatory systems is the transactivation 
response element (TAR) of the HIV mRNA [Karn, 1999]. Specific binding of the Tat protein 
to TAR is essential for virus transcription. Without bound Tat protein the elongation of the 
HIV transcript is early aborted due to a poorly processive RNA polymerase II. Bound Tat 
recruits  a  Tat-associated  kinase  which  activates  the  RNA  polymerase.  The  activated 
polymerase is able to synthesize the remainder of the HIV transcript [Karn, 1999]. 
 
 
 
Figure 1.6 TAR RNA regulatory element. TAR RNA consists of two stem loop regions and a 
bulge of three nucleotides. The bulge is responsible for the specific interaction to the Tat 
protein, essential for HIV replication.  Chapter 1  20 
 
 
The TAR RNA represents a potential target for defeating HIV as well as a model 
system to deepen the understanding of RNA-small molecule interactions and the development 
of drugs for RNA targets in general. The structure of TAR consists of two rigid double strand 
stems connected by a flexible bulge of three bases, which provides a specific binding pocket 
for the Tat protein [Karn, 1999] (Figure 1.6). A variety of molecules have been found that 
inhibit the Tat-TAR interaction and consequently virus replication [Froeyen & Herdewijn, 
2002; Krebs et al., 2003]. Among these molecules are peptidic derivatives of the binding 
motive from Tat like argininamide, antibiotics like neomycin, and a set of small molecules 
with non-natural scaffolds. Most classes of bulge-binding ligands, for which structures have 
been determined, bind in distinct regions and stabilize different conformations of the bulge 
[Du et al., 2002]. 
The availability of a small set of RNA-ligand complex NMR structures renders the 
TAR  RNA  as  an  interesting  target  for  ligand  and  structure  based  virtual  screening.  The 
reported  problems  in  RNA  docking  make  the  ligand  based  approach  more  attractive  at 
present. 
 
 
1.15 Taspase1 
Taspase1 is a threonine aspartase which catalyzes the proteolytic cleavage of MLL (Mixed-
Linage Leukemia) protein, resulting in its activation [Hsieh et al., 2003]. MLL is required for 
the maintenance of HOX gene expression in embryogenesis and hematopoiesis. Chromosome 
translocations  leading  to  chimera  proteins  of  the  N-terminus  of  MLL  and  varying 
translocation partners result in human infant leukemia. This effect is associated with an up-
regulation of HOX genes. Specific inhibition of taspase1 might present a possibility to treat 
human infant leukemia [Hsieh et al., 2003]. 
Taspase1  cleaves  MLL  directly  after  an  aspartate  at  two  positions  with  sequences 
D/GADD  and  D/GVDD,  respectively.  An  N-terminal  threonine  acts  as  an  active  site 
nucleophile for the cleavage reaction. Other known threonine proteases are found in the 20S 
proteasome  and  the  archaea  proteasome  and  the  catalytic  subunit  of  the  Escherichia  coli 
(E.coli) HsIV [Hsieh et al., 2003]. These proteases are not structurally related to taspase1.  
Taspase1  reveals  sequence  similarity  to  glycosylasparaginase  and  L-asparaginase, 
which  also  have  an  N-terminal  threonine  involved  in  the  reaction  mechanism. Introduction  21 
Glycosylasparaginases catalyze the cleavage of N-acetylglucosamine-asparagine to 1-amino-
N-acetylglucosamine and aspartate. L-asparaginase catalyzes the conversion of L-asparagine 
to  L-aspartate. All three classes of proteins  are translated in  an inactive form. Activation 
occurs by an autoproteolysis step catalyzed by the N-terminal threonine [Hsieh et al., 2003].  
Inhibitors have not been reported for taspase1, but crystal structures are available for 
glycosylasparaginases and L-asparaginases [Oinonen et al., 1995; Prahl et al., 2004]. This 
renders taspase1 a target for homology-model based drug design.  2 Computational Methods 
 
 
2.1 Correlation-vector based descriptors 
Three types of correlation vector descriptors were applied in this thesis, which all belong to 
the group of potential pharmacophore point (PPP) pair descriptors: the topological CATS 
descriptor [Schneider et al., 1999], the three-dimensional CATS3D descriptor and the surface-
based SURFCATS descriptor (Figure 2.1). Auto- and crosscorrelation between all types of 
PPPs are transformed into a histogram, counting for the frequencies of the respective pairs of 
PPPs. The pairs of PPPs are further subdivided into distance “bins” which were topological 
distances in the two-dimensional case and distance ranges in the three-dimensional case. Each 
dimension (“bin”) of the CATS3D CV was calculated according to Equation 2.1. 
 
      ∑∑ =
i j
T
d ij
T
d , CV d ,        (Eq. 2.1) 
 
where i and j are atom indices, d is a distance or a distance range, T is the pair of PPP 
types of atoms i and j, and 
T
d d  (Kronecker delta) evaluates to 1 for all pairs of atoms of type T 
within the distance range d.  
 
 
2.1.1 CATS 
The  CATS  (Chemically  advanced  template  search)  descriptor  is  a  topological  atom-pair 
descriptor developed by Schneider and coworkers [Schneider et al., 1999]. The descriptor 
consists of the frequencies of pairs of PPPs within defined topological distances. Distances 
were calculated as the shortest paths between two PPPs. PPP-PPP distances were considered 
from 0 to 10 bonds.  
The PPP definition was as follows: Hydrogen-bond donors were oxygen atoms of OH-
groups and nitrogen atoms of NH- or NH2-groups. Hydrogen-bond acceptors were oxygen 
atoms and nitrogen atoms not adjacent to a hydrogen atom. Positively charged or ionizable 
atoms were defined  as atoms with a positive charge or nitrogen atoms of an NH2-group. Computational Methods  23 
Negatively charged or ionizable atoms were defined as atoms with a negative charge and 
carbon, sulfur or phosphorous atoms of a COOH-. SOOH-, or POOH-group. Lipophilic atoms 
were chlorine, bromine, or iodine, sulfur atoms adjacent to exactly two carbon atoms, and 
carbon atoms adjacent only to carbon atoms. With this definition atoms were assigned to no, 
one or two PPP-types. Using 10 topological distances “bins” for each of the 15 combinations 
of PPPs resulted in a descriptor of 150 dimensions. 
The CATS descriptor was calculated with the program speedcatsdotcom (version 1.02) 
by Uli Fechner [Fechner et al., 2003]. Scaling was done with the parameter –d 3, which 
corresponds to scaling2 in CATS3D (see Section 2.1.2). 
 
 
 
 
Figure  2.1  The  CATS-family  of  descriptors:  CATS,  CATS3D  and  SURFCATS.  All 
descriptors are based on a potential pharmacophore (PPP) type description of the underlying 
molecule. For each descriptor, pairs of PPPs are transformed into a correlation vector. CATS 
is calculated from the topological distances of atom-based PPP pairs. For CATS3D the spatial 
distances between atom-based PPPs are used instead. SURFACTS uses the spatial distances 
between PPPs on the contact surface of a molecule. Here the PPPs represent the atom-types of 
the nearest atom to each surface point. Yellow = hydrophobic PPP, cyan = hydrogen-bond 
acceptor, magenta = hydrogen-bond donor, blue = cation, white = no pharmacophore type 
assigned.  
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2.1.2 CATS3D 
The CATS3D descriptor is an extension of the CATS descriptor into three-dimensional space. 
CATS3D  was  developed  and  implemented  as  part  of  this  work.  An  overview  over  the 
CATS3D principle is shown in Figure 2.2.  
 
 
 
 
Figure 2.2 Calculation of the CATS3D correlation vector. Atoms are colored according to 
their  pharmacophore  atom-type  (yellow  =  hydrophobe,  cyan  =  hydrogen-bond  acceptor). 
Distances are measured between all pairs of atoms, and frequencies of pairs are determined 
for all pairs of pharmacophoric types and for defined distance ranges (“bins”). As an example, 
a section of the resulting CV representing hydrogen-bond acceptor – hydrophobe pairs is 
shown. 
 
 
The main difference in the correlation vector representation of a 3D conformation in 
comparison to a topological representation of a molecule is that the distances between the 
atoms are no longer shortest paths. Instead, Euclidean distances between all atoms were used. 
Distances between atoms are not restricted to integer values, thus the distances had to be 
partitioned into a set of distance bins. Several such binning schemes have been proposed 
[Wagener  et  al.,  1995;  Sheridan  et  al.,  1996;  Brown  &  Martin,  1996].  For  CATS3D  20 
distance bins that cover distances from 0 to 20 Å in steps of 1 Å were employed, i.e. if a pair 
of PPPs is found with a distance of 6.17 Å it is counted in the bin from 6 to 7 Å. Distances up 
to 20 Å were considered to include information of most pairs of atoms in the descriptor, even 
for large ligands.  
For CATS3D the modified PATTY atom-types [Bush & Sheridan, 1993] available 
with  the  pH4_aType  function  in  MOE  (Molecular  Operating  Environment)  [Chemical 
Computing Group] were used. This function provides six PPP types: cation (+), anion (-), Computational Methods  25 
hydrogen-bond acceptor (A), hydrogen-bond donor (D), polar (P, hydrogen-bond acceptor 
AND hydrogen-bond donor) and hydrophobic (H). Whereas the topological CATS descriptor 
allows assignments of more than a single PPP type to one atom, the CATS3D descriptor 
employs a single PPP type per atom. 
Using 20 distance bins for each of the 21 possible combinations of PPP pairs resulted 
in a descriptor of 420 dimensions. The values of the dimensional were calculated according to 
Eq. 2 with the difference that each pair of PPPs was only counted once and pairs of PPPs with 
themselves were not considered. 
 
Three different scaling methods were implemented for the CATS3D descriptor: 
·  No scaling (“unscaled”).  
·  Division by the number of PPPs of a molecule (“scaling1”).  
·  Division of each of the 21 possible pairs of PPPs by the added occurrences of the two 
respective PPPs (“scaling2”). 
Scaling2  was  always  applied  unless  otherwise  indicated.  Scaling1  is  the  scaling  scheme 
originally developed for the CATS descriptor.  
 
The CATS3D descriptor was implemented in the software spacecats. Spacecats was 
written in the SVL language in MOE [Chemical Computing Group].  
 
Note to the program MOE: all calculations were performed with program versions 2003.02 
and 2004.03. To our knowledge there were no differences between the two versions with an 
impact  on  the  calculations  in  this  thesis.  Results  obtained  with  earlier  versions  are  not 
included in this work due to a major revision in the pharmacophore type definitions. 
 
 
2.1.3 SURFCATS 
The SURFCATS approach is a further extension of the CATS3D concept. The interaction 
between  ligand  and  receptor  is  mediated  by  the  surface  between  the  two  molecules. 
Accordingly it might be advantageous to describe molecules by their surface properties.  
The surface points for the calculation of SURFCATS were taken from the molecular 
surface which was calculated with the Gauss-Connolly function in MOE with a spacing of 2 
Å. The molecular surface is defined by the inward-facing part of a virtual probe sphere rolling 
on the van der Waals surface of the molecule  [Richards, 1977]. Accordingly this surface Chapter 2  26 
definition represents the contact space between ligand and receptor. Each surface point was 
assigned to the PPP type of the nearest atom. Like with CATS3D 20 equal distance bins were 
used from 0 to 20 Å with a stepsize of 1 Å. The SURFCATS CV was calculated exactly like 
the CATS3D CV except that surface points were used as PPPs instead of atoms. Scaling2 was 
always applied. 
The SURFCATS descriptor was implemented in the software surfcats. Surfcats was 
written in the SVL language of MOE [Chemical Computing Group]. 
 
 
2.2 Descriptor vector based virtual screening 
For descriptor vector-based similarity searching, three distance indices were employed: the 
Manhattan distance, the Euclidean distance and the Tanimoto similarity coefficient. The first 
two metrics  express distances, i.e. similar molecules have distances lower than dissimilar 
molecules.  For  similarity  metrics  this  relation  is  inverted.  To  avoid  confusion  the  term 
“similarity”  will  be  used  for  both  similarity  and  distance  metrics.  The  definitions  of  the 
metrics are given in Table 2.1. Since all CATS derived descriptors contain non-binary data-
values, the continuous version of the Tanimoto coefficient was applied. This version of the 
Tanimoto coefficient gives identical results for binary-data. A more detailed description of 
similarity metrics is given in [Willett et al., 1998]. 
 
Table 2.1 Equations of similarity metrics for continuous variables. A and B are vectors (here: 
molecular descriptor representations), N is the total number of vector elements, xi the value of 
the vector element i, DA,B denotes the distance and SA,B the similarity between objects A and B. 
Note that the range of the Tanimoto coefficient is 0 to 1 if all attributes of A and B are 
restricted to non-negative values. 
 
Similarity metric  Equation  Range 
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Virtual screening was employed in two ways, using two programs: rankIt by Uli Fechner 
[Fechner et al., 2003] and SQUIDscreen. The workflow of the two programs is illustrated in 
Figure  2.3.  Both  programs  were  designed  to  rank  a  database  of  molecular  descriptors 
according to the similarity to  a reference molecular descriptor,  applying slightly different 
virtual screening protocols (Figure 2.3). The output of both programs is a ranked list for each 
reference molecular descriptor and the respective enrichment factor. SQUIDscreen is also 
able to handle multiple conformations of molecules in the virtual screening database. For this 
purpose  each  conformation  of  a  molecule  must  be  encoded  separately.  For  the  result 
SQUIDscreen selects the conformation with the best similarity score. Other conformations are 
discarded from the ranked result list.  
 
 
 
Figure  2.3  Virtual  screening  protocols  of  the  programs  rankIt  and  SQUIDscreen.  rankIt 
iteratively takes reference molecules from the  pool of actives (1) of the virtual screening 
database,  performs  virtual  screening  (2),  and  returns  the  reference  back  into  the  virtual 
screening database (3).  This procedure is repeated for all active molecules. SQUIDscreen 
operates  on  distinct  sets  of  reference  molecules  from  the  virtual  screening  database.  In 
SQUIDscreen all reference molecules are iteratively submitted to virtual screening.  
 
 
2.2.1 Retrospective screening evaluation 
A quantitative measure for the evaluation of virtual screening results based on the obtained 
hit-lists is the enrichment factor ef [Xu & Agrafiotis, 2002]. This index quantifies the ability 
of a method to retrieve more active molecules than expected by random. The ef is defined as: Chapter 2  28 
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where Fact and Dact are the numbers of annotated active molecules in a subset and the 
whole database, and Fall and Dall are the total numbers of molecules in the subset and the 
whole database respectively. An enrichment factor of 1 corresponds to a random distribution 
of active molecules in the ranked database, thus an effective pharmacophore model results in 
an ef above 1.  
Subsets which were considered for the calculation of the ef were the first 1% and the 
first 5% of a ranked hit-list from virtual screening. The usage of a 5% subset of the hit-lists 
results in statistically more significant results. In real applications it is not always possible to 
test such large fraction of a database. This is especially important if only small numbers of 
active molecules are applied. 
 
2.3 SQUID 
SQUID Fuzzy Pharmacophore models approximate the spatial distribution of pharmacophoric 
points in an alignment of molecules by a set of generalized potential pharmacophore points 
(PPPs)  of  Gaussian  probability  densities.
  Atoms  in  the  alignment  comprising  the  same 
pharmacophoric  features  were  clustered  into  PPPs  for  a  more  general  and  “fuzzy” 
representation of the major characteristics of the alignment. The resolution of the model was 
defined  by  the  cluster  radius,  which  is  the  parameter  that  affects  how  strict  features  are 
clustered into PPPs. The ideal resolution of the pharmacophore model had to be determined 
separately for each set of aligned ligands.  
Each PPP in the pharmacophore model was represented by four attributes. The first 
attribute was the pharmacophore type of the atoms which are represented by the PPP, the 
second  was  the  PPP  position  in  3D  space,  the  third  was  the  standard  deviation  σ  which 
characterized the width of the distribution of the atoms that were represented by a PPP (in 
graphical illustrations of SQUID pharmacophore models σ is visualized by the radius of the 
PPPs).  The  fourth  attribute  (the  conservation  weight  w)  weighted  each  PPP  by  its 
conservation  among  the  molecules  of  the  alignment  (in  graphical  illustrations  of  SQUID 
pharmacophore models w is visualized by the intensity of the color of a PPP). This was done 
under the assumption that more conserved features of a set of molecules binding to the same Computational Methods  29 
receptor with comparable affinity  are more important for the binding than less conserved 
features. 
 
 
 
Figure  2.4  Calculation  of  the  SQUID  fuzzy  pharmacophore  correlation  vector. 
Pharmacophore atom-types are assigned to all atoms of a set of aligned molecules (yellow = 
hydrophobe, green = polar). Maxima in the LFDs (red) are determined to be used as cluster 
seeds. In this example a cluster radius (rc) of 1.5 Å was used. Standard deviations (σ) and 
conservation  weights  (w)  are  calculated  for  each  PPP  that  resulted  from  the  clustering 
procedure.  Finally  distances  between  all  pairs  of  PPPs  are  measured  and  the  three-
dimensional representation is transformed into a correlation vector by equation 2.5. As an 
example, a section of the resulting CV representing polar – hydrophobe pairs is shown. 
 
 
2.3.1 Calculation of the SQUID pharmacophore model 
A schematic overview of the calculation of a SQUID pharmacophore is given in Figure 2.4. 
The starting point was an alignment of known active reference compounds. Assignment of 
pharmacophoric types (cation, anion, hydrogen-bond acceptor, hydrogen-bond donor, polar, 
or  hydrophobic  as  defined  with  the  pH4_aType  function  in  MOE  [Chemical  Computing 
Group]) transformed the alignment into a field of pharmacophoric features. Maxima in the 
local feature densities (LFD) were used as cluster seeds to cluster the features into PPPs for a Chapter 2  30 
more general representation of the underlying alignment. For each atom k of type t in the 
alignment the LFD was calculated by 
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where  i  are  all  atoms  of  type  t  in  the  molecular  ensemble,  D2  is  the  Euclidean  distance 
between two atoms and rc is the cluster radius. Positions of atoms of type t for which no other 
atom of type t within rc was found yielding a higher LFD were taken as cluster seeds for PPPs 
of  type  t.  All  atoms  were  subsequently  clustered  to  their  nearest  cluster  seed  of  their 
respective type. The geometric center of the atoms of a cluster was taken as the position of the 
resulting PPP. The median distance of all atoms contributing to a PPP to the center of the PPP 
was taken as the value of the standard deviation σ of the PPP. For this value a minimum of 0.5 
Å was used. The conservation weights of the PPPs were calculated by  
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where m is the number of molecules in the model. This function returns a maximum value of 
1 for PPPs representing the same number of atoms from all molecules of the ensemble and a 
minimum of n
-1 for PPPs which consist only of atoms of one molecule.  
For virtual screening the three-dimensional distribution of PPPs was transformed into 
a two point PPP-CV (Figure 2.4), arranged exactly like the CATS3D CV. The SQUID CV 
represents the three-dimensional distribution of Gaussian densities in the form the distribution 
of pairs of PPPs over the distance bins and over the feature types. The transformation was 
calculated according to Equation 2.5.  
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where p and q are PPPs, d is a distance range (“bin”), T is the pair of pharmacophoric 
types of p and q (e.g. Figure 2.4: p = hydrophobic, q = polar), w are the PPP conservation 
weights, σ is the standard deviation of a PPP, centerd is the center of the distance range d, and 
δ
T (Kronecker delta) evaluates to 1 for all pairs of PPPs of types T. D2 is the Euclidean Computational Methods  31 
distance metric. The factor of 0.5 in the sum avoids double counting of pairs. Pairs of PPPs 
with themselves were not considered. The values of each dimension were scaled by the total 
number of possible pairs of PPPs of the two features considered. Finally the CV was scaled to 
a maximum value of 1, i.e. the largest value in the descriptor was scaled to a value of one and 
the other values were scaled proportionally. Like the CATS3D descriptor, the SQUID CV 
consisted of 420 dimensions, representing the same distance bins and pairs of atom-types. The 
SQUID  CV  was  used  to  rank  molecules  encoded  with  the  CATS3D  descriptor.  When 
CATS3D was used to encode molecules for SQUID database screening, the final CATS3D 
descriptor vector was also scaled to a maximum value of 1.  
The calculation of the SQUID CV was done with the program SQUID which was 
written in the SVL language of MOE [Chemical Computing Group]. 
 
 
 
 
 
Figure  2.5  The  SQUID  similarity  score.  The  numerator  of  the  term  describes  rewarding 
contributions of the score, i.e. CATS3D dimensions in regions with a high probability in the 
SQUID  correlation  vector  result  in  high  score  (match).  CATS3D  dimensions  in  low 
probability  regions  have  a  low  impact  on  that  term  (no  match).  The  term  for  penalizing 
contributions (the denominator) weights CATS3D dimensions by the inverse SQUID vector.  Chapter 2  32 
2.3.2 Virtual Screening 
For  virtual  screening  the  SQUID  CV  representation  was  used  to  weight  CATS3D 
representations  of  molecules  according  to  their  fitness  according  to  their  distribution  of 
pharmacophoric features. The SQUID CV and the CATS3D CVs differ significantly in the 
meaning of their content. The SQUID CV describes a broad range of descriptor areas which 
are favorable for the desired biological activity, while the CATS3D descriptor contains only a 
smaller subset of the actual occurrences of atom-pairs in a specific ligand. Consequently, 
similarity metrics like the Euclidean distance or the Tanimoto index, which are based on the 
assumption that both descriptors, which are to be compared, represent objects in the same 
way, cannot be used to assess the activity of the molecules under consideration. To overcome 
this problem a SQUID similarity score was developed (Eq. 2.6): 
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where xiA is the value of the i-th element of the SQUID CV, xiB is the value of the i-th 
element of a molecule CV and N is the total number of dimensions. The idea of the SQUID 
similarity is further illustrated in Figure 2.5. The value xiA may be considered as the idealized 
probability of the presence of features in xiB. This results in high scores for molecules with 
many features in regions of the query descriptor which have a high probability. To penalize 
the presence of such atom pairs in regions with a low probability, the denominator weights the 
presence of atom pairs with the inverted probabilities of the descriptor of the pharmacophore 
model (a value of 1 was added to the denominator to avoid division by zero and high scores 
resulting from a very low value in the denominator of the term).  
For virtual screening additional weights (“feature-type weights”) were used to weight 
the importance of each of the pharmacophoric features-types (e.g. hydrophobic or hydrogen-
bond donor) in the CV. The sums of the single feature-type weights were used to weight the 
importance of each pair of feature-types in the CV. The sum of the probabilities in the CV for 
each pair of features over all distance bins was scaled to the value of the feature-type weights. 
Finally the whole CV was scaled to a maximum of 1. It was found that a simple optimization 
by permutation of all combinations of the weight values {0.1, 0.2, 0.3, 0.4, 0.5} for each of 
the single features and subsequent testing of these weights in virtual screening was sufficient 
to retrieve good virtual screening results.  Computational Methods  33 
Evaluation of the different pharmacophore models obtained from different cluster-
radii and feature type weights was done with the program SQUIDopt which is based on the 
workflow of the program SQUIDscreen (Figure 2.3). In SQUIDopt all pharmacophore model 
variants (e.g. models from different cluster radii or different feature type weights) serve as 
references for virtual screening. In this way the different models can be prioritized and the 
model with the best ef value could be used for further virtual screening. In cases where the ef 
was not discriminative enough to favor one or a small set of models a more sensitive measure 
was used, the enrichment value ev: 
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where ef(i%) is the enrichment factor for the first i% of the hit-list. This returns the 
weighted sum of the enrichment factors of the whole database. The smaller the fraction of the 
database, the higher is the weight for the ef. 
Virtual screening was performed with the program SQUIDscreen, which was written 
in C++.  
 
 
2.4 Methods of Section 4.1: Influence of similarity metrics 
and descriptor vector scaling on CATS3D retrospective 
screening 
 
Data set 
For  the  retrospective  screening  experiments  the  COBRA  database  (version  2.1;  4705 
molecules)  [Schneider  &  Schneider,  2003]  of  annotated  reference  molecules  from  recent 
scientific literature was employed. Twelve different non-overlapping subsets of COBRA were 
defined as active molecules (used as query) and the respective remainder of the dataset as 
inactive  molecules.  The  sets  of  actives  contained  molecules  that  bind  to  the  angiotensin 
converting  enzyme  (ACE,  44  compounds),  cyclooxygenase  2  (COX2,  93),  corticotropin 
releasing factor (CRF antagonists, 63), dipeptidyl-peptidase IV (DPP, 25), G-protein coupled 
receptors  (GPCR,  1642),  human  immunodeficiency  virus  protease  (HIVP,  58),  matrix 
metalloprotease (MMP, 77), neurokinin receptors (NK, 188), nuclear receptors (NUC, 211), Chapter 2  34 
peroxisome  proliferator-activated  receptor  (PPAR,  35),  beta-amyloid  converting  enzyme 
(BACE, 44) and thrombin (THR, 188).  
For  all  COBRA  molecules  hydrogens  were  added  with  CLIFF  and  single  3D 
conformations  were  calculated  with  CORINA  (version  2.64)  [CORINA].  CATS3D 
descriptors were calculated using the three scaling schemes no-scaling, scaling1 and scaling2. 
 
Virtual screening 
For  all  12  activity  classes  of  the  COBRA  database,  and  for  the  three  scaling  schemes 
retrospective  screening  experiments  were  performed  with  the  program  rankIt,  using  the 
Manhattan  distance,  the  Euclidean  distance  and  the  Tanimoto  similarity.  The  relative 
performance of the different parameter sets was assessed by enrichment factors. 
 
 
2.5 Methods  of  Section  4.2:  Impact  of  conformational 
flexibility on CATS3D virtual screening 
 
Data set 
The PDBbind database [Wang et al., 2004] (version 2002) served as a reference set of high-
quality crystal structures of receptor-bound ligands for the virtual screening experiments. For 
retrospective  screening  we  used  the  COBRA  database  [Schneider  &  Schneider,  2003] 
(version 3.12) consisting of 5,376 annotated ligands compiled from scientific literature. The 
ligands  of  the  PDBbind  database  were  grouped  according  to  their  target  annotation.  All 
clusters  containing  less  then  five  ligands  were  removed.  Clusters  were  also  removed  for 
which no ligands were found in the COBRA database with the same target annotation as in 
PDBbind.  From  multiple  incidences  of  identical  ligands  all  but  the  one  with  the  best 
resolution were removed. The final set of reference ligands consisted of 11 groups (“activity 
classes”) with a total number of 177 ligands. The final set of ligands with the corresponding 
PDB identifier is given in Table 2.2. 
The  corresponding  set  of  “active”  ligands  in  the  COBRA  database  contained  674 
molecules, which means that the COBRA database contained 4,702 additional ligands that 
were not considered as “active” in either of the 11 activity classes. The final set of annotated 
activity classes and their abbreviations were: acetylcholinesterase (ACHE, 6 compounds from 
PDBbind, 13 compounds from COBRA, overlap: 0), carbonic anhydrase II (CAII, 30, 25, 2), Computational Methods  35 
elastase  (ELA,  8,  8,  0),  factor  Xa  (FXA,  5,  226,  5),  HIV-protease  (HIVP,  58,  61,  8), 
neuraminidase (NEU, 8, 28, 1), protein tyrosine kinase c-src (PTK-CSRC, 7, 16, 0), protein 
tyrosine phosphatase 1b (PTP1B, 5, 36, 0), stromelysin 1 (STRO1, 7, 19, 0), thrombin (THR, 
32, 194, 10), and urokinase type plasminogen activator (UTPA, 11, 48, 3). Since we were not 
interested in the absolute performance of the method, but in the relative performance using 
different degrees of conformational information, we did not remove ligands that were present 
in both databases (“overlap”).  
 
Table  2.2. Ligands from the PDBbind dataset selected as reference  molecules for virtual 
screening.  
 
Activity class  PDB identifier 
Acetylcholinesterase  1e66, 1gpk, 1gpn, 1h22, 1h23, 1vot 
Carbonic anhydrase II  1a42, 1avn, 1bcd, 1bn1, 1bn3, 1bn4, 1bnn, 1bnq, 1bnt, 1bnu, 
1bnv, 1bnw, 1bzm, 1cil, 1cim, 1cin, 1cnw, 1cnx, 1cny, 1g45, 
1g48, 1g4j, 1g4o, 1g52, 1h4n, 1if7, 1if8, 1okl, 1okn, 1ydb 
Elastase  1bma, 1ela, 1elb, 1elc, 1eld, 1ele, 1inc, 7est 
Factor Xa  1ezq, 1f0r, 1f0s, 1fjs, 1ksn, 1xka 
HIV-protease  1a30, 1a94, 1aaq, 1ajv, 1ajx, 1b6j, 1b6k, 1b6l, 1b6n, 1b6o, 1b6p, 
1bdq, 1bwa, 1bwb, 1c70, 1d4k, 1d4l, 1d4y, 1dmp, 1g2k, 1g35, 
1hbv, 1hih, 1hiv, 1hos, 1hpo, 1hps, 1hpv, 1hpx, 1hsh, 1htf, 1htg, 
1hvh, 1hvi, 1hvj, 1hvl, 1hvr, 1hwr, 1hxw, 1izh, 1k6p, 1k6t, 1k6v, 
1mtr, 1ody, 1ohr, 1pro, 1qbs, 1qbu, 1sbg, 2bpv, 2bpy, 3aid, 4hvp, 
5hvp, 7hvp, 7upj, 8hvp 
Neuraminidase  1f8c, 1f8d, 1f8e, 2qwb, 2qwc, 2qwe, 2qwf, 2qwg 
Protein tyrosine kinase 
c-src 
1a07, 1a08, 1a09, 1a1b, 1a1c, 1a1e, 1is0 
Protein tyrosine 
phosphatase 1b 
1c83, 1c84, 1c87, 1c88, 1ecv 
Stromelysin 1  1b8y, 1caq, 1ciz, 1hfs, 1sln, 1usn, 2usn 
Thrombin  1d3d, 1d3p, 1d4p, 1d6w, 1d9i, 1etr, 1ets, 1ett, 1g37, 1ghv, 1ghy, 
1gi4, 1gj5, 1kts, 1qbv, 1tmt, 1tom, 1uvt, 7kme, 1a4w, 1bcu, 1bhx, 
1c1u, 1c1v, 1c4u, 1c4v, 1c5n, 1c5o, 1fpc, 1jwt, 1k21, 1k22 
Urokinase type 
plasminogen activator 
1f5k, 1f5l, 1gi7, 1gi8, 1gi9, 1gj7, 1gj8, 1gj9, 1gja, 1gjc, 1gjd, Chapter 2  36 
Calculation of conformations 
Single  three-dimensional  conformations  were  calculated  with  CORINA  [Sadowski  et  al., 
1994] and multiple three-dimensional conformations were calculated with ROTATE (version 
1.15) [Schwab, 2003], based on the CORINA conformations. Conformations were calculated 
for the selected reference molecules from the PDBbind database and all molecules from the 
COBRA database. For each database single conformations were calculated with CORINA. To 
restrict  the  number  of  possible  output  conformations  from  ROTATE  only  the  five  most 
central rotatable bonds were subjected to torsion angle variation, and conformations with an 
internal (symbolic) energy of more than 100 kJ/mol above the lowest-energy conformation 
were rejected. The resulting conformations were further clustered in torsion angle space to 
obtain only representative conformations. To obtain databases of different conformational 
resolutions (i.e. different numbers of conformations) different thresholds of 120° (resulting 
database further referred to as R1), 60° (R2) and 45° (R3) were applied. CATS3D descriptors 
were calculated for all four COBRA databases with different conformations and the PDBbind 
crystal structure conformations using scaling2. 
 
Superposition and calculation of the RMSD 
Rigid body superimposition of molecules was performed to compare two conformations of 
one molecule. The similarity of two conformations was quantified by the RMSD (root mean 
square deviation) value of Cartesian atom positions. This was done with the program Match3d 
by  Jens  Sadowski.  Match3d  takes  into  account  the  symmetry  of  nondistinguishable  but 
differently  numbered  groups  (e.g.  the  two  oxygen  atoms  in  a  carboxylate  group)  for  the 
calculation and thereby avoids artificially introduced high RMSD values. Only non-hydrogen 
atoms were considered for the calculation. 
 
Virtual screening 
The  crystal  structure  conformations  of  the  11  ligand  classes  were  used  as  references  for 
retrospective  screening  of  the  COBRA  database  versions  with  different  numbers  of 
conformations, using the program SQUIDscreen with the Manhattan distance. The relative 
performance of the different amounts of conformations was assessed by enrichment factors. 
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2.6 Methods of Section 4.3: Virtual screening and scaffold 
hopping  efficiency  of  alignment-free  pharmacophore 
pair descriptors 
 
Data set 
For the retrospective screening experiments the COBRA database (version 2.1) [Schneider & 
Schneider, 2003] was employed using the same activity classes as in Section 4.1, except that 
the  two  very  general  classes  G-protein  coupled  receptors  (GPCR)  and  nuclear  receptors 
(NUC) were discarded for the experiments. For the virtual screening experiments hydrogens 
were added with CLIFF and single 3D conformations were calculated with CORINA (version 
2.64) [Sadowski, 1994]. CATS, CATS3D and SURFCATS descriptors were calculated with 
scaling2. The MACCS keys were calculated with MOE [Chemical Computing Group]. 
 
Molecular equivalence numbers 
Molecular equivalence indices [Xu & Johnson, 2001; Xu & Johnson, 2002] were used to 
identify  identical  scaffolds  in  molecular  databases.  The  calculations  were  done  with  the 
program Meqi (Molecular equivalence indices) [Pannanugget Consulting]. Meqi reduces the 
molecular representation to the scaffold of a molecule and calculates an equivalence number 
with a modified version of the Morgan algorithm [Morgan, 1965]. For the calculation of 
equivalence numbers all molecules were preprocessed in the following way in Meqi: First all 
hydrogens  were  stripped  off  of  the  molecules.  Second,  all  atoms  were  transformed  into 
carbons with the command “Vertex-labeling.list: C ?”. Third, all bonds were transformed to 
single bonds with the command “Edge-labeling list: 1 1 2 3 4”.  
Two  different  definitions  of  scaffolds  were  used  for  the  equivalence  number 
calculation: cyclic system (scaffold) and reduced cyclic system (reduced scaffold) (Figure 
2.6). Scaffolds represent the molecule without sidechains, indifferent for types of atoms and 
bonds.  Scaffolds  are  chosen  with  the  “Subgraphs:  CyclicSystem”  button.  Reduced 
representations are characterized by a simplifying representation of rings, which does not 
further  discriminate  between  rings  comprised  of  different  numbers  of  heavy  atoms. 
Conjugated systems with different numbers of rings are not considered as identical. Reduced 
representations were obtained with the command “Topology: Reduced”. Exact representations 
of rings were used with “Topology: Unchanged”. Other parameters of the program were held Chapter 2  38 
constant for all calculations: “Embedding: Unembed”, “Components: Group”, “Attachment 
type: RingSys”. 
 
 
 
Figure 2.6  Definition  of  cyclic  system  “Scaffold”  (Sc)  and  reduced  cyclic  system 
“Reduced Scaffold” (ReSc). In this work we defined the scaffold of a molecule as the side-
chain depleted molecular graph without annotation of atom-types. A reduced scaffold is a 
more general representation which does not discriminate between rings consisting of different 
numbers  of  heavy  atoms,  but  systems  containing  different  numbers  of  rings  are  still  not 
considered being equal. 
 
 
Virtual screening 
For all 10 activity classes of the COBRA database, and for the four molecular descriptors 
CATS, CATS3D, SURFACTS and the MACCS keys retrospective screening experiments 
were  performed  with  the  program  rankIt,  using  the  Manhattan  distance,  the  Euclidean 
distance and the Tanimoto similarity. The relative performance of the different parameter sets 
was assessed by enrichment factors. To compare the enrichment of scaffolds and reduced 
scaffolds,  enrichment  factors  were  calculated  from  the  first  occurrences  of  each  unique 
scaffold and reduced scaffold in the set of active molecules.  
 
 
2.7 Methods  of  Section  4.4:  Prospective  screening  for 
mGlurR5 allosteric modulators with CATS3D 
 
Data set 
A set of seven allosteric inhibitors of mGluR5 with reported low nanomolar activity was 
compiled from scientific and patent literature [Gasparini et al., 1999; Mutel et al., 2002; 
Cosford et al., 2003; Gasparini et al., 2003] as reference compounds in virtual screening. Computational Methods  39 
For prospective screening the Asinex Gold compound collection [ASINEX] (version 
april  2003)  was  used,  which  contained  194,563  molecules.  As  a  pre-screening  filter  we 
selected the 20,000 most “drug-like” compounds [Schneider & Schneider, 2004] in the same 
manner as described previously for the SPECS database. 3D-conformations of the screening 
compounds were calculated in MOE using the MMFF94 force field [Halgren, 1996]. The 
results  were  restricted  to  a  maximum  of  20  lowest  energy  conformations  per  molecule. 
CATS3D descriptors were calculated with the scaling2 option. 
For the analysis of the virtual screening results CATS descriptors were calculated with 
the program speedcatsdotcom [Fechner et al., 2003] with default parameters and the MACCS 
keys were calculated with MOE [Chemical Computing Group]. 
 
Alignment of reference molecules 
To form a hypothesis about receptor-bound 3D-conformations of the reference molecules the 
flexible alignment tool of MOE was used with default parameters and the MMFF94 forcefield 
[Halgren, 1996]. Ligands were successively aligned, starting with the most rigid molecule to 
the most flexible molecule.  
 
Virtual screening 
Prospective screening was performed with each of the reference molecules with SQUIDscreen 
using the Manhattan distance.  
 
 
2.8 Methods  of  Section  4.5:  Prospective  screening  for 
mGluR5  allosteric  modulators  with  an  artificial  neural 
network approach based on CATS3D representations  
 
Data sets 
For neural network training 68 mGluR5 allosteric antagonists from literature, patents and 
from unpublished results of Merz Pharmaceuticals, and 158 allosteric antagonists of mGluR1 
from patents and literature were used. Molecules that were not active on either mGluR5 or 
mGluR1 were compiled from the COBRA database (version 3.12) [Schneider & Schneider, Chapter 2  40 
2003]. From the COBRA database all molecules were removed with a substring “mGluR” in 
the identifier. 
For all molecules single 3D conformations were calculated with CORINA [Sadowski, 
1994]. CATS3D descriptors were calculated with scaling2. MACCS keys were calculated 
with MOE [Chemical Computing Group]. 
 
Maximal diverse subset selection  
Maximal diverse subsets were selected with the MaxMin algorithm [Kennard & Stone, 1996]. 
The  algorithm  starts  with  an  initial  molecule  as  the  subset  selection.  Successively,  the 
molecule from the remaining molecules, which  is most dissimilar to the already selected 
molecules, is added to the selected molecules. The procedure stops, when the desired number 
of molecules is selected. For subset selection the program MaxMinSelection [Schmucker et 
al.,  2004]  by  Michael  Schmucker  was  used,  employing  the  Euclidean  distance  for 
dissimilarity assessment. An extended version of the program by Uli Fechner was used which 
enables the initialization with a randomly selected molecule in the selected.  
 
Shannon entropy based variable selection  
Selection  of  variables  is  important  for  predictive  QSAR  results  if  not  all  variables  in  a 
descriptor, e.g. all 420 CATS3D dimensions, contain information which is related with the 
prediction problem. Other variables might not show much or any variance and are though not 
useful for predictions either. We used Shannon entropy based variable selection, which is 
based on the Shannon entropy concept formulated by Shannon in 1963 [Shannon, 1963]. This 
concept  was  shown  to  be  successful  in  descriptor  selection  for  classification  and  QSAR 
applications [Stahura et al., 2000;  Godden  &  Bajorath, 2003]. The Shannon entropy  is a 
measure for the distribution of a variable over a range of values. If all possible states of a 
variable are equally populated the Shannon entropy is at maximum. If only a single state is 
populated,  the  variable  has  a  minimum  of  entropy.  Variables  with  larger  values  for  the 
Shannon entropy are preferred over variables with lower entropy. 
The Shannon entropy is defined by Equation 2.8: 
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pi  is  the  probability  of  observing  a  particular  descriptor  value,  falling  into  a  bin  i.  For 
continuous variables, the range of values of the descriptor is partitioned into N equal sized 
bins. ci is the number of instances having a descriptor value falling into bin i.  
In the formulation of Eq. 2.8 the Shannon entropy is dependent on the number of bins. A bin 
number independent formulation is the scaled Shannon entropy (Eq. 2.9) 
 
N SE sSE 2 log = .          (Eq. 2.9) 
 
The range of sSE is from 0 to 1. For our studies we used N = 100, defined from the minimum 
to the maximum value. Variables were selected with a sSE ≥ 0.3.  
 
Autoscaling  
Autoscaling was used as a pre-procession step for the principle component analysis. With 
autoscaling variables are scaled by their standard deviation, leading to data with zero mean 
and unit variance. In this way differences between variables resulting from different value 
ranges and different size ranges are eliminated. A scaled variable x
* is obtained by Equation 
2.10: 
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xik is the value of the k
th dimension of molecule i,  k x  is the mean value of all xik and sk is the 
standard deviation. Autoscaling results in data vectors scaled to length  1 - n . 
 
Principle component analysis (PCA)  
Principle  component  analysis  is  a  method  to  obtain  uncorrelated  variables.  Correlated 
variables of a descriptor introduce a bias for these descriptor variables, which can deteriorate 
the performance of prediction methods. PCA can also be used for the visualization of high 
dimensional data in a two- or three-dimensional coordinate system. 
Uncorrelated  variables  are  obtained  by  a  linear  projection  from  an  original  m-
dimensional space X into a lower d-dimensional space S by S = XL. The projection is defined 
by the loadings matrix L
T which contains d vectors of m coefficients. The matrix containing 
the d new coordinates or variables for each molecular object is called the scoring matrix S.  Chapter 2  42 
The principle components (PC) represent the new coordinate system of the projected 
variables. The first PC coordinate axis is directed parallel to the maximum variance of the 
distribution of the data points in the original space. Accordingly the first PC explains most of 
the variance in the data. The second PC is orthogonal to the first PC and explains most of the 
remaining variance of the data. m PCs explain the full variance of the data. An efficient 
algorithm for the calculation of the PCs is the NIPALS algorithm [Wold, 1966; Wold, 1975], 
which was utilized here.  
The eigenvalue of a PC is the variance which is explained by the PC. The eigenvalue 
is calculated by the sum of the squared loadings of the PC. To obtain a small set of relevant 
uncorrelated variables, only PCs with eigenvalues ≥ 1 were selected.  
 
PCA transforms were calculated with the program nipals by Alexander Böcker.  
 
Feed-forward artificial neural networks  
The most widespread architecture of ANNs is multilayered feed-forward networks. The non-
linear  behavior  of  multilayered  feed-forward  neural  networks  enables  ANNs  to  learn  in 
principle any relationship between input and output. For our studies we used three layered 
fully-connected networks with an input layer, a hidden layer and an output layer (Figure 2.7).  
 
 
 
Figure 2.7 Three layered feed-forward artificial neural network. The input layer consists of as 
many neurons as the dimensionality of the input data. The optimal number of hidden neurons 
has  to  be  determined  experimentally.  The  hidden  layer  and  the  output  layer  consist  of 
sigmoidal neurons. w and v are the weights of the input to the hidden neurons and from the 
hidden neurons to the output neuron, respectively. J j are the bias values from the hidden 
layer and 
out J  is the bias of the output neuron. Computational Methods  43 
The output of a three-layered ANN can be expressed by Equation 2.11: 
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where wij are the weights from the input to the hidden neurons, vj are the weight from the 
hidden to the output neurons, J j are the bias values from the hidden layer and 
out J  is the bias 
of the output neuron. Sigm (Eq. 2.12) is the sigmoidal function 
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The bias and weight values were determined in a training procedure employing a (1, λ) 
evolution strategy [Schneider & So, 2003]. Evolutionary strategies (ES) are assumed to be 
favorable in comparison to gradient based optimization methods like the backpropagation 
algorithm for optimization tasks in complex multimodal fitness-landscapes like found within 
drug discovery projects [Schneider & So, 2003]. A (1, λ) evolution strategy selects from a 
pool of samples only the fittest (the first parameter in (1, λ)), that is used as a parent for the 
generation of λ offsprings. The parent dies after reproduction. This is assumed to avoid the 
selection of local minima solutions. The ES starts with a random set of weights and bias 
values and generates a set of children with Gaussian distributed variations. At the beginning 
of the optimization process, the width of the Gaussian distribution (the step -size F) is large to 
facilitate the search for the approximate location of the global optimum. As the algorithm 
proceeds to the optimum F becomes smaller. This is realized by inclusion of the F values into 
the evolutionary optimization.  
The evaluation of prediction accuracy of the candidate ANNs in the training was done 
by the mean square error (MSE) function (Eq. 2.14) 
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where  S  is  the  number  of  data  samples.  The  MSE  quantifies  the  distance  between  the 
predicted values to the desired values from the training samples. 
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The  accuracy  of  classification  tasks  was  assessed  by  the  Matthews  correlation 
coefficient (Eq 2.15): 
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where P is the number of positive correct prediction, N is the number of negative correct 
predictions, O is the number of false-positives (overpredictions), and U is the number of false-
negatives (underpredictions). The results of the cc range from -1 to 1. A cc of 1 means a 
perfect prediction, a cc of 0 corresponds to a random prediction and a cc of -1 means a 100% 
wrong prediction. A threshold of 0.5 was used to classify objects as active or inactive for the 
calculation of the cc. 
A problem in neural network training is overfitting of the ANN to the training data. 
This results in a loss of generalization for the prediction of new data. The ANN has learnt the 
examples but no rules to separate the class of actives from inactives. To avoid overfitting the 
original dataset is randomly split into training and test data sets. The training set is used for 
the training of the ANN and the test set is used to supervise the generalization ability of the 
ANN. The training is stopped when the prediction accuracy of the test set starts to decrease 
after an initial phase of improvement while the prediction of the training set still improves. 
The random split into training and test data followed by training is repeated several times to 
obtained statistically significant stopping criteria. This procedure is called cross-validation. 
The  training  of  ANNs  was  done  with  the  program  profi  by  Gisbert  Schneider 
[Schneider  &  Wrede,  1993].  Ten  times  cross-validation  was  applied  splitting  the  data  in 
equally sized fractions of 50% / 50%. For the evolution strategy 500 solutions per generation, 
an initial step size of s = 1 and a minimal step size of s = 0.001, with a reset step-size of 0.01 
were used. The reset step size is the minimum value of F for each new generated child in the 
evolution strategy. For the training of classification tasks active molecules were marked with 
a target value of 1 and inactives with a target value of 0.  
Using  a  consensus  score  obtained  from  an  ensemble  of  neural  networks  has  been 
shown to improve the quality of predictions in comparison with a single ANN [So & Karplus, 
1996;  Kauffman  &  Jurs,  2000].  Accordingly  average  values  from  the  scores  of  multiple 
neural networks were used for the prediction of properties.  Computational Methods  45 
Self organizing maps (SOMs)  
SOMs  represent  a  class  of  unsupervised  neural  networks  which  are  mainly  applied  for 
clustering, feature extraction and topology preserving projections [Schneider & So, 2003]. 
SOMs consist of a single layer of neurons that have the same dimensionality as the data 
vectors. The two-dimensional distribution of neurons resembles the distribution of data points 
in the original high dimensional space. There is no predicted output value for an input object 
but a winner neuron which is most similar to the input object. Each neuron represents a 
prototype vector for the data objects which are most similar to this neuron. The field within 
which data points are assigned to a neuron is called the receptive field of this neuron. A 
neuron is activated if a data points falls into its receptive field. The preservation of the data 
topology is achieved by the definition of a topology in the neuron layer. This layer is fitted 
onto the original data distribution, preserving the original topology of the data. To avoid 
boundary problems the maps have a toroidal topology. 
The training of SOMs was done according to Kohonen [Kohonen, 1982]: 
(1) Initialize the map with N = N1 * N2 neurons ci with reference vectors 
i c w  chosen 
randomly from the distribution p(ζ) of training patterns. Initialize connections between 
the neurons to form a rectangular N1 x N2 grid. The time parameter t is set to 0. 
(2) Randomly select a training pattern ζ from p(ζ) as input signal. 
(3) Determine the winner neuron with the smallest Euclidean distance to the input signal.  
(4) Adapt each neuron in the SOM to the training pattern. 
(5) Increase the time parameter: t = t + 1. 
(6) If t < tmax continue with step (2), else terminate. 
 
The adaptation of a neuron r to a training pattern ζ is done according to: 
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is  the  Gaussian  neighborhood  function  around  the  winner  neuron  s  and  D1  is  the 
Manhattan distance. The time dependent standard deviation is defined as  Chapter 2  46 
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and the time dependent learning rate is defined as  
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The training of SOMs was calculated with the program som_create by Gisbert 
Schneider using 5 x 5 = 25 neurons, tmax = 85000, σinitial = 5 and εinitial = 1, and εinitial and 
σinitial = (tmax / number of training patterns). Visualization of SOMS was done with the 
program som_show by Gisbert Schneider. 
 
 
2.9 Methods  of  Section  4.6:  Retrospective  evaluation  of 
SQUID fuzzy pharmacophore models 
 
Data set 
Pharmacophore models were calculated for COX-2 and thrombin on the basis of molecules 
which were reported in pharmacophore models for the  respective targets [Palomer et al., 
2002;  Patel  et  al.,  2002].  For  calculation  of  a  COX-2  pharmacophore  model,  the  crystal 
structures of COX-2 with the specific inhibitor SC-558 (1CX2) and the structures of COX-2 
with the unspecific inhibitors flurbiprofen (3PGH) and indomethacin (4COX) were used to 
model  a  template  alignment  for  the  flexible  alignment  of  the  specific  COX-2  inhibitors 
rofecoxib and molecule 5 (M5) from Palomer et al. [Palomer et al., 2002]. For calculation of 
the  thrombin  pharmacophore  model  the  crystal  structures  with  PDB  codes  1C4V,  1D4P, 
1D6W, 1D9I, 1DWD, 1FPC and 1TOM were used [Patel et al., 2002]. 
For retrospective screening we used the COBRA database [Schneider & Schneider, 
2003] (version 2.1). Two versions were calculated: one database with single conformations 
was  calculated  with  CORINA  [Sadowski,  1994]  and  one  database  of  up  to  50  energy 
minimized conformations was calculated with MOE [Chemical Computing Group] using the 
MMFF94  forcefield [Halgren, 1996]. For  retrospective screening the molecules that were 
used for the pharmacophore model generation were removed from the datasets. The resulting 
datasets consisted of 92 active molecules and 4611 inactive molecules for COX-2, and 188 Computational Methods  47 
actives and 4517 inactive compounds for thrombin. The CATS3D descriptor for the COBRA 
sets was calculated using scaling2. 
 
Alignment of reference molecules 
Alignments of inhibitors were either obtained by the flexible alignment tool in MOE with 
default parameters and the MMFF94 forcefield [Halgren, 1996] or the homology align tool in 
MOE using default parameters. 
 
Virtual screening 
Virtual  screening  with  SQUID  pharmacophore  models  was  performed  with  the  program 
SQUIDscreen. CATS3D similarity searching was also performed with SQUIDscreen using 
the Euclidean distance. MOE pharmacophore models were calculated using the PCH_ALL 
atom-type scheme, which consists of atom-types for cationic, anionic, hydrogen-bond donor, 
hydrogen-bond acceptor, aromatic ring centers, and hydrophobic interactions. 
 
 
2.10 Methods  of  Section  4.7:  Prospective  screening  for 
inhibitors of the Tat-TAR RNA interaction with a SQUID 
fuzzy pharmacophore model and CATS3D 
 
Data set 
Two  reference  inhibitors  for  the  Tat  TAR  interaction  were  taken  from  literature: 
acetylpromazine  [Lind  et  al.,  2002]  in  the  receptor  bound  conformation  from  the  NMR 
structure 1LVJ [Du2002] that served as a template for the flexible alignment of CGP40336A 
[Hamy et al., 1998]. 
For the optimization of the “feature-type weights” the two reference ligands, used for 
the pharmacophore calculation, were used for retrospective screening in the COBRA database 
[Schneider  &  Schneider,  2003]  (version  3.12).  Up  to  20  low  energy  conformations  were 
calculated with MOE [Chemical Computing Group] for each of the molecules in this database 
using the MMFF94 forcefield [Halgren, 1996].  
For  prospective  screening  the  SPECS  database  [SPECS]  (june  2003  version)  with 
229,658 molecules was used. To obtain higher quality results and to restrict the calculation of Chapter 2  48 
3D  conformations  the  20,000  most  druglike  molecules  were  selected,  as  predicted  by  an 
artificial  neural  network  approach  [Schneider  &  Schneider,  2004].  For  each  of  these 
molecules multiple conformations were calculated in MOE like for the COBRA molecules.  
 
Calculation of drug-likeness score 
“Drug-likeness”  was  calculated  according  to  a  procedure  described  in  [Schneider  & 
Schneider, 2004]. Three parameters were used for the calculation: i) the output (“score”) of an 
artificial neural network that was trained to distinguish between “drugs” and “nondrugs”, 
based on CATS representations of molecules, ii) predicted aqueous solubility [Engkvist & 
Wrede,  2002],  and  iii)  calculated  polar  surface  area  (PSA)  (ASA_P  option  from  MOE). 
Subsequent principal component analysis of this three-dimensional “drug-likeness” space was 
performed to obtain uncorrelated variables. A ranking of compounds was performed on the 
basis  of  their  distance  to  “optimal”  variable  values  (i.e.,  high  drug-likeness  score;  high 
solubility  value;  PSA  <  140  Å2).  A  detailed  description  of  this  procedure  is  given  in 
[Schneider & Schneider, 2004]. 
 
Alignment of reference molecules 
For the alignments of the known reference Tat-TAR interaction inhibitors ligands the flexible 
alignment  tool  in  MOE  was  used  with  default  parameters  and  the  MMFF94  forcefield 
[Chemical Computing Group]. 
 
Virtual screening 
Virtual  screening  with  SQUID  pharmacophore  models  was  performed  with  the  program 
SQUIDscreen. CATS3D similarity searching was performed with SQUIDscreen using the 
Manhattan distance. 
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2.11 Methods  of  Section  4.8:  Prospective  screening  for 
taspase1  inhibitors  with  a  receptor-derived 
pharmacophore model 
 
Data set 
The  sequence  of  the  human  taspase1  was  obtained  from  swiss-prot  (entry  Q9H6P5). 
Homologous  crystal  structures  that  were  used  as  template  for  the  homology  models 
calculation were 1T3M, 2GAW and 1APZ.  
For  prospective  screening  the  SPECS  database  [SPECS]  (june  2003  version)  with 
229,658 molecules was used. To obtain higher quality results and to restrict the calculation of 
3D conformations the database was filtered according to the Lipinski “rule of five” [Lipinski 
et al., 1997] and additional target specific filters prior to conformation calculation. For each 
of these remaining molecules up to 20 low energy conformations were calculated in MOE like 
using the MMFF94 forcefield [Halgren, 1996]. Finally all bases were protonated and all acids 
deprotonated with the MOE database/wash function. 
 
BLAST search 
The BLAST [Altschul et al., 1997] search was performed using the sequence of taspase1 as 
query. The BLOSUM62 matrix with a gap opening penalty of 11 and a gap extension penalty 
of 1 was applied.  
 
Homology modeling 
Homology models were calculated with MOE [Chemical Computing Group]. Sequence and 
structure based alignments were calculated with the Homology/Align function in MOE, using 
the  default  values  (blosum62  substitution  matrix  with  a  gap  start  panelty  of  7  and  gap 
extention  panelty  of  1).  The  visualization  of  the  alignments  was  done  with  the  program 
CHROMA [Goodstadt & Ponting, 2001]. 
Ten  models  were  calculated  based  on  the  alignment.  The  coordinates  of  the  final 
model were calculated as the average of the atom coordinates of the intermediate models. 
Refinement of the model was done by minimizing the sidechains of the models (backbone 
atoms  were  held  fixed)  with  the  MMFF94xx  forcefield  including  solvatation  to  a  RMS Chapter 2  50 
gradient  of  0.1.  Minimization  was  done  using  chiral  constraints,  i.e.  the  chirality  of  the 
molecule was held fixed. Results were controlled with the protein report function of MOE. 
Docking 
Docking  calculations  were  computed  with  the  program  GOLD  [Jones  et  al.,  1997].  For 
GOLD,  the  genetic  algorithm  parameters  were  used  with  the  standard  default  settings. 
Chemscore was applied as fitness function [Eldridge et al., 1997]. Early termination was 
disabled.  
 
Database filtering 
The SPECS database was filtered according to the Lipinski “rule of five” [Lipinski et al., 
1997] and target specific filters, based on the MOE descriptors in Table 2.3. Molecules were 
discarded from the SPECS database which satisfied one of the criteria based on an extended 
version of the “rule of five”: > 500 Da, logP > 5, > 5 hydrogen-bond donors, > 10 hydrogen-
bond acceptors, > 10 rotatable bonds. Since the inhibitors were thought to depend on one 
acidic group, all molecules with less than one acidic group were removed. Molecules with Br, 
I, B, P, S- and nitro groups and sulfat as only single acidic group were also removed 
 
Table 2.3. MOE Descriptors 
 
Descriptor name  Description 
Weight  Molecular mass 
logP(o/w)  logarithm  of  the  octanol  /  water  partition 
coefficient 
a_don  number of hydrogen-bond donors 
a_acc  number of hydrogen-bond acceptors 
b_rotN  number of rotatable bonds 
a_nBr  number of bromine atoms 
a_nI  number of iodine atoms 
a_nP  number of phosphorus atoms 
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Virtual screening 
Virtual screening was performed with the MOE pharmacophore search tool.  
 
 3 Experimental Section 
 
Note: The following methods and experimental procedures were not applied by the author of 
the thesis. Inclusion of the experimental details is for the purpose of completeness of the 
scientific results. 
 
 
3.1 Determination of IC50 values for mGluR 
 
Materials 
[3H]-MPEP was obtained from Tocris Cookson (Bristol, UK). MPEP was synthesized for in-
house use as a reference compound according to [Gasparini et al., 1999; Sashida et al., 1988]. 
Test compounds were purchased as dry powder from ASINEX Ltd. (Moscow, Russia). The 
ASINEX Gold Collection Database was provided by ASINEX  Ltd. [3H]-MRZ 3415 was 
synthesized by Amersham Biosciences (Buckinghamshire, UK). MRZ 3415 was synthesized 
for in-house use as a reference compound by the Latvian Institute of Organic Synthesis (Riga, 
Latvia). 
 
Membrane preparation 
Male  Sprague  Dawly  Rats  (approx.  200-250  g)  were  anaesthetized  and  decapitated. 
Forebrains were removed and homogenized (Ultra Turrax, 8 strokes, 600 rpm) in 0.32 M 
Sucrose. The suspension was centrifuged at 1,500 g for 4 min. using a Centrikon T-2050 
Ultracentrifuge  (Tegimenta  AG,  Rotkreuz,  Switzerland).  Supernatant  was  removed  and 
centrifuged at 20,800 g for 20 min. The resulting pellet was re-suspended in ice-cold distilled 
water and centrifuged at 7,600 g for 20 min. Supernatant and loosely associated flocculent 
membrane  material  (buffy  coat)  were  removed  by  gentle  trituration  of  the  pellet  and 
centrifuged at 75,000 g for 20 min. Supernatant was discarded and the membrane pellet was 
resuspended  by  sonication  in  Tris-Buffer  (5  mM,  pH  7.4)  and  afterwards  centrifuged  at 
75,000 g for 20 min. The last step was repeated twice and membranes were re-suspended in 
Tris-Buffer (50 mM, pH 7.5). Experimental Section  53 
The concentration of protein was determined by the Lowry protein assay with bovine 
serum albumin as a standard. Membranes were stored frozen at –24°C, thawed on the day of 
the assay and washed again four times at 75,000g for 20 min. 
 
All centrifugation steps were carried out at 4°C. 
 
[3H]-MPEP binding 
After thawing, membranes were washed four times with ice-cold binding buffer containing 50 
mM Tris-HCl, pH 7.5. Binding assays were performed at room temperature in duplicate using 
fixed concentrations of  test compound (10 µM). The assay was incubated for 1 h in the 
presence of radiotracer (5 nM) and membranes (1.2 mg/ml) and non-specific binding was 
estimated using 10 µM MPEP. Binding was terminated by rapid filtration through GF 52 
glass-fiber filters (Schleicher&Schuell, Dassel, Germany) using a 1225 Sampling Manifold 
(Millipore GmbH, Eschborn, Germany). Filters were washed twice with ice-cold assay-buffer 
and  transferred  to  scintillation  vials.  After  addition  of  Ultima-GoldTM  MV  (Packard 
Bioscience, Groningen, The Netherlands) radioactivity collected on the filters was counted in 
a 1500 Tri-Carb Packard Scintillation Counter. 
 
[3H]-MRZ 3415 Binding 
After thawing, membranes were washed four times with ice-cold binding buffer containing 50 
mM Tris-HCl, pH 7.5. Binding assays were performed at room temperature in quadruplicate 
on  96-well  format  using  fixed  concentrations  of  test  compound  (10 µM).  The  assay  was 
incubated for 1 h in the presence of radiotracer (1 nM) and membranes (0.8 mg/ml) and non-
specific  binding  was  estimated  using  10  µM  MRZ  3415.  Directly  after  transferring  the 
reaction volume onto a 96-well multiscreen plate with glass fiber filter 0.22 µm (Millipore 
GmbH, Eschborn, Germany) binding was terminated by rapid filtration using a multiscreen 
vacuum manifold (Millipore GmbH, Eschborn, Germany). Afterwards, filters were washed 
four times with ice-cold assay-buffer and Ultima-GoldTM MV Scintillation Cocktail (Packard 
Bioscience, Groningen, The Netherlands) was added. After 14 h – 16 h radioactivity was 
counted  in  a  MicroBetaÒTrilux  (Perkin  Elmer  Life  Sciences  GmbH,  Rodgau-Jügesheim, 
Germany).  
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Solubility Determination 
40 µl of the stock-solution (10 mM, dimethyl  sulfoxyd (DMSO) as solvent) of each test 
compound were diluted with 1.96 ml DMSO to a final concentration of 200 µM. 100 µl of 
this solution were diluted by addition of 1.99 ml of a solvent consisting of methanol and 
deionized water (1:1). The resulting solution A has a concentration of 10 µM of the test 
compound containing 5% DMSO. Solution B was prepared in the same manner but using 
Tris-buffer 50 mM, pH 7.5 as solvent instead of the methanol/deionized water mixture. 
To determine peaks of the different solutions a HP Series 1100 HPLC device with 
diode array detector (Agilent Technologies, Waldbronn, Germany) was used. Both solutions 
flew separately through a SymmetryTM C18 Column (Waters Corporation, Milford, MA) 
with  a  average  pressure  of  190  atmosphere.  The  resulting  peaks  of  both  solutions  were 
compared at a wavelength where the “area under the curve” (AUC) of the peak of solution A 
and solution B respectively displayed a maximum. The AUC of solution A was defined as 
100%-value. Thus, the solubility of each test compound was determined as follows: 
 
100 * [%] Solubility
 
 
A solution
B solution
AUC
AUC
=            (Eq. 3.1) 
 
IC50-value Estimation 
IC50 values were estimated from the % of control values from the scintillation assay with a 
four parameter logistic equation. If both the radio-ligand and the competitor reversibly bind to 
the same binding site, binding at equilibrium follows equation 3.2. 
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If s is assumed to be 1 equation 3.2 can be reformulated to: 
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where s = slope factor = 1; 
x = concentration of test compound [µM] in the assay; Experimental Section  55 
y = result of the binding assay for the test compound [% of control]. 
 
Ki-values were calculated from the IC50-values by the Cheng-Prussof Equation [Cheng & 
Prussof, 1973].  
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where L corresponds to the radio-ligand concentration and Kd to its dissociation constant. 
 
 
3.2 Determination of IC50 values for TAR-RNA 
 
Materials 
Argininamide was purchased from Sigma Chemical Corp. (St. Louis, USA). The molecules 
resulting from virtual screening were purchased from SPECS (Delftechpark, The Netherlands) 
as 10 mM stock solutions in DMSO, and diluted for binding assays with DEPC- treated water 
to 1 mM or 100 µM, respectively. Fluorescence based binding assays
[20] were performed in 96 
well  microplates  at  37°C.  Reader:  FluoStar  Galaxy  (BMG  Labtechnologies,  Offenburg, 
Germany),  excitation  wavelength  540  nm,  emission  wavelength  590  nm.  Microplates: 
Corning 6860, black, non binding surface. The dye labeled Tat49-57–sequence fluoresceine–
AAARKKRRQRRRAAAC–rhodamine (1 µM stock solution) was purchased from Thermo 
Electron  Corporation  (Ulm,  Germany).  Oligonucleotides  were  obtained  from  Biospring 
(Frankfurt, Germany). 
 
In vitro transcription 
Equimolar amounts of T7-primer (5‘-TAATACGACTCACTATAG-3‘) and TAR template 
(5‘-GGCCAGAGAGCTCCCAGGCTCAGATCTGGCCCTATAGTGAGTCGTATTA-3‘) 
were  mixed  in  TE  buffer  (10  mM  Tris-HCl,  1  mM  EDTA;  pH  7.4)  to  give  a  final 
concentration of 50 pmol / µL in a volume of 100 µL. After heating to 90 °C for 5 minutes, 
the reaction was allowed to cool down slowly to room temperature. All in vitro transcriptions 
were performed with T7 polymerase containing RiboMax
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Systems Kit (#P1300; Promega, Mannheim, Germany)  as described by  the manufacturer. 
Subsequent to transcription the DNA template was removed as follows: After heating the 
transcription mixture to 95 °C for 5 minutes it was chilled immediately on ice. 10 µL RQ1 
DNase buffer (Promega) and 20 µL RQ1 RNase-free DNase (20 U, Promega) were added 
and the mix was incubated for 30 minutes at 37 °C. Following phenol / chloroform extraction, 
RNA was precipitated with 3 volumes of ethanol in the presence of 0.3 M sodium acetate (pH 
5.2).  The  RNA  was  desalted  on  a  NAP
TM  column  (Amersham  Biosciences,  Freiburg, 
Germany). After lyophilisation, the RNA pellet was redissolved in DEPC treated water to a 
concentration of 100 µM (stock solution) or 1 µM (final dilution), respectively. 
 
FRET assay 
The following stock solutions were used in the assay: labeled Tat-peptide (1 µM), TAR-RNA 
(1 µM), TK buffer (500 mM Tris-HCl, 200 mM KCl, 0.1% Triton-X 100, pH 7.4). The final 
volume per well was 100 µL. The fluorescence of pure Tat peptide was determined first: 10 
µL stock solution of Tat and 10 µL TK buffer were filled up with DEPC treated water to 100 
µL. 10 µL of Tat solution, 10 µL of TAR solution (each 1 µM), 10 µL TK buffer, and 70 µL 
DEPC treated water were then mixed in a second well to measure the emission of the Tat-
TAR complex. Having established the numbers for free and for bound peptide, single point 
measurements of potential inhibitors were carried out at concentrations of 1000, 100, and 10 
µM by using 10 µL of the stock solutions (10 mM, 1 mM, and 100 µM). RNA and peptide 
concentrations were kept constant at 100 nM in each well (10 µL Tat, 10 µL TAR, 10 µL TK 
buffer,  10  µL  inhibitor,  and  60  µL  DEPC  treated  water).  Addition  of  DMSO  strongly 
increases  the  fluorescence  of  rhodamine  independently  from  peptide-RNA  binding.  To 
eliminate this effect, samples of Tat and of Tat-TAR (each 100 nM) were also measured in 
the presence of 10 %, 1 %, or 0.1 % DMSO. Dividing these numbers by the value obtained in 
pure  water  generated  the  correction  factors.  For  compounds  which  showed  an  inhibitory 
effect in the preliminary test, complete titration curves were determined from 11 data points. 
The molecular concentration at which the fitted titration curve intersected with the mean value 
of the fluorescence counts of the Tat-TAR complex and uncomplexed Tat was used as the 
IC50 value of a molecule. 
 
 
 4 Main Section 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The main section is organized in the following way: Sections 1-3 cover the retrospective 
evaluation  of  pharmacophore  pair  descriptors  (CATS,  CATS3D  and  SURFCATS)  with 
respect to similarity metrics, scaling, multiple conformations and scaffold hopping. Sections 4 
and 5 cover the SQUID fuzzy pharmacophore model approach, including the evaluation of the 
method and a prospective virtual screening for Tat-TAR inhibitors. Section 6 and 7 report 
prospective  virtual  screening  experiments  for  allosteric  antagonists  of  the  metabotropic 
glutamate receptor 5 using CATS3D similarity  searching and an artificial neural network 
approach. Section 8 addresses the prospective virtual screening with a ligand- and binding-
site-based pharmacophore model of taspase1. 
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4.1 Influence  of  similarity  metrics  and  descriptor  vector 
scaling on CATS3D retrospective screening 
The CATS3D descriptor is a three-dimensional extension of the topological pharmacophore-
pair CATS descriptor developed by Schneider [Schneider et al., 1999] for ligand based virtual 
screening. Several parameters can influence the effectiveness of virtual screening. Among 
these are the set of reference molecules, the molecular descriptor and the similarity metric. 
We wanted to test if there are some general optimal settings for virtual screening with the 
CATS3D descriptor. In detail we wanted to test the influence of different similarity indices, 
namely  the  Manhattan  distance,  the  Euclidean  distance  and  the  Tanimoto  similarity 
coefficient (Table 2.1). Further we were interested in the effect of different scaling schemes 
on the performance of the CATS3D descriptor. Three different scaling schemes were tested: 
·  No scaling (“no-scaling”).  
·  Division by the number of PPPs of a molecule (“scaling1”).  
·  Division of each of the 21 possible pairs of PPPs by the added occurrences of the two 
respective PPPs (“scaling2”). 
No-scaling corresponds to the histogram of pairs of PPPs in a molecule. Scaling1 was the 
original scaling scheme reported for the CATS descriptor [Schneider et al., 1999]. The aim of 
scaling1 is to reduce dissimilarities of molecules based on different molecular size. Scaling2 
is an extension of scaling1, first reported for CATS3D [Fechner et al., 2003]. The aim of 
scaling2 is to reduce the bias of highly populated types of PPPs (mainly the hydrophobic 
PPPs) on the similarity between molecules.  
For  the  retrospective  screening  experiments  we  employed  the  COBRA  database 
(version 2.1) [Schneider & Schneider, 2003] of annotated reference molecules from recent 
scientific  literature.  Twelve  different  datasets  were  compiled  from  the  COBRA  database. 
These non-overlapping  subsets were defined as active molecules (used as query) and the 
respective  remainder  of  the  dataset  as  inactive  molecules.  The  sets  of  actives  contained 
molecules that bind to angiotensin converting enzyme (ACE, 44 compounds), cyclooxygenase 
2 (COX2, 93), corticotropin releasing factor (CRF antagonists, 63), dipeptidyl-peptidase IV 
(DPP,  25),  G-protein  coupled  receptors  (GPCR,  1642),  human  immunodeficiency  virus 
protease (HIVP, 58), matrix metalloprotease (MMP, 77), neurokinin receptors (NK, 188), 
nuclear receptors (NUC, 211), peroxisome proliferator-activated receptor (PPAR, 35), beta-
amyloid converting enzyme (BACE, 44), and thrombin (THR, 188). For the virtual screening 
experiments single CORINA [Sadowski et al., 1994] 3D conformations were used.  Main Section  59 
 
 
 
Figure 4.1. Average of the enrichment factors over the 12 activity classes for the different 
scaling methods and similarity metrics from retrospective screening of the COBRA database. 
Blue bars denote 1% enrichment and red bars 5% enrichment factors.  
 
 
Each  of  the  molecules  from  the  subsets  was  employed  as  query  for  one  virtual 
screening experiment. Averages of the enrichment factors over all twelve classes are shown in 
Figure 4.1 for the first 1% and 5% of the hit-lists. Apparently the performance of the three 
scaling schemes was scaling2 > scaling1 > no-scaling, independent of the similarity metric 
applied. The performance of the similarity metrics showed no clear ranking. For no-scaling 
and  scaling1  the  Manhattan  distance  was  found  to  be  best.  For  scaling2  the  Tanimoto 
coefficient was the best performing similarity metric. The differences between the similarity 
metrics were significantly smaller than between the scaling schemes. The standard deviations 
of the average ef values were found to be up to 64 % of the mean values (ef(5%) for no-
scaling with Tanimoto in Figure 4.1). Accordingly the results have to be taken with care. To 
assess the significance of the average efs we further investigated the results of the individual 
target classes.  
The enrichment factors for all classes are given in Table 4.1. For all classes expect 
GPCR  significant  ef  values  were  found.  GPCR  is  a  very  general  class  comprising  many 
different receptors. Thus a lack of significant enrichment is not surprising. NUC, another Chapter 4  60 
general  class,  was  successful  in  retrospective  screening.  The  major  trend  found  for  the 
average ef values was confirmed. Though large standard deviations were also found in the 
single activity classes the major trend of the average ef values seems to be confirmed. For 
almost all classes the best ef values for 1% of the hit-list were found with scaling2. Only for 
HIVP  with  Manhattan  distance  and  no-scaling  or  scaling1,  and  for  NK  with  Manhattan 
distance and the Tanimoto coefficient with no-scaling resulted in better or equal ef values 
than for the respective screenings using scaling2. For 5% of the hit-list more examples were 
found  with  equal  or  better  ef  values  using  scaling  schemes  other  than  scaling2.  For  the 
Tanimoto coefficient, this was only found for no-scaling NK.  
 
 
4.1.1 Conclusion 
The  impact  of  different  scaling  schemes  (no-scaling,  scaling1,  and  scaling2)  and 
different similarity metrics (Manhattan distance, Euclidean distance, and Tanimoto similarity) 
on  virtual  screening  with  the  CATS3D  descriptor  was  investigated  with  retrospective 
screening  in  ten  target  classes  of  the  COBRA  database.  The  results  suggest  a  general 
preference for scaling2 (scaling by the added occurrences of the PPP pairs). Scaling2 was 
found to be best for most of the target classes. Accordingly for all further experiments this 
scaling scheme was applied. Using scaling2 the Tanimoto coefficient was found to be best. 
The differences between the similarity metrics were low in comparison to the differences 
between the scaling schemes. Therefore one could also suggest the use of the Manhattan 
distance for the screening of large datasets, since the Manhattan distance is the fastest of the 
three applied similarity metrics.  
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Table 4.1. Retrospective screening results for CATS3D using different scaling schemes and 
similarity metrics. Three scaling schemes (no-scaling, scaling1, and scaling2) and the three 
similarity metrics Manhattan distance (Manh), Euclidean distance (Euc), and the Tanimoto 
similarity (Tani) were applied. Values in brackets are standard deviations. 
 
    no-scaling    scaling1    scaling2 
% DB    Manh  Euc  Tani    Manh  Euc  Tani    Manh  Euc  Tani 
ACE                         
1    12 (11)  12 (10)  12 (10)    14 (11)  12 (10)  13 (10)    16 (11)  17 (11)  20 (13) 
5    4 (3)  4 (3)  4 (4)    5 (3)  5 (3)  5 (3)    6 (3)  6 (4)  7 (4) 
COX2                         
1    17 (11)  16 (11)  17 (12)    18 (11)  18 (12)  19 (12)    21 (12)  20 (13)  22 (13) 
5    7 (4)  6 (3)  7 (4)    8 (4)  7 (4)  7 (4)    9 (4)  8 (4)  9 (4) 
CRF                         
1    19 (11)  15 (10)  15 (9)    21 (11)  15 (9)  15 (8)    22 (10)  21 (10)  20 (11) 
5    8 (3)  6 (3)  6 (3)    9 (3)  7 (3)  7 (3)    10 (3)  10 (3)  10 (3) 
DPP                         
1    13 (8)  9 (6)  9 (7)    13 (9)  11 (8)  11 (8)    16 (11)  16 (12)  15 (13) 
5    4 (2)  4 (2)  4 (2)    5 (2)  4 (2)  3 (2)    5 (3)  5 (3)  4 (3) 
GPCR                         
1    2 (1)  2 (1)  2 (1)    2 (1)  2 (1)  2 (1)    2 (1)  2 (1)  2 (1) 
5    1 (0)  1 (0)  1 (0)    1 (0)  1 (0)  1 (0)    1 (0)  1 (0)  1 (0) 
HIVP                         
1    13 (8)  13 (8)  14 (8)    13 (8)  13 (7)  14 (7)    12 (8)  15 (9)  20 (10) 
5    7 (4)  7 (4)  8 (4)    6 (3)  7 (3)  8 (3)    5 (3)  7 (4)  9 (4) 
MMP                         
1    7 (5)  5 (4)  5 (4)    7 (5)  5 (4)  6 (4)    10 (7)  11 (7)  13 (8) 
5    3 (2)  3 (2)  3 (2)    3 (2)  3 (2)  3 (2)    4 (3)  4 (2)  5 (3) 
NK                         
1    13 (8)  11 (7)  12 (7)    12 (8)  11 (7)  12 (8)    11 (7)  12 (8)  15 (8) 
5    7 (4)  6 (3)  7 (4)    6 (3)  6 (3)  7 (4)    5 (3)  6 (3)  8 (3) 
NUC                         
1    7 (6)  6 (5)  7 (5)    7 (6)  7 (5)  7 (5)    8 (6)  7 (5)  8 (6) 
5    4 (3)  3 (2)  4 (2)    4 (3)  3 (2)  4 (2)    4 (3)  4 (3)  5 (3) 
PPAR                         
1    7 (5)  5 (4)  4 (5)    7 (6)  5 (5)  6 (5)    9 (7)  9 (8)  8 (8) 
5    3 (2)  2 (2)  2 (2)    3 (2)  2 (2)  2 (2)    3 (2)  3 (2)  3 (3) 
BACE                         
1    7 (5)  5 (3)  4 (2)    8 (6)  6 (4)  5 (4)    12 (10)  12 (10)  11 (9) 
5    2 (2)  2 (1)  2 (1)    3 (2)  2 (1)  2 (1)    3 (2)  3 (3)  4 (3) 
THR                         
1    6 (4)  5 (3)  5 (3)    6 (4)  6 (4)  6 (4)    7 (5)  8 (5)  9 (5) 
5    3 (2)  3 (1)  3 (1)    3 (2)  3 (2)  3 (2)    3 (2)  4 (2)  5 (2) 
average                         
1% 
  10.1  
(5.1) 
8.6  
(4.7) 
8.8  
(5.1) 
  10.7  
(5.4) 
9.2  
(4.9) 
9.6  
(5.1) 
  12.2  
(5.8) 
12.4  
(5.6) 
13.5  
(6.2) 
5% 
  4.5  
(2.3) 
4.0  
(2.2) 
4.3  
(2.4) 
  4.7  
(2.3) 
4.1  
(2.0) 
4.3  
(2.2) 
  4.8  
(2.5) 
5.1  
(2.4) 
5.7  
(2.7) 
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4.2 Impact of conformational flexibility on CATS3D virtual 
screening 
Virtual screening methods like docking or three-dimensional pharmacophore searching rely 
on  the  on  the  “bioactive”  conformation  of  molecules  to  asses  the  biological  effect  of  a 
molecule. Three-dimensional pharmacophore correlation vector methods have been shown to 
produce  reasonable  results  using  only  a  small  set  of  conformations  or  even  a  single 
conformation per molecule [Sheridan1 et al., 1996, Brown & Martin, 1996, Section 4.1].  
While it is a comparably easy task for small and rigid ligands with only few rotatable 
bonds to sample the conformational space exhaustively, there are still practical limits in the 
number of conformations that can be handled efficiently due to the exponential explosion of 
the number of potential conformations with an increasing number of rotatable bonds [Schwab, 
2003]. Accordingly three-dimensional methods which rely only moderately on the presence of 
an exact fitting conformer would be interesting for virtual screening. 
In  the  present  study  we  examined  the  influence  of  the  incorporation  of  different 
amounts  of  multiple  conformations  on  the  ability  of  the  CATS3D  approach  to  find 
isofunctional  molecules  in  a  retrospective  screening  experiment.  Therefore  reference 
molecules  from  co-crystal  structures  were  used  as  queries  for  the  retrospective  virtual 
screening experiments. Different numbers of conformations were calculated for the virtual 
screening database. We compared the effect of using the different virtual screening libraries. 
The PDBbind database [Wang et al., 2004] (version 2002) served as a reference set of 
high-quality crystal structures of receptor-bound ligands for the virtual screening experiments. 
For retrospective screening we used the COBRA database [Schneider & Schneider, 2003] 
(version 3.12) consisting of 5,376 annotated ligands compiled from scientific literature. The 
ligands  of  the  PDBbind  database  were  grouped  according  to  their  target  annotation.  All 
clusters  containing  less  then  five  ligands  were  removed.  Clusters  were  also  removed  for 
which no ligands were found in the COBRA database with the same target annotation as in 
PDBbind.  From  multiple  incidences  of  identical  ligands  all  but  the  one  with  the  best 
resolution were removed. The final set of reference ligands consisted of 11 groups (“activity 
classes”) with a total number of 177 ligands. The corresponding set of “active” ligands in the 
COBRA  database  contained  674  molecules,  which  means  that  the  COBRA  database 
contained 4,702 additional ligands that were not considered as “active” in either of the 11 
activity  classes.  The  final  set  of  annotated  activity  classes  and  their  abbreviations  were: 
acetylcholinesterase  (ACHE,  6  compounds  from  PDBbind,  13  compounds  from  COBRA, Main Section  63 
overlap: 0), carbonic anhydrase II (CAII, 30, 25, 2), elastase (ELA, 8, 8, 0), factor Xa (FXA, 
5, 226, 5), HIV-protease (HIVP, 58, 61, 8), neuraminidase (NEU, 8, 28, 1), protein tyrosine 
kinase  c-src  (PTK-CSRC,  7,  16,  0),  protein  tyrosine  phosphatase  1b  (PTP1B,  5,  36,  0), 
stromelysin  1  (STRO1,  7,  19,  0),  thrombin  (THR,  32,  194,  10),  and  urokinase  type 
plasminogen  activator  (UTPA,  11,  48,  3).  Since  we  were  not  interested  in  the  absolute 
performance  of  the  method,  but  in  the  relative  performance  using  different  degrees  of 
conformational information, we did not remove ligands that were present in both databases 
(“overlap”).  An  overview  over  the  average  number  of  rotatable  bonds  and  the  average 
molecular weights of the activity classes is given in Table 4.2. Before further procession of 
the data all molecules were neutralized with a script written in the SVL-language of MOE 
[Chemical Computing Group]. 
 
Table 4.2. Average number of rotatable bonds and molecular weight of the activity classes. 
Values in brackets are standard deviations. 
    PDBbind     COBRA  
Activity 
class 
   Rotatable 
bonds 
Molecular 
weight 
  Rotatable 
bonds 
Molecular 
weight 
ACHE    6.7 (5.8)  334 (116)    8.2 (4.5)  253 (81) 
CAII    7.2 (3.5)  321 (84)    7.3 (3.0)  366 (100) 
ELA    16.4 (3.2)  545 (60)    10.9 (4.2)  431 (126) 
FXA    11.0 (5.3)  435 (29)    12.0 (5.7)  489 (82) 
HIVP    21.7 (9.7)  637 (116)    19.3 (6.2)  614 (116) 
NEU    12.9 (1.4)  305 (20)    12.6 (7.7)  320 (130) 
PTK-CSRC    24.9 (3.4)  557 (64)    7.6 (3.2)  444 (80) 
PTP1B    6.0 (0.0)  277 (34)    10.2 (6.4)  464 (150) 
STRO1    12.9 (6.4)  487 (108)    17.1 (5.6)  489 (106) 
THR    10.7 (5.0)  423 (125)    15.4 (5.1)  500 (107) 
UTPA    6.6 (1.9)  294 (86)    10.2 (5.8)  165 (116) 
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4.2.1 Calculation of conformations for the PDBbind dataset and the 
COBRA database 
Conformations  were  calculated  for  the  selected  reference  molecules  from  the  PDBbind 
database  and  all  molecules  from  the  COBRA  database.  For  each  database  single 
conformations  were  calculated  with  CORINA.  To  restrict  the  number  of  possible  output 
conformations from ROTATE only the five most central rotatable bonds were subjected to 
torsion angle variation, and conformations with an internal (symbolic) energy of more than 
100 kJ/mol above the lowest-energy conformation were rejected. The resulting conformations 
were classified after the calculation in torsion angle space by applying different thresholds to 
further reduce the number of conformers. 
 
 
 
Figure 4.2. The torsion angle. a) – f) Example of the torsion angle variation of the central 
rotatable bond of butane in steps of 60°. b), d) and f) correspond to minima in the torsion 
energy;  a),  c)  and  f)  correspond  to  unfavorable  states  with  maxima  in  the  torsion  angle 
energy. g) illustrates the five innermost rotatable bonds of the Factor Xa inhibitor Fxv673 
(Roman letters at the bonds in dark grey), that were used for the conformation generation with 
ROTRATE. 
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Table 4.3. Average number of conformations per molecule calculated for 11 activity classes. 
Multiple conformations were calculated with the following thresholds for the classification in 
torsion angle space: R1: 120 °, R2: 60° and R3: 45°. 
 
    PDBbind    COBRA 
Activity 
class 
  R1  R2  R3    R1  R2  R3 
ACHE    1.7  10.7  19.2    1.5  10.7  20.8 
CAII    3.5  18.9  31.3    3.1  22.0  38.9 
ELA    3.8  34.9  51.5    2.8  27.0  54.9 
FXA    3.8  38.4  69.0    3.9  32.8  59.4 
HIVP    2.9  30.1  56.4    2.8  28.9  51.4 
NEU    2.0  24.5  45.1    2.4  19.0  35.2 
PTK-CSRC    2.6  26.7  48.0    4.0  21.9  41.4 
PTP1B    4.0  14.6  25.6    3.2  25.4  46.9 
STRO1    3.4  35.4  64.9    3.2  31.0  55.6 
THR    3.5  26.5  49.6    3.4  34.3  63.6 
UTPA    3.3  11.0  19.2    3.3  22.8  48.0 
Average    3.1  24.7  43.6    3.1  25.1  46.9 
 
 
For the final classification we used torsion angle thresholds of 120° (resulting database further 
referred to as R1), 60° (R2) and 45° (R3). Table 4.3 gives an overview over the average 
number of conformations that were calculated per molecule for the different activity classes of 
both  datasets.  On  average  approximately  three  conformations  were  generated  for  each 
molecule in the R1 datasets, roughly 25 conformations in the R2 and about 45 conformations 
per molecule in the R3 datasets. For some of the activity classes (e.g. PTP1B, UTPA) the 
number of conformations differed significantly between the reference dataset and the COBRA 
database. Since the number of possible conformations is mainly determined by the number 
bonds which were rotated, this difference indicates that the topological similarity between the 
entries of these classes was low. 
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Table  4.4.  Average  best  RMSD  of  the  calculated  conformations  to  the  reference 
conformations  of  the  PDBbind  molecules.  Improvements  are  given  for  usage  of  multiple 
conformations in comparison to the RMSD obtained with a single CORINA conformation. 
The  improvement  I  (Rx,  x=1,2,3)  was  calculated  by  RMSD  (CORINA  conformation)  / 
RMSD (best Rx conformation). Values in brackets are standard deviations. 
    RMSD in Å     Improvement over 
CORINA  
Activity 
class 
  CORINA  R1  R2  R3    I (R1)  I (R2)  I (R3) 
ACHE    1.5 (1.8)  1.1 (1.2)  0.7 (0.7)  0.7 (0.8)    1.4  2.1  2.0 
CAII    1.1 (0.4)  0.9 (0.4)  0.8 (0.4)  0.8 (0.4)    1.2  1.4  1.5 
ELA    2.2 (0.4)  1.6 (0.3)  1.4 (0.4)  1.3 (0.4)    1.4  1.6  1.7 
FXA    2.0 (0.4)  1.7 (0.4)  1.0 (0.2)  0.8 (0.2)    1.2  2.1  2.5 
HIVP    3.1 (0.8)  2.6 (0.9)  2.2 (0.7)  2.1 (0.7)    1.2  1.4  1.5 
NEU    1.0 (0.6)  1.2 (0.4)  0.8 (0.5)  0.8 (0.5)    0.9  1.3  1.3 
PTK-CSRC    2.2 (0.5)  2.2 (0.2)  1.8 (0.1)  1.8 (0.1)    1.0  1.2  1.2 
PTP1B    0.9 (0.2)  0.5 (0.1)  0.4 (0.1)  0.4 (0.0)    1.6  2.1  2.4 
STRO1    2.1 (0.8)  1.5 (0.7)  1.2 (0.6)  1.2 (0.6)    1.4  1.7  1.8 
THR    1.9 (0.9)  1.4 (0.8)  1.2 (0.7)  1.1 (0.7)    1.4  1.6  1.7 
UTPA    0.9 (0.5)  0.5 (0.4)  0.4 (0.3)  0.4 (0.2)    1.7  2.3  2.4 
Average    1.7 (0.7)  1.4 (0.6)  1.1 (0.6)  1.0 (0.5)    1.3 
 (0.2) 
1.7  
(0.4) 
1.8  
(0.5) 
 
 
4.2.2 Reproducing the crystal-structure conformations of reference 
ligands 
In order to assess the reproduction of the receptor-bound conformations of the PDBbind 
reference  ligands  we  calculated  the  RMSD  value  of  all  generated  conformations  to  their 
corresponding experimentally determined geometry. The results of the calculation are shown 
in Table 4.4. In a recent publication [Boström, 2002] an RMSD of less than 0.5 Å to the 
reference conformation was considered as a successfully reproduced conformation. According 
to this threshold, only for two activity classes (PTP1B, UTPA) the bioactive conformation 
could be reproduced, even with the R3 database containing the largest number of calculated 
conformations. Applying a less stringent RMSD criterion of 1 Å, the CORINA conformations Main Section  67 
already reproduced the bioactive conformation for three of the eleven activity classes (NEU, 
PTP1B, UTPA). For six activity classes the bioactive conformation could be reproduced in 
the R3 database. The best RMSD values were found for PTP1B and UTPA, the two classes 
with the minimum of rotatable bonds of 6 and 6.5 on average (Table 4.2), using the maximum 
of conformations. Only for two classes RMSD values higher than 1.3 Å were obtained: for 
HIVP and PTK-CSRC, the two classes with the largest number of rotatable bonds (21.7 for 
HIVP,  24.9  for  PTK-CSRC).  Interestingly,  the  largest  improvement  using  more 
conformations could be obtained for Factor Xa inhibitors (FXA) which have 11 rotatable 
bonds  on  average  (Table  4.2).  For  UTPA  and  PTP1B  the  second-  and  the  third-best 
improvement were found. The smallest improvement was obtained for PTK-CSRC, which is 
probably caused by the fact that not all rotors were processed for the generation of multiple 
conformations and these two classes had the most additional bonds that were not rotated. 
 
 
 
Figure 4.3. Superposition of the CORINA conformation (red) and the best R3 conformation 
(green) of the Factor Xa inhibitor Fxv673 (PDB code 1KSN) to the reference conformation 
from the crystal structure. 
 
 
An  example  of  the  Factor  Xa  inhibitor  Fxv673  (PDB  code  1KSN)  CORINA 
conformation (red) and the best R3 conformation (green) superimposed onto the reference is 
shown in Figure 4.3. The bound ligand conformation has a central kink that is not found in the 
geometrically more stretched CORINA conformation (RMSD = 2.3 Å). The best ROTATE 
conformation  reproduced  the  kink  which  resulted  in  an  improved  RMSD  of  1.1  Å. 
Summarizing,  using  more  conformations  resulted  in  a  lower  RMSD,  and  in  most  cases 
conformations were found close to the receptor-bound conformation.  Chapter 4  68 
 
4.2.3 Retrospective screening 
In order to determine the impact of multiple conformations on 3D similarity searching the 
presumable “bioactive” conformations of the reference ligands selected from the PDBbind 
database were used to screen the COBRA database for ligands with similar biological activity. 
The  results  of  the  retrospective  screening  experiments  are  compiled  in  Table  4.5.  Most 
reference classes were able to significantly enrich the first percent of the ranked database with 
molecules from the same activity class. Surprisingly, for PTK-CSRC and PTP1B no actives at 
all were found in the top 1% of the ranked database. In comparison to the other activity 
classes  significant  differences  in  the  average  number  of  rotatable  bonds  and  the  average 
molecular weight of the reference molecules and the molecules from the COBRA database 
can be found (Table 4.2). This indicates that the ligand sets from the two databases differed 
from  each  other  and  were  therefore  not  considered  as  “similar”  by  the  virtual  screening 
method.  
For  probing  the  impact  of  multiple  conformations  for  similarity  searching  with 
CAT3D  correlation  vectors  we  were  interested  in  the  improvement  of  using  multiple 
conformations over single conformations and not just in the overall performance of  each 
class. Interestingly, while significant improvement was observed for several of the activity 
classes, on average no significant improvement in the enrichment factor was observed when 
multiple conformations were incorporated. The largest improvement was observed for FXA 
and THR yielding an enrichment factor of 1.8 for R2 and R3, respectively. For the other 
activity classes much smaller improvements were detected.  For ACHE even a significant 
deterioration was observed. In all cases no large difference in the ef between R2 and R3 was 
observed. 
Furthermore, no obvious correlation between the improvement of the RMSD from 
Table 4.4 and the improvement in similarity searching (Table 4.5) was found. Figure 4.4 
shows the plots of the enrichment factors versus the best RMSD values to the receptor-bound 
(bioactive) conformation found in the various conformational ensembles (single CORINA 
conformation, R1, R2, and R3) for the different activity classes. For example for UTPA, for 
which the RMSD could be largely improved for the PDBbind dataset, the usage of multiple 
conformations for COBRA led only to a small improvement for R3. On the other hand, FXA 
resulted in the largest improvement in both RMSD and in enrichment. HIVP and STRO1, the 
two  classes  with  the  most  rotatable  bonds  in  the  COBRA  dataset,  showed  nearly  no 
improvement for R3. In R1 both classes even showed a small deterioration in the ef. This is Main Section  69 
likely to be due to the rotation of only the five innermost rotatable bonds in the molecules. 
This limitation seems to prevent the reproduction of the crystal structure, i.e. the presumably 
“bioactive”  conformation.  This  substantiates  the  observation  in  the  previous  experiment 
where the two classes with more than 20 rotatable bonds resulted in the two largest RMSD 
values (HIVP and PTK-CSRC in Table 4.4). Regarding the ef values, both HIVP and STRO1 
performed well, even with a single conformation. In contrast, THR, which ranked third in the 
number  of  rotatable  bonds  in  the  COBRA  database,  improved  significantly  with  more 
conformations (Table 4.5, Figure 4.3). For ELA with an average number of 11.9 rotatable 
bonds in the COBRA database (Table 4.2), the enrichment did not increase although the 
RMSD  to  the  receptor-bound  conformation  was  lowered  from  2.2  Å  (CORINA  single 
conformation) to 1.3 Å (R3 database).  
 
Table 4.5. Result of the retrospective screening of the COBRA database with the PDBbind 
reference structures. Enrichment factors were calculated for the first percent of the ranked 
databases. The improvement I (Rx, x=1,2,3) was calculated by ef (best Rx conformation) / ef 
(CORINA conformation. Values in brackets are standard deviations.  
    Enrichment factor    Improvement over 
CORINA 
Activity 
class 
  CORINA  R1  R2  R3    I (R1)  I (R2)  I (R3) 
ACHE    5.1 (4.0)  2.5 (3.9)  1.3 (3.1)  1.3 (3.1)    0.5  0.3  0.3 
CAII    3.8 (4.0)  4.5 (3.9)  4.6 (4.0)  4.6 (4.7)    1.2  1.2  1.2 
ELA    1.6 (4.4)  1.6 (4.4)  1.6 (4.4)  1.6 (4.4)    1.0  1.0  1.0 
FXA    4.8 (2.4)  7.0 (2.3)  8.5 (2.3)  8.7 (2.5)    1.5  1.8  1.8 
HIVP    12.2 (11.8)  11.4 (11.2)  13.2 (13.1)  13.3 (13.3)    0.9  1.1  1.1 
NEU    22.2 (10.5)  21.3 (11.0)  23.5 (10.0)  22.1 (10.3)    1.0  1.1  1.0 
PTK-CSRC    0.0 (0.0)  0.0 (0.0)  0.0 (0.0)  0.0 (0.0)    -  -  - 
PTP1B    0.0 (0.0)  0.0 (0.0)  0.0 (0.0)  0.0 (0.0)    -  -  - 
STRO1    9.0 (8.9)  6.7 (7.2)  8.2 (9.0)  9.0 (10.7)    0.7  0.9  1.0 
THR    2.9 (3.7)  4.0 (4.8)  5.2 (5.8)  5.3 (5.8)    1.4  1.8  1.8 
UTPA    4.9 (5.8)  6.6 (8.4)  6.2 (8.9)  6.0 (8.9)    1.3  1.3  1.2 
Average    6.0 (6.5)  6.0 (6.1)  6.6 (6.9)  6.5 (6.6)    1.1 
 (0.3) 
1.1 
 (0.4) 
1.1  
(0.4) 
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Figure 4.4. Enrichment factors, ef (cf. Table 4.5), versus the best RMSD values, obtained 
with the four conformational ensembles (CORINA, R1, R2, and R3; cf. Table 4.4) for each of 
the activity classes. ACHE: acetylcholinesterase, CAII: carbonic anhydrase II, ELA: elastase, 
FXA: factor Xa, HIVP: HIV-protease, NEU: neuraminidase, PTK-CSRC: protein tyrosine 
kinase c-src, PTP1B: protein tyrosine phosphatase 1b, STRO: stromelysin 1, THR: thrombin, 
UTPA: urokinase type plasminogen activator. 
 
 
To find an explanation for the low impact of multiple conformations on similarity 
searching, we further investigated the Manhattan distances of the molecules obtained from 
different  conformational  samplings  to  the  reference  molecules.  In  Table  4.6  the  average 
Manhattan distances from the best scoring conformations of all active molecules from the 
COBRA database to the reference molecules are given. Only an average improvement of 1.1 
was found using R3 in comparison to the COBRA conformations. For comparison the average 
Manhattan distances of the 10 best scoring inactives from each virtual screening experiment 
to the respective reference molecular descriptor are given in Table 4.7. Again an average 
improvement of 1.1 was found using R3 instead of single COBRA conformations. For ACHE 
no improvement was found for the active molecules but a small improvement of 1.1 (I(R3)) Main Section  71 
was found for the inactives. This explains the decreased enrichment factor for ACHE using 
multiple conformations.  
 
Table 4.6. Average Manhattan distances of the actives from the COBRA database to the 
reference  molecules  from  the  PDBbind  database.  The  improvement  I  (Rx,  x=1,2,3)  was 
calculated by average distance (Rx) / average distance (CORINA). Values in brackets are 
standard deviations.  
 
    Average Manhattan distance to the reference 
molecules 
  Improvement over 
CORINA 
Activity 
class 
  CORINA  R1  R2  R3    I (R1)  I (R2)  I (R3) 
ACHE    9.5 (3.8)  9.4 (3.8)  9.2 (3.8)  9.2 (3.8)    1.0  1.0  1.0 
CAII    10.3 (3.2)  10.0 (3.1)  9.7 (3.1)  9.6 (3.1)    1.0  1.1  1.1 
ELA    10.7 (2.4)  10.3 (2.2)  10.0 (2.2)  9.9 (2.2)    1.0  1.1  1.1 
FXA    12.4 (3.5)  11.9 (3.5)  11.4 (3.4)  11.3 (3.5)    1.0  1.1  1.1 
HIVP    15.3 (4.4)  14.9 (4.4)  14.2 (4.5)  14.1 (4.5)    1.0  1.1  1.1 
NEU    9.9 (2.8)  9.6 (2.7)  9.3 (2.7)  9.2 (2.7)    1.0  1.1  1.1 
PTK-CSRC    13.2 (2.7)  12.6 (2.6)  12.0 (2.5)  11.9 (2.5)    1.0  1.1  1.1 
PTP1B    14.4 (3.9)  13.7 (4.0)  13.1 (4.1)  13.0 (4.1)    1.1  1.1  1.1 
STRO1    19.8 (4.8)  19.0 (4.8)  18.7 (4.8)  18.7 (4.8)    1.0  1.1  1.1 
THR    12.7 (3.5)  12.3 (3.3)  12.0 (3.2)  12.0 (3.1)    1.0  1.1  1.1 
UTPA    11.1 (4.0)  10.8 (3.9)  10.5 (3.8)  10.5 (3.8)    1.0  1.1  1.1 
Average    12.7 (3.0)  12.2 (2.8)  11.8 (2.8)  11.8 (2.8)    1.0 
 (0.0) 
1.1 
 (0.0) 
1.1  
(0.0) 
 
 
4.2.4 Conclusion 
Investigating the impact of multiple conformations on 3D similarity searching with CATS3D, 
it was demonstrated that using only a single conformation per molecule already resulted in 
significant enrichment of actives. This observation was also made for ligand classes with 
many rotatable bonds. On average these results did not significantly improve using multiple 
conformations. Nevertheless, for some classes of molecules considerable improvement in the 
enrichment of active molecules was observed. Furthermore, no clear correlation between the Chapter 4  72 
improvement of the enrichment factor and the improvement of the RMSD to the bioactive 
conformation  could  be  derived  when  screening  with  CATS3D  correlation  vectors.  It  was 
found that the Manhattan distance of single conformations did not change significantly using 
more conformations. This was observed for molecules with the same activity as well as for 
false-positives. Since the calculation of multiple conformations is computationally expensive 
it  seems  to  be  preferential  to  use  single  conformations  for  large  databases,  e.g.  virtual 
combinatorial libraries, for a first-pass virtual screen. Single conformations can be computed 
efficiently with CORINA, even for large databases. In a second screening round, e.g. with 
smaller  databases  or  flexible  ligands,  it  can  be  worthwhile  considering  multiple 
conformations. 
 
Table 4.7. Average Manhattan distances of the best inactives from the COBRA database to 
the references molecules from the PDBbind database. The 10 best scoring inactive molecules 
from each retrospective screening experiment were used as inactives. The improvement I (Rx, 
x=1,2,3) was calculated by average distance (Rx) / average distance (CORINA). Values in 
brackets are standard deviations. 
    Average Manhattan distance to the reference 
molecules 
  Improvement over 
CORINA 
Activity 
class 
  CORINA  R1  R2  R3    I (R1)  I (R2)  I 
(R3) 
ACHE    5.7 (2.7)  5.3 (2.6)  5.1 (2.6)  5.0 (2.6)    1.1  1.1  1.1 
CAII    5.5 (1.9)  5.3 (1.9)  5.1 (1.9)  5.1 (1.9)    1.0  1.1  1.1 
ELA    6.2 (1.5)  5.8 (1.4)  5.4 (1.4)  5.3 (1.4)    1.1  1.1  1.2 
FXA    7.8 (2.2)  7.6 (2.1)  7.3 (2.1)  7.2 (2.2)    1.0  1.1  1.1 
HIVP    10.5 (3.4)  10.1 (3.3)  9.6 (3.2)  9.5 (3.2)    1.0  1.1  1.1 
NEU    7.2 (1.1)  7.0 (1.0)  6.5 (1.1)  6.4 (1.1)    1.0  1.1  1.1 
PTK-CSRC    7.9 (2.0)  7.5 (2.1)  7.1 (1.9)  7.0 (1.9)    1.1  1.1  1.1 
PTP1B    7.5 (2.6)  7.2 (2.6)  6.8 (2.5)  6.7 (2.4)    1.0  1.1  1.1 
STRO1    14.8 (4.0)  14.4 (3.9)  13.8 (4.0)  13.7 (3.9)    1.0  1.1  1.1 
THR    6.3 (0.6)  6.2 (0.6)  6.0 (0.6)  5.9 (0.6)    1.0  1.1  1.1 
UTPA    5.1 (1.5)  4.9 (1.4)  4.7 (1.4)  4.7 (1.4)    1.0  1.1  1.1 
Average    7.7 (2.8)  7.4 (2.7)  7.0 (2.6)  7.0 (2.6)    1.0 
 (0.0) 
1.1  
(0.0) 
1.1  
(0.0) 
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4.3 Virtual  screening  and  scaffold  hopping  efficiency  of 
alignment-free pharmacophore pair descriptors 
Manipulating  living  systems  at  the  molecular  level  requires  profound  knowledge  of  the 
variability of small molecule effectors that provoke a particular cellular response. Medicinal 
chemistry relies on libraries of molecular probes that can be rationally designed to contain a 
desired degree of chemotype diversity. Despite great advances in the field of virtual screening 
and  rational  compound  library  design,  “scaffold-hopping”  remains  a  challenging  goal 
[Schneider & Fechner, 2005]. The concept of scaffold-hopping aims at finding isofunctional 
but structurally dissimilar molecular entities [Schneider et al., 1999, Schneider et al., 2000; 
Böhm et al., 2004, Jenkins et al., 2004]. Ideal screening methods that perform successful 
scaffold-hops would not only find a maximum number but also a maximally diverse set of 
active  compounds  from  a  given  chemical  subspace.  Only  until  recently,  the  focus  in  the 
development  and  evaluation  of  virtual  screening  methods  has  often  been  purely  on  the 
retrieval of large numbers of “active” molecules -- irrespective of the number of retrieved 
chemotypes. This has led to the impression that methods employing a low level of abstraction 
from  the  molecular  structure,  e.g.  substructure  fingerprints,  are  among  the  most  efficient 
ligand-based  virtual  screening  methods  [Brown  &  Martin,  1996;  Hert  et  al.,  2004b].  In 
contrast  to  substructure-based  molecular  descriptors,  pharmacophore  models  and 
physicochemical  metrics  represent  a  comparably  high  level  of  abstraction  from  chemical 
structure.  Consequently,  such  methods  have  been  employed  for  screening  library  design 
relying on their scaffold-hopping potential [Schneider et al., 1999; Schneider et al., 2000; 
Matter, 1997; Nærum et al., 2002]. In this study we compared the scaffold-hopping efficiency 
of  similarity  searching  with  topological,  three-dimensional  and  molecular  surface-based 
pharmacophore pair descriptors and a substructure fingerprint method. 
Similarity searching is founded on the similarity principle which states that similar 
molecules exhibit similar biological effects [Johnson & Maggiora, 1990]. A straightforward 
approach for similarity searching is to compare the connection tables to assess the similarity 
between two molecules. Such methods include  substructure  fingerprints like the MACCS 
keys  [MDL  Information  Systems]  which  are  based  on  exact  chemical  substructures. 
Substructure matching approaches were reported to be among the most successful for virtual 
screening [Brown & Martin, 1996; Hert et al., 2004b]. The classification of intermolecular 
interactions into general pharmacophore types provides a means to obtain a more general 
description of the underlying chemotypes of molecules [Schneider et al., 2000; Mason & Chapter 4  74 
Good,  2001].  Three  such  descriptors  were  employed  in  this  work:  the topological  CATS 
descriptor  [Schneider  et  al.  1999;  Fechner  et  al.,  2003],  the  three-dimensional  CATS3D 
descriptor, and the molecular surface based SURFCATS descriptor.  
Molecular representations that are grounded on three-dimensional conformations like 
molecular  surface-based  descriptors  are  independent  from  the  molecular  connectivity  and 
should have a favorable scaffold-hopping potential [Bender & Glen, 2004; Clark, 2004]. For 
comparison  with  a  conceptually  different  descriptor  the  MACCS  keys  were  used  as 
implemented in MOE. 
To assess the degree of scaffold-hopping, one must define the term “scaffold”. Here, 
we followed the concept of Xu and Johnson employing the software suite Meqi [Pannanugget 
Consulting L. L. C.], which has recently been devised for the analysis of chemical libraries 
[Xu & Johnson, 2001; Xu & Johnson, 2002]. Two different definitions of a scaffold were 
applied: cyclic system (“Scaffold”, Sc) and reduced cyclic system (“Reduced Scaffold, ReSc) 
(Figure  2.6).  In  Meqi,  each  molecular  topology  is  specified  by  a  particular  molecular 
equivalence index (meqi) which is used to distinguish between different scaffolds and reduced 
scaffolds. 
Ligands from ten different target classes from the COBRA database [Schneider & 
Schneider,  2003]  of  annotated  ligands  were  used  as  reference  for  retrospective  virtual 
screening: angiotensin converting enzyme (ACE, 44 compounds, 28 scaffolds, 17 reduced 
scaffolds),  cyclooxygenase  2  (COX2,  94,  27,  14),  corticotropin  releasing  factor  (CRF 
antagonists, 63, 33, 23), dipeptidyl-peptidase IV (DPP, 25, 13, 7), human immunodeficiency 
virus protease (HIVP, 58, 46, 31), matrix metalloproteinase (MMP, 77, 47, 19), neurokinin 
receptors (NK, 118, 65, 49), peroxisome proliferator-activated receptor (PPAR, 35, 29, 17), 
beta-amyloid converting enzyme (BACE, 44, 13, 12), and thrombin (THR, 188, 100, 36). 
According to the number of scaffolds and reduced scaffolds in relation to the number of 
molecules the datasets range from sets with a low scaffold diversity (e.g. COX2) to sets with a 
large  relative  scaffold  diversity  (e.g.  PPAR,  HIVP).  The  complete  COBRA  database 
contained  1,628  different  scaffolds  and  637  distinct  reduced  scaffolds.  For  retrospective 
screening each molecule from each target class was taken iteratively as the reference molecule 
for a virtual screening experiment, where all other molecules were ranked according to their 
similarity to the reference molecule. For quantification of “similarity” three similarity indices 
were employed: Manhattan distance, Euclidean distance, and Tanimoto similarity (Table 2.1). Main Section  75 
To  summarize:  For  the  retrospective  screening  experiments  we  employed  ten  different 
datasets,  four  descriptors  (CATS,  CATS3D,  SURFCATS,  MACCS),  and  three  molecular 
representations (atomic, scaffold, and reduced scaffold representation).  
 
 
 
Figure 4.5. Average relative performance for the first 5% over 10 ligand classes from the 
COBRA  database.  Comparison  of  the  performance  of  MACCS,  CATS,  CATS3D  and 
SURFCATS  for  molecules,  scaffolds  (Sc)  and  reduced  scaffolds  (ReSc).  Three  similarity 
metrics  were  applied:  the  Tanimoto  similarity,  the  Euclidean  distance  and  the  Manhattan 
distance. 
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The average relative performance of the four methods for the first 5% of the database 
over the ten activity classes is summarized in Figure 4.5. The relative performance of one 
particular method within one activity class was defined as the ef yielded with this method 
divided by the average ef of the four methods (using the same similarity index). The influence 
of  different  similarity  indices  on  the  overall  enrichment  was  low,  for  most  parts 
indistinguishable within the standard deviations. For all molecular representations the order of 
the methods in terms of the enrichment factors for the top 5% of the hit-lists was found to be 
MACCS > CATS > CATS3D = SURFCATS when looking at the average values only. With 
regard  to  the  enrichment  of  scaffolds  and  reduced  scaffolds  CATS,  CATS3D  and 
SURFCATS slightly improved in comparison to the MACCS keys.  
 
Table  4.8.  Enrichment  factors  of  different  molecular  representations  (“Molecules”, 
“Scaffolds”, “Reduced Scaffolds”) over the activity classes. ef values are given for the first 
1% and 5% of the hit-lists. The Tanimoto coefficient was used to rank the molecules.  
 
  Molecules 
% DB  MACCS  CATS  CATS3D  SURFCATS 
ACE         
1  22 (11)  23 (13)  20 (13)  21 (15) 
5  9 (4)  11 ( 5)  7 ( 4)  8 ( 4) 
COX2         
1  27 (17)  14 ( 9)  22 (13)  19 (11) 
5  11 (6)  5 ( 3)  9 ( 4)  8 ( 4) 
CRF         
1  28 (15)  13 ( 8)  20 (11)  16 (10) 
5  12 (4)  7 ( 3)  10 ( 3)  9 ( 3) 
DPP         
1  21 (14)  12 ( 9)  15 (13)  13 (10) 
5  6 (4)  4 ( 4)  4 ( 3)  3 ( 2) 
HIVP         
1  14 ( 7)  24 (11)  19 (10)  20 (11) 
5  6 (2)  11 ( 3)  9 ( 4)  9 ( 4) 
MMP         
1  13 ( 9)  12 ( 7)  13 ( 8)  12 ( 9) 
5  5 (3)  5 ( 2)  5 ( 3)  5 ( 3) 
NK         
1  9 ( 6)  8 ( 4)  15 ( 8)  9 ( 6) 
5  5 (2)  5 ( 2)  7 ( 3)  5 ( 3) 
PPAR         
1  17 (17)  17 (12)  8 ( 8)  10 ( 8) 
5  5 (4)  6 ( 3)  3 ( 3)  4 ( 2) 
BACE         
1  13 (10)  12 (10)  11 ( 9)  6 ( 5) 
5  6 (4)  4 ( 3)  4 ( 3)  3 ( 2) 
THR         
1  12 ( 6)  14 ( 7)  9 ( 5)  8 ( 5) 
5  6 (2)  9 ( 4)  5 ( 2)  5 ( 3) 
((continued below)) 
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    Scaffolds    Reduced Scaffolds 
% DB    MACCS  CATS  CATS3D  SURFCATS    MACCS  CATS  CATS3D  SURFCATS 
ACE                     
1    22 (11)  27 (12)  21 (11)  20 (10)    25 (12)  29 (12)  23 (10)  22 ( 8) 
5    9 (3)  12 ( 3)   7 ( 2)   8 ( 3)     9 (3)  11 ( 3)   8 ( 3)   8 ( 2) 
COX2                     
1    27 (15)  16 ( 8)  23 ( 9)  21 (10)    33 (15)  20 (10)  25 (10)  26 (11) 
5    10 (4)   5 ( 2)   8 ( 3)   8 ( 3)    10 (3)   6 ( 2)   8 ( 2)   9 ( 3) 
CRF                     
1    24 (12)  16 (10)  22 (12)  17 (10)    28 (13)  19 (11)  23 (11)  19 (12) 
5    11 (4)   7 ( 4)  10 ( 3)   9 ( 3)    11 (4)   7 ( 3)   9 ( 3)   8 ( 3) 
DPP-IV                     
1    21 (13)  12 ( 8)  16 (12)  14 (12)    24 (12)  18 (11)  23 (15)  20 (16) 
5     7 (4)   6 ( 5)   4 ( 3)   4 ( 2)     9 (5)   7 ( 4)   6 ( 4)   5 ( 3) 
HIVP                     
1    15 ( 8)  26 (13)  22 (12)  23 (13)    21 (11)  34 (15)  28 (15)  31 (16) 
5     6 (3)  11 ( 4)  10 ( 4)  10 ( 4)     8 (3)  13 ( 4)  11 ( 4)  11 ( 4) 
MMP                     
1    17 (11)  15 ( 9)  16 (11)  16 (12)    24 (14)  24 (12)  24 (13)  23 (13) 
5     6 (3)   6 ( 3)   6 ( 3)   7 ( 4)     8 (3)   8 ( 3)   8 ( 3)   8 ( 4) 
NK                     
1    10 ( 6)   9 ( 4)  16 ( 8)  10 ( 6)    12 ( 6)  11 ( 5)  16 ( 8)  11 ( 7) 
5     5 (2)   5 ( 2)   8 ( 3)   6 ( 3)     6 (2)   6 ( 2)   8 ( 3)   6 ( 3) 
PPAR                     
1    16 (14)  17 (11)   8 ( 8)  10 ( 8)    19 (16)  23 (14)  10 ( 9)  14 (10) 
5     5 (3)   6 ( 3)   3 ( 2)   4 ( 2)     7 (4)   8 ( 3)   4 ( 2)   5 ( 2) 
BACE                     
1    14 ( 9)  14 (10)  12 ( 7)   8 ( 5)    15 ( 9)  16 (11)  13 ( 8)   9 ( 6) 
5     4 (3)   4 ( 2)   4 ( 2)   3 ( 2)     4 (3)   5 ( 3)   4 ( 2)   3 ( 2) 
THR                     
1    15 ( 6)  19 ( 9)  12 ( 7)  11 ( 7)    19 ( 8)  28 (12)  19 ( 9)  18 ( 9) 
5     7 (2)  10 ( 4)   6 ( 3)   6 ( 3)     8 (3)  11 ( 4)   8 ( 3)   7 ( 3) 
 
 
An explanation for the high performance of the MACCS keys in scaffold enrichment 
might be that the connectivity of the substructures is not accounted for by this descriptor. This 
can lead to an effective retrieval of molecules with slightly different scaffolds but similar 
side-chain decoration. Does this finding justify the conclusion that substructure fingerprints 
are best-suited for the purpose of scaffold-hopping? To find an answer to this question, a 
more detailed analysis was performed looking on the enrichment of the individual activity 
classes.  We  calculated  ef  values  for  all  ten  different  classes,  yielded  with  the  Tanimoto 
coefficient (Table 4.8; results for the Manhattan distance and the Euclidean distance can be 
found in Appendix 6.1). None of the descriptors performed generally superior to the other 
descriptors within the error bars. Judging from the average values only, MACCS performed 
best for COX2, CRF, and DPP for full molecules, scaffolds and reduced scaffolds. CATS 
performed  best  for  ACE,  HIVP  and  THR,  and  CATS3D  for  NK  in  all  molecular 
representations.  SURFCATS  was  not  found  to be  best  for  any  one  class.  However,  each 
descriptor of the CATS family was found to be better than the other family members for some 
ligand classes. This underlines the dependence of the descriptor performance on the screening Chapter 4  78 
database. In other words, there is no globally best descriptor. It has to be stressed that this 
interpretation has limited relevance due to the large standard deviations and represents trends 
only. Further investigations with additional descriptors and metrics, and larger high-quality 
drug databases will be needed to scrutinize these findings. 
 
 
 
 
Figure 4.6. Scaffold diversity of the ligand classes. The diversity is given by the number of 
scaffolds (light gray) or reduced scaffolds (dark gray) relative to the number of molecules in a 
data set. With enrichment factors for the first 5% MACCS performed best fort he classes 
COX2,  CRF  and  DPP,  CATS  performed  best  for  the  classes  ACE,  HIVP  and  THR  and 
CATS3D performed best for NK. 
 
 
Figure  4.6  shows  the  fraction  of  scaffolds  and  reduced  scaffolds  found  in  the  ten 
ligand classes. For the classes preferred by MACCS the average fraction of scaffolds was 0.44 
(± 0.13) and the average fraction of reduced scaffolds was 0.27 (± 0.11). For CATS the 
fractions were 0.65 (± 0.13) and 0.37 (± 0.17), and for CATS3D 0.55 and 0.42, respectively. 
One might speculate that MACCS performed best in classes with low numbers of different 
topologies,  i.e.  low  scaffold  diversity.  CATS  and  CATS3D  performed  best  in  classes 
revealing a high degree of scaffold diversity. We conclude that pharmacophore descriptors 
might  be  more  suited  for  designing  diverse  compound  libraries  compared  to  substructure 
fingerprints. Still one must be aware that these results are comparable within the error margin.  Main Section  79 
In  an  earlier  publication  we  reported  that  different  descriptors  are  often  found  to 
retrieve different molecules, despite having equal enrichment factors [Fechner et al., 2003]. In 
the present study we witness a similar situation: descriptors complement each other in the 
retrieval of different scaffolds and reduced scaffolds (Table 4.9).  
 
 
Table 4.9. Overlap of the results for pairs of descriptors in the first 5% of the hit-list. Shown 
are the average numbers over all ten classes of retrieved scaffold representations which were 
found  by  both  methods.  The  numbers  on  the  diagonal  (shown  in  bold)  are  the  average 
numbers of scaffolds found with the respective descriptor. The employed similarity index was 
the Tanimoto coefficient.  
 
Scaffold representations 
 
Descriptor  MACCS  CATS  CATS3D  SURFCATS 
MACCS  13.8       
CATS  8.6  15.4     
CATS3D  8.2  9.3  13.2   
SURFCATS  7.7  8.9  9.8  12.9 
 
Reduced Scaffold representations 
 
Descriptor  MACCS  CATS  CATS3D  SURFCATS 
MACCS  8.9       
CATS  6.1  9.8     
CATS3D  5.8  6.5  8.7   
SURFCATS  5.3  6.1  6.5  8.1 
 
 
Two  of  the  virtual  hit-lists  were  further  investigated:  the  results  for  the  COX-2 
inhibitors celecoxib (Figure 4.7) and rofecoxib (Figure 4.8). For each scaffold class, the best-
ranking hits were surveyed. Although the two reference molecules share a common reduced 
scaffold different scaffold classes were retrieved on different ranking positions. Again, the 
four similarity searching methods differed in their ability to retrieve diverse scaffold which 
results in a complementation of the methods. This outcome is remarkable especially because 
of the striking relatedness of the query structures. 
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Figure 4.7. Best hits for each reduced scaffold obtained with celecoxib. For each descriptor 
the best scored molecule in each reduced scaffold class is shown that was retrieved in the first 
1 % of the ranked database.  
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Figure 4.8. Best hits for each reduced scaffold obtained with rofecoxib. For each descriptor 
the best scored molecule in each reduced scaffold class is shown that was retrieved in the first 
1 % of the ranked database.  Chapter 4  82 
 
The two reduced scaffolds that were found exclusively with the MACCS keys for 
rofecoxib (ReSc classes 6 and 7) reflect that MACCS keys include no direct information of 
the size of the retrieved molecules. These molecules might have been rejected by the other 
methods due to their large size. Large reduced scaffolds were also found with CATS for 
celecoxib (ReSc class 2), which might have resulted from the restriction of the descriptor to a 
maximal path length of 10 bonds. Such a cut-off might be inappropriate for a database with 
potentially long ligands and respective pharmacophores, such as those annotated to HIVP, 
MMP, and PPAR – particularly in prospective screens 
 
4.3.1 Conclusion 
Concluding,  we  found  that  both  substructure  fingerprints  (MACCS)  and 
pharmacophore-pair descriptors (CATS) are suited for retrospective scaffold retrieval. For 
more  diverse  ligand  classes  the  pharmacophore-based  CATS  descriptors  slightly 
outperformed  substructure  (MACCS)  keys  as  an  average  trend.  The  fact  that  structurally 
focused  collections  of  pharmacologically  active  compounds  are  typically  employed  for 
retrospective  screening  studies  might  explain  the  often  found  high  performance  of 
substructure keys or related descriptors. Our results suggest that for the particular purpose of 
scaffold-hopping  a  reasonable  strategy  might  be  to  use  more  generalizing  molecular 
representations like pharmacophore descriptors. The use of several complementing methods 
can also be recommended for the purpose of scaffold hopping. We hope that our study will 
stimulate further investigations on this important topic of medicinal chemistry. 
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4.4 Prospective  screening  for  mGlurR5  allosteric 
modulators with CATS3D 
Allosteric  modulators  for  the  metabotropic  glutamate  receptor  5  are  a  promising  class  of 
molecules  for  addressing  several  disorders  of  the  central  nervous  system  [Hermans  & 
Challiss, 2001]. Being part of the pharmaceutical interesting class of GPCRs, for which rare 
receptor structure information is available, mGluR5 is an ideal target to test ligand based 
virtual screening approaches.  
 
 
 
Figure 4.9. Allosteric mGluR5 antagonists. 
 
 
First  selective  allosteric  antagonists  for  mGluR5,  SIB-1751  (4.4.1)  and  SIB-1893 
(4.4.2),  were  published  in  1999  [Varney  et  al.,  1999].  SIB-1751  was  identified  by  high-
throughput  screening  (HTS),  and  SIB-1893  resulted  from  a  UNITY  search  for  analogues 
[Varney et al., 1999]. In phosphoinositol (PI) hydrolysis assays the two molecules revealed 
IC50 values of 3.1 µM and 2.3 µM, respectively. Chemical variation of SIB-1893 resulted in 
the  much  more  potent  highly  selective  mGluR5  antagonist  2-methyl-6-(phenylethynyl)-
pyridine (MPEP, 4.4.3, Figure 4.9) with an IC50 of 36 nM in PI hydrolysis assays [Gasparini 
et al., 1999]. Several MPEP-analogues (4.4.4–4.4.9, Figure 4.9) [4: Cosford et al., 2003; 5-8: Chapter 4  84 
Mutel et al., 2002; 9: Gasparini et al., 2003] with reported low nanomolar activity have been 
published in the scientific and patent literature since then. Nonetheless, the mode of action of 
these  ligands  is  not  completely  understood.  Recent  publications  of  MPEP  and  MPEP 
derivatives also reported off-target activity [4: Cosford et al., 2003; 5-8: Mutel et al., 2002; 9: 
Gasparini et al., 2003] and a short plasma half life [Anderson et al., 2003]. In particular, the 
latter could be attributed to potential metabolic instability of the ethynyl linker.  
Pharmacophore-based similarity searching has been proven to be suited for finding 
new ligands which exhibit similar biological activity but are based on a different chemical 
scaffold [Böhm & Schneider, 2000]. Using a set of known specific allosteric antagonists of 
mGluR5  (4.4.3-4.4.9)  [Gasparini  et  al.,  1999;  Cosford  et  al.,  2003;  Mutel  et  al.,  2002; 
Gasparini et al., 2003], which were compiled from scientific and patent literature, as a query 
we  applied  a  hierarchical,  ligand-based  virtual  screening  approach  to  identify  novel 
compounds  accomplishing  mGluR5  modulation.  First,  a  “drug-likeness”  estimation  by  an 
artificial neural network system was employed for prescreening to focus only on molecules 
with  a  predicted  “drug-like”  structure  [Schneider  &  Schneider,  2004].  For  subsequent 
similarity searching we used the CATS3D descriptor.  
 
 
 
Figure  4.10.  Flexible  pharmacophore-based  alignment  of  reference  molecules  4.4.3-4.4.9. 
Red: oxygen; blue: nitrogen; yellow: sulfur; gray: carbon. 
 
 
To form a hypothesis about receptor-bound 3D-conformations of 4.4.3-4.4.9 we used 
the flexible alignment tool of MOE (Figure 4.10). Ligands were successively aligned from 
4.4.3 to 4.4.9 and conformations were chosen based on existing knowledge among the best 
ranked results. Molecule 4.4.9 was manually adjusted to fit to the alignment, i.e. the angle Main Section  85 
between the two planes of the ring systems was set to 90° (Merz, unpublished results). These 
individual 3D conformations served as query structures for CATS3D similarity searching. 
In search for new ligands we virtually screened the Asinex Gold compound collection, 
version of April 2003 [ASINEX], which contained 194,563 molecules. As a pre-screening 
filter we selected the 20,000 most “drug-like” compounds as described previously [Schneider 
& Schneider, 2004]. The result of this procedure can be seen, e.g., for the neural network 
prediction: the average drug-likeness score of the complete Asinex Gold collection according 
to the artificial neural network was 0.36 (s = 0.28), for our screening set the score was 0.60 
(s = 0.23) (higher values indicate more “drug-like” molecules).  
3D-conformations  of  the  screening  compounds  were  calculated  in  MOE  using  the 
MMFF94  force  field.  The  results  were  restricted  to  a  maximum  of  20  lowest  energy 
conformations per molecule. Similarity between a database entry and a reference molecule 
was expressed by the Manhattan distance. Separate similarity searches were performed with 
each of the molecules 4.4.3-4.4.9, and 27 of the top-scoring molecules (Figure 4.11) were 
selected for experimental testing. Molecules were chosen which had low Manhattan distances 
to one of the reference molecules and which were not too similar to the previously selected 
molecules, as judged by visual inspection  from a medicinal chemistry  perspective (Table 
4.10).  
 
Table 4.10. Results of virtual screening and the binding assays 
Virtual Screening    Binding Assay 
Molecule 
no. 
Most 
similar 
reference 
molecule 
Rank 
(CATS3D) 
CATS3D 
Manhattan 
distance 
CATS2D 
Manhattan 
distance 
MACCS 
Tanimoto 
similarity 
  Ki mGluR5 
(µM) 
Ki mGluR1 
(µM) 
Selectivity 
(Ki mGluR1 / 
Ki mGluR5) 
10  3  1  0.68  2.85  0.21    24  > 100  > 4.2 
11  3  4  0.88  2.2  0.2    > 100  63  < 0.6 
12  3  5  0.94  5.03  0.17    > 100  41  < 0.4 
13  3  6  0.95  3.79  0.22    > 100  > 100  1 
14  3  7  1.02  2.64  0.17    > 100  > 100  1 
15  3  17  1.12  3.06  0.24    > 100  > 100  1 
16  4  1  1.52  2.54  0.35    > 100  > 100  1 
17  4  3  1.67  5.27  0.22    > 100  > 100  1 
18  4  4  1.67  2.34  0.34    > 100  > 100  1 
19  4  6  1.73  1.88  0.25    > 100  > 100  1 
20  5  3  2.14  1.79  0.42    > 100  > 100  1 
21  5  7  2.22  1.79  0.36    > 100  > 100  1 
22  5  38  2.52  2.66  0.38    41  64  1.6 
23  6  5  1.41  2.23  0.48    33  61  1.8 
24  6  6  1.45  1.91  0.31    12  17  1.5 
25  7  2  1.55  2.69  0.38    35  > 100  > 2.9 
26  7  3  1.56  2.41  0.39    > 100  > 100  1 
27  7  5  1.6  2.62  0.53    > 100  14  < 0.14 
28  8  2  0.79  5.49  0.38    > 100  > 100  1 
29  8  7  0.91  5.37  0.24    > 100  > 100  1 
30  8  9  1  5.37  0.31    40  > 100  2.54 
31  8  12  1.14  4.81  0.28    > 100  > 100  1 
32  8  36  1.3  5.33  0.2    14  45  3.2 
33  9  1  1.49  2.19  0.46    63  > 100  > 1.6 
34  9  2  1.54  1.94  0.45    38  > 100  > 2.7 
35  9  5  1.59  2.59  0.46    > 100  > 100  1 
36  9  7  1.64  6.63  0.46    > 100  > 100  1 Chapter 4  86 
 
 
Figure 4.11. Molecules selected from CATS3D virtual screening. Main Section  87 
To estimate the degree of “scaffold-hopping” we compared the average distance of 
each molecule 4.4.10-4.4.36 to its respective nearest reference (<Dlib>) compound with the 
average distance between the reference molecules 4.4.3-4.4.9 (<Dref>). Three such indices 
were  employed:  the  CATS3D  Manhattan  distance,  the  topological  CATS2D  Manhattan 
distance, and the substructure-based MACCS key Tanimoto similarity from MOE. While the 
average  CATS3D  distance  of  the  library  compounds  to  their  reference  molecules  was 
significantly smaller in comparison to the average distance between the reference molecules 
(<Dlib> = 1.41 (± 0.45); <Dref> = 2.66 (± 0.89)), <Dlib> was only marginally smaller than 
<Dref> for CATS2D (3.31 (± 1.48) vs. 3.6 (± 1.4)). With the MACCS keys <Dlib> was smaller 
than  <Dref>  (0.33  (±  0.11)  vs.  0.39  (±  0.15)),  indicating  a  greater  similarity  among  the 
reference  set  than  between  the  virtual  screening  hits  and  the  reference  molecules.  This 
demonstrates  that  the  compiled  library  contains  scaffolds  which  are  different  from  the 
references  (as  estimated  by  MACCS  substructure  fingerprints)  but  are  still  considered 
isofunctional by the CATS pharmacophore approaches.  
In vitro binding studies for mGluR5 were performed on the basis of a [³H]MPEP 
displacement assay. Estimates of Ki values for the ligands were made from measurements at a 
fixed concentration of 10 µM. Selectivity of the ligands versus mGluR1, the most similar 
receptor to mGluR5 within the mGluR family,
 was assessed by a displacement assay with the 
Merz proprietary selective mGluR1 antagonist MRZ 3415. Nine molecules (4.4.10, 4.4.22, 
4.4.23, 4.4.24, 4.4.25, 4.4.30, 4.4.32, 4.4.33, 4.4.34) exhibited a Ki value below 70 µM for 
mGluR5 (Table 4.10), with structure 4.4.10 being the most selective inhibitor. With our assay 
system we determined a Ki of 12.5 nM for MPEP on mGluR5. 
The  predicted  rank-order  of  the  tested  library  compounds  does  not  correlate  with 
binding affinity (Table 4.10). It is evident that the Manhattan distance, which was used for 
compound prioritization, does not distinguish between molecular attributes that are relevant or 
irrelevant for a particular receptor-ligand interaction. Furthermore, the small list of virtual hits 
that was compiled for each reference molecule prevents a sound statistical evaluation.
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Figure  4.12.  Flexible  alignment  of  the  most  potent  found  mGluR5  modulators  to  the 
alignment of reference molecules 4.4.3-4.4.9 (green). Alignments are shown for (a) 4.4.23, 
4.4.24, 4.4.25, 4.4.32, (b) 4.4.10, (c) 4.4.33, 4.4.34, (d) 4.4.22.  
 
 
The best found nine molecules were aligned to the reference molecule alignment with 
the MOE flexible alignment tool (Figure 4.12). 4.4.23, 4.4.24, 4.4.25, 4.4.32 fitted well into 
the reference alignment (Figure 4.12a) with the keto-group of each molecule superposed onto 
the pyridine nitrogen as a hydrogen-bond acceptor substitute, and the various linker moieties 
aligned to the triple bond linkers of the MPEP derivatives. For 4.4.30 a comparable binding 
mode might be anticipated, which was not found by the flexible alignment since MOE did not 
recognize the oxazolidine oxygen of 4.4.30 as a potential hydrogen-bond acceptor. Based on 
the  alignment  it  cannot  be  decided  whether  molecules  4.4.10,  4.4.33,  4.4.34  and  4.4.22 
(Figure 4.12b-d) were actually aligned in a reasonable fashion. For these molecules large 
substructure elements were placed in the MPEP linker region which we assume to bind to into 
a narrow part of the receptor binding pocket. To our surprise 4.4.28 and 4.4.31 -- analogs of 
ligands 4.4.10 and 4.4.30 – showed to be inactive. For both molecules this effect might be 
explained by steric restrictions in the receptor. Main Section  89 
The selectivity of the hits was low. Compound 4.4.27 was even found to be a potent 
and selective binder of mGluR1. This might indicate the existence of similar binding pockets 
in both receptor subtypes. Overlap of the binding pockets for antagonists of both receptor 
subtypes has already been shown [Pagano et al., 2000].
 Similar binding pockets are further 
supported by the weaker mGluR1 selective binder 4.4.11, which is similar to 4.4.23, 4.4.24 
and 4.4.25. These are more selective towards mGluR5. Compound 4.4.14 was inactive in both 
mGluR1 and mGluR5 binding studies, although it might be regarded as a close analogue of 
4.4.11. A higher selectivity of the compounds might be achieved by incorporation of selective 
molecules acting on mGluR1 in the virtual screening procedure. These might be used as an 
anti-target in additional similarity searching experiments. Molecules with a high similarity to 
mGluR5 ligands and a low similarity to mGluR1 ligands might exhibit a better selectivity 
profile.  
A  challenging  goal  of  pharmacophore-based  similarity  searching  is  “scaffold-
hopping”. This aim was clearly met in this study. Isofunctional alternatives to the MPEP 
scaffold were found, which provide several starting points for lead structure development. As 
an important outcome, the metabolically unstable triple-bond linker present in the MPEP-
derived reference molecules is substituted by various alternatives in the compounds that were 
selected  by  virtual  screening.  Noteworthy,  the  double-bond  linker  of  4.4.23,  4.4.24,  and 
4.4.32 is structurally identical to the one present in SIB-1893 and similar to the linker type of 
SIB-1757, both of which were not present in the reference collection (Figure 4.9). Some of 
the tested compounds (4.4.12, 4.4.13, 4.4.15) resemble structural similarity to the recently 
reported mGluR5 antagonist 4.4.37 [Wang et al., 2004] (Figure 4.13), that was found by HTS. 
This  further  underlines  the  ability  of  the  CATS3D  approach  to  find  isofunctional  but 
structurally different scaffolds. Molecule 4.4.38, a recently reported mGluR5 antagonist with 
a tetrazole linker (Figure 4.13) [Roppe et al., 2004], shows that more voluminous groups like 
in 4.4.22 might also be allowed in the linker region, assuming an identical binding mode. The 
novel  scaffolds  of  compounds  4.4.33  and  4.4.34  present  a  promising  opportunity  for 
straightforward combinatorial design with the aim to significantly improve binding behavior. 
One possible reason for the low selectivity of 4.4.23, 4.4.24, 4.4.25 and 4.4.32 might 
be due to the replacement of the SIB-1893 pyridine by a keto-group. While the hydrogen-
bond acceptor functionality of the pyridine is maintained, the substitution results in a loss of 
possible steric and stacking interactions. These findings indicate that the receptor subtype 
selectivity  of  MPEP-like  mGluR5  antagonists  might  be  based  on  steric  or  π-π  stacking 
interactions mediated by the pyridine ring. Reference molecule 4.4.9, which lacks an aromatic Chapter 4  90 
ring,  supports  the  hypothesis  that  a  defined  steric  interaction  in  the  region  of  the  MPEP 
pyridine might be sufficient for selectivity. 
 
 
 
 
Figure 4.13. Recently reported mGluR5 antagonists with new scaffolds. 
 
 
4.4.1 Conclusion 
 Summarizing, it has been demonstrated that pharmacophore-based similarity searching can 
lead  to  novel,  isofunctional  molecular  scaffolds  that  provide  a  basis  for  lead  structure 
development. The target was an allosteric binding site of a pharmacologically challenging 
GPCR. Although homology-based models of the MPEP binding pocket have been published 
recently [Pagano et al., 2000, Malherbe et al., 2003], successful virtual screening exploiting 
this  information  has  not  been  reported  until  now.  The  entirely  ligand-based  CATS3D 
approach can thus be seen as a working alternative to more demanding structure-based design 
techniques with the main aim to develop novel lead series. 
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4.5 Prospective  screening  for  mGluR5  allosteric 
modulators with an artificial neural network approach 
based on CATS3D representations 
 
Artificial neural networks (ANN) are an attractive tool for the identification of molecules with 
a desired biological activity. In this section we used an ensemble of ANNs and self organizing 
maps  (SOMs)  to  find  new  specific  and  diverse  allosteric  antagonists  of  mGluR5.  The 
following setup was employed (Figure 4.14):  
1.  10 ANNs were trained on the prediction of mGluR5 activity. 
2.  Two ANNs were trained on the selectivity against mGluR1. 
3.  Self organizing maps were used to select representative subsets of the predicted virtual 
hits for pharmacological characterization. 
 
 
 
Figure 4.14. Combination of supervised and unsupervised artificial neural networks for the 
compilation of a focused diverse mGluR5 library. The focus is realized with ensembles of 
supervised  feed-forward  networks  for  the  prediction  of  general  “mGluR5-likeness”  and 
“mGluR5 vs. mGluR1 selectivity”. Diversity is obtained with unsupervised self organizing 
map (SOM) selection of representative subsets of the best fraction of hits from the previous 
steps. 
 
 
Many  allosteric  antagonists  of  mGluR5  have  been  described  in  patents  and  in 
scientific literature. However the structural classes of ligands are very dissimilar and it is Chapter 4  92 
unclear how the classes are related to each other from the view of the binding mode in the 
receptor. The availability of many different active molecules is a genuine starting point for a 
machine  learning  algorithm.  On  the  other  hand,  potential  different  binding  modes  and 
different sub-pockets in the binding site of these ligands might hamper such an approach, 
where all ligands are considered as active. The origin of the activity data from different assay 
systems as well as the absence of an obvious alignment of the ligands renders a classification 
method more appropriate than an approach for the prediction of inhibition constants. Artificial 
neural networks (ANN) have been shown to be successful in complex classification tasks in 
drug  discovery  related  projects.  Our  aim  was  to  create  a  prediction  tool  to  identify  new 
molecules with specific mGluR5 allosteric modulator activity. Using CATS3D as molecular 
descriptor,  the  inherent  suitability  of  this  descriptor  for  scaffold  hopping  should  further 
support this goal. 
For this approach we combined supervised and unsupervised ANNs. First, ensembles 
of supervised ANNs were trained to separate molecules which possess mGluR5 allosteric 
antagonist  activity    (“mGluR5-likeness”)  from  molecules  without  that  property  and  from 
molecules  with  mGluR1  allosteric  antagonist  activity.  Second,  unsupervised  ANNs,  self 
organizing maps (SOMs), were used to cluster the best scoring molecules and to retrieve 
representative subsets for experimental testing. Recently an approach was reported combining 
self organizing maps (SOMs) with feed-forward neural networks [Gini et al., 2004]. In these 
studies SOMs were used as a pre-processing tool to cluster similar molecules. For each of the 
clusters  separate  neural  networks  were  trained.  These  methods  obtained  an  improved 
prediction accuracy of activities of molecules since neural networks were trained on similarly 
acting molecules in comparison to a single ANN trained on all molecules [Gini et al., 2004]. 
This approach is similar to the approach of counterpropagation networks [Zupan & Gasteiger, 
1999]. Counterpropagation networks consist of one SOM layer, that is trained unsupervised, 
and an additional output layer for the prediction of observables, that is trained in a supervised 
manner. However for such an approach sufficiently large datasets are crucial for a successful 
training  of  the  large  number  of  neural  networks.  In  comparison  to  our  approach  this 
combination of unsupervised and supervised neural networks results in a set of local models 
with the aim of the highest possible prediction accuracy. Our approach results in a global 
model with the aim to identify properties of active molecules and to find novel structural 
clusters which were not identified before.  
In  a  recent  article  it  was  stated  that  the  similarity  of  molecules  with  predicted 
properties to the training set is a good indicator for the accuracy of the prediction [Sheridan et Main Section  93 
al., 2004]. We were interested if this relation was also found for our ANN SOM combination 
approach,  namely  if  there  were  more  molecules  retrieved  from  SOM  neurons  containing 
molecules from the training set in comparison to neurons without training molecules, or not. 
 
4.5.1 Training of feedforward ANNs 
Neural networks were trained on two classification tasks. One set of ANNs was trained on the 
distinction between mGluR5 allosteric antagonists (further referred to as “actives”) from other 
molecules  (further  referred  to  as  “inactives”).  Another  set  of  ANNs  was  trained  on  the 
distinction between actives and mGluR1 allosteric antagonists (further referred to as “side-
actives”), the most similar receptor to mGluR5. The training set for the actives consisted of 68 
mGluR5 allosteric antagonists from literature, patents and from unpublished molecules from 
Merz  Pharmaceuticals  GmbH  (Frankfurt).  The  side-actives  set  consisted  of  158  allosteric 
antagonists of mGluR1 from patents and literature. Inactives were compiled from the COBRA 
database. The training procedure of ANNs requires approximately equally sized fractions of 
molecules form two classes. To obtain a reasonable sampling of the molecules of the COBRA 
database,  five  different  training  sets  of  100  molecules  were  compiled  using  the  MaxMin 
algorithm [Kennard & Stone, 1996] for maximal diverse subset selection. The dissimilarity 
was calculated based on the CATS3D descriptor.  
For the training of neural networks with the aim to discriminate between actives and 
inactives all five COBRA subsets were merged with the set of 68 actives, resulting in five 
data sets of 168 molecules. For all five sets all variables from the CATS3D descriptor with a 
scaled  Shannon  entropy  (Eq.  2.8)  of  less  than  0.3  were  eliminated,  leading  to  75  to  79 
remaining variables. The resulting datasets are further referred to with M5vsCO1 (mGluR5 vs. 
COBRA  set  1),  M5vsCO2,  M5vsCO3,  M5vsCO4  and  M5vsCO5.  Table  4.11  gives  an 
overview over the selected variables for the data sets. The selection differed only in few cases 
for variables describing larger distances. Variables including cation- and anion-interactions 
were not selected since all molecules were neutralized before descriptor calculation. 
Training  with  uncorrelated  variables  can  result  in  improved  prediction  quality 
[Schneider & So, 2003]. To test this hypothesis for our classification tasks we calculated 
uncorrelated  versions  of  M5vsCO1  to  M5vsCO5.  All  variables  were  autoscaled  and  a 
principle  component  analysis  (PCA)  was  performed.  All  principle  components  with 
eigenvalues  above  or  equal  to  1  were  used  for  further  calculations.  This  resulted  in  ten 
principle components for each of the data sets. The five resulting data sets with uncorrelated 
variables  are  further  referred  to  as  M5vsCO1pca,  M5vsCO2pca,  …,  M5vsCO5pca.  The Chapter 4  94 
percentages of explained variance of the first two principle components were 69.8 % and 11.1 
%, 70.3 % and 10.9 %, 69.2 % and 11.6 %, 70.2 % and 10.7 %, and 70.0 % and 11.0 %, 
respectively. Accordingly in all five data sets more than 80 % of the variance is explained by 
the  first  two  principle  components.  This  indicated  that  the  variables  of  the  CATS3D 
descriptor were highly correlated for the description of these data sets. Projections of actives 
and inactives using the first 2 principle components revealed that the CATS3D description 
seemed to be appropriate to separate active molecules from inactive molecules (Figure 4.15).  
 
Table 4.11. Variables selected by scaled Shannon entropy for the different data sets. 
The variables are coded in the following way: e.g. PA 3-11 means that all polar – hydrogen 
bond-acceptor bins with distance ranges from 2 to 3, 3 to 4, … , 10 to 11 Å are selected. P = 
polar, A = hydrogen-bond acceptor, D = hydrogen-bond donor, H = hydrophobic. 
 
selected 
descriptors 
M5vsCO1  M5vsCO2  M5vsCO3  M5vsCO4  M5vsCO5  M5vsM1 
PA  3-11  3-12  3-10  3-12  3-10   
PH  2-15  2-16  2-15  2-15  2-15   
DA  3-9  3-9  3-7  3-9  3-9   
DH  2-13  2-13  2-14  2-14  2-14  3-7 
AA  3-8  3-9  3-8  3-10  3-8   
AH  2-15  2-15  2-14  2-15  2-15  2-13 
HH  2-17  2-17  2-17  2-17  2-17  2-14 
total 
number 
77  79  75  79  77  29 
 
 
For the training of neural networks to discriminate between actives and side-actives 
the datasets of 68 actives and 158 side-actives were merged. Variables with a scaled Shannon 
entropy below 0.3 were eliminated, resulting in 29 remaining variables. This dataset is further 
referred to as M5vsM1 (mGluR5 vs. mGluR1). Due to the smaller variation of the molecules 
in this data set in comparison to the COBRA subsets, a smaller number of variables were 
selected having entropies above 0.3. Details on the selected variables are shown in Table 4.11. 
Uncorrelated  variables  were  obtained  by  autoscaling  and  subsequent  PCA.  The  resulting 
dataset is further referred to as M5vsM1pca. Seven principle components were found with Main Section  95 
eigenvalues above 1. The first PC explained 59.8 % and the second PC explained 17.4 % of 
the variance in the data.  
 
 
 
Figure  4.15. Principle component projection of the data sets used for the training of the 
supervised  neural  networks.  Five  datasets  were  used  for  “mGluR5-likeness”  prediction 
(M5vsCO1,  …,  M5vsCO5)  and  one  dataset  was  used  for  the  “mGluR5  vs.  mGluR1 
selectivity”  prediction  (M5vsM1).  White  dots  represent  actives  and  black  dots  represent 
inactives or side-actives. 
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The projection of the first two principle components is shown in Figure 4.15. It is 
apparent that mGluR5 and mGluR1 were not easily separable by a linear function. However 
both subsets form several clusters and should therefore be separable by a non-linear classifier 
like ANN. On the other hand some of the regions overlap which supports the results from 
Section 4.4, that selectivity between the two classes is determined by small variations of the 
ligands, which are not yet clearly understood.  
 
Table 4.12. Results of the 10-fold cross-validation for M5vsCO1 to M5vsCO5. The average 
cc values for the training- and test-sets were calculated after 100 steps of training. Selected 
nets are printed in bold. Standard deviations are given in brackets. 
 
  M5vsCO1  M5vsCO2  M5vsCO3  M5vsCO4  M5vsCO5 
no. 
hidden 
neurons 
train  test  train  test  train  test  train  test  train  test 
1  0.98 
(0.03) 
0.79 
(0.06) 
0.97 
(0.04) 
0.78 
(0.05) 
0.98 
(0.03) 
0.80 
(0.09) 
0.99 
(0.02) 
0.83 
(0.06) 
1 (0)  0.84 
(0.05) 
2  0.99 
(0.01) 
0.84 
(0.06) 
1 (0)  0.85 
(0.06) 
0.99 
(0.01) 
0.87 
(0.04) 
1 (0.01)  0.86 
(0.03) 
1 (0)  0.83 
(0.07) 
3  1 (0)  0.83 
(0.07) 
1 (0)  0.86 
(0.04) 
1 (0)  0.86 
(0.07) 
1 (0.01)  0.84 
(0.08) 
1 (0)  0.85 
(0.07) 
4  1 (0)  0.86 
(0.06) 
1 (0)  0.87 
(0.08) 
1 (0)  0.88 
(0.05) 
1 (0)  0.86 
(0.07) 
1 (0)  0.88 
(0.04) 
5  1 (0)  0.86 
(0.06) 
1 (0)  0.87 
(0.06) 
1 (0)  0.85 
(0.05) 
1 (0)  0.88 
(0.04) 
1 (0)  0.85 
(0.05) 
6  1 (0)  0.86 
(0.06) 
1 (0)  0.83 
(0.04) 
1 (0)  0.85 
(0.05) 
1 (0)  0.86 
(0.05) 
1 (0)  0.89 
(0.03) 
7  1 (0)  0.87 
(0.05) 
1 (0)  0.84 
(0.07) 
1 (0)  0.91 
(0.03) 
1 (0)  0.84 
(0.08) 
1 (0)  0.88 
(0.05) 
8  1 (0)  0.86 
(0.05) 
1 (0)  0.85 
(0.06) 
1 (0)  0.88 
(0.04) 
1 (0)  0.84 
(0.05) 
1 (0)  0.88 
(0.05) 
9  1 (0)  0.87 
(0.03) 
1 (0)  0.88 
(0.04) 
1 (0)  0.89 
(0.03) 
1 (0)  0.83 
(0.06) 
1 (0)  0.87 
(0.06) 
10  1 (0)  0.88 
(0.02) 
1 (0)  0.86 
(0.06) 
1 (0)  0.91 
(0.04) 
1 (0)  0.85 
(0.05) 
1 (0)  0.86 
(0.07) 
11  1 (0)  0.85 
(0.05) 
1 (0)  0.85 
(0.06) 
1 (0)  0.89 
(0.06) 
1 (0)  0.88 
(0.05) 
1 (0)  0.89 
(0.03) 
12  1 (0)  0.85 
(0.03) 
1 (0)  0.87 
(0.07) 
1 (0)  0.89 
(0.04) 
1 (0)  0.84 
(0.06) 
1 (0)  0.90 
(0.04) 
13  1 (0)  0.85 
(0.05) 
1 (0)  0.86 
(0.06) 
1 (0)  0.90 
(0.04) 
1 (0)  0.85 
(0.05) 
1 (0)  0.89 
(0.04) 
 
 
All twelve described data sets were employed for the training of neural networks. The 
optimal  number  of  hidden  neurons  and  the  optimal  number  of  training  steps  had  to  be 
determined for each of the twelve datasets. Several numbers of hidden neurons were tested for 
each of the datasets with ten-fold cross-validation. Cross-validation was employed by random 
division of the datasets into equal sized fractions of training and test data. This procedure was Main Section  97 
repeated ten times to obtain an estimation of network performance. A number of 100 steps 
were used for the training. In preliminary training experiments 100 steps seemed to be a 
reasonable compromise between a sufficiently large number of training steps to extract the 
underlying  structure  activity  relationship  and  overtraining  of  the  neural  networks,  which 
prevents generalization of the predictions.  
 
Table  4.13. Results of the 10 fold cross-validation for M5vsCO1pca to M5vsCO5p. The 
average cc values for the training- and test-sets were calculated after 100 steps of training. 
Selected nets are printed in bold. Standard deviations are given in brackets. 
 
  M5vsCO1pca  M5vsCO2pca  M5vsCO3pca  M5vsCO4pca  M5vsCO5pca 
no. 
hidden 
neurons 
train  test  train  test  train  test  train  test  train  test 
1  0.95 
(0.02) 
0.79 
(0.05) 
0.97 
(0.02) 
0.84 
(0.04) 
0.97 
(0.02) 
0.82 
(0.05) 
0.97 
(0.05) 
0.78 
(0.05) 
0.97 
(0.03) 
0.80 
(0.06) 
2  0.99 
(0.02) 
0.83 
(0.08) 
0.98 
(0.02) 
0.87 
(0.07) 
1 (0)  0.85 
(0.06) 
0.99 
(0.02) 
0.82 
(0.05) 
1 
(0.01) 
0.87 
(0.06) 
3  1 (0.01)  0.81 
(0.08) 
0.99 
(0.02) 
0.83 
(0.07) 
1 
(0.01) 
0.86 
(0.06) 
1 (0)  0.85 
(0.06) 
0.99 
(0.01) 
0.82 
(0.06) 
4  1 (0)  0.84 
(0.05) 
1 (0)  0.87 
(0.06) 
1 (0)  0.88 
(0.03) 
1 
(0.01) 
0.84 
(0.06) 
1 (0)  0.83 
(0.06) 
5  1 (0.01)  0.82 
(0.07) 
1 
(0.01) 
0.87 
(0.04) 
1 (0)  0.90 
(0.03) 
1 (0)  0.85 
(0.05) 
1 (0)  0.85 
(0.06) 
6  1 (0)  0.86 
(0.04) 
1 (0)  0.86 
(0.06) 
1 (0)  0.91 
(0.03) 
1 (0)  0.84 
(0.04) 
1 (0)  0.87 
(0.06) 
7  1 (0)  0.89 
(0.03) 
1 (0)  0.84 
(0.06) 
1 (0)  0.92 
(0.05) 
1 (0)  0.85 
(0.05) 
1 (0)  0.86 
(0.06) 
8  1 (0)  0.85 
(0.05) 
1 
(0.01) 
0.87 
(0.04) 
1 (0)  0.91 
(0.04) 
1 (0)  0.84 
(0.05) 
1 (0)  0.85 
(0.05) 
 
 
Table  4.14.  Results  of  the  10  fold  cross-validation  for  M5vsM1  and  M5vsM1pca.  The 
average cc values for the training- and test-sets were calculated after 100 steps of training. 
Selected nets are printed in bold. Standard deviations are given in brackets. 
 
  M5vsM1  M5vsM1pca 
no. hidden 
neurons  train  test  train  test 
1  0.99 (0.02)  0.87 (0.05)  0.96 (0.02)  0.8 (0.05) 
2  1 (0.01)  0.88 (0.03)  0.98 (0.02)  0.81 (0.06) 
3  1 (0.01)  0.89 (0.05)  0.96 (0.02)  0.84 (0.07) 
4  1 (0.01)  0.88 (0.04)  0.98 (0.02)  0.83 (0.05) 
5  0.99 (0.01)  0.91 (0.02)  0.99 (0.01)  0.78 (0.06) 
6  1 (0.01)  0.88 (0.04)  0.99 (0.02)  0.79 (0.08) 
7  1 (0.01)  0.88 (0.05)     
8  0.98 (0.02)  0.9 (0.04)     
9  0.99 (0.01)  0.89 (0.05)     
10  0.99 (0.01)  0.9 (0.04)     
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The evaluation of different number of hidden neurons for the ANN training is given in 
detail in Tables 4.12, 4.13, and 4.14. In all active/inactive classification networks the test data 
was 100% correctly predicted employing more than two or three hidden neurons. For the 
actives/side-actives networks this was not true. Using larger numbers of hidden neurons did 
not  always  lead  to  100%  prediction  accuracy.  This  effect  might  be  grounded  on  neural 
network training using too few training steps or on the complexity of the separation task.  
ANNs were selected with the best Matthews cc in the training and the test data. In the 
case that more than one network obtained equal best cc values, the net with the lowest number 
of  hidden  neurons  was  selected.  Employing  the  best  found  number  of  hidden  neurons, 
successful  predictions  of  the  test  sets  were  obtained  with  Matthews  coefficients  equal  or 
larger  than  0.84  for  all  test  data  sets.  For  the  actives/inactives  separation  only  small 
differences in the test data prediction accuracy were found between the raw descriptor values 
and the uncorrelated variables (best found Matthews cc = 0.91 vs. 0.92 for the test data). For 
the  actives/side-actives  separation,  the  raw  descriptor  values  performed  better  than  the 
uncorrelated variables (best found Matthews cc = 0.91 vs. 0.84 for the test data). This might 
be caused by the difference of the classification task. A general classification task applied to 
relatively easily separable data like with the actives/inactives classification might profit or at 
least not be hampered by a more general data presentation with uncorrelated variables. For the 
specific and complex separation of actives and side-actives details of the descriptors might 
have  played  a  role,  which  were  lost  in  the  uncorrelated  variables.  Additionally,  more 
descriptor variables automatically lead to a better separation between data classes, but also 
favors overfitting of the descriptor values to the observed data.  
 
 
 
Figure 4.16. Frequency of predicted score values for the molecules of the Enamine database.  Main Section  99 
 
For  each  data  set  for  actives/inactives  classification  the  parameters  of  the  best 
performing model with the minimum number of hidden neurons were selected for the final 
training.  The  selected  nets  are  printed  in  bold  in  Tables  4.12,  4.13  and  4.14.  For  the 
actives/side-actives classification ANNs with uncorrelated variables were not used. Instead 
two nets with two and five hidden neurons were selected with the original variables. Final 
neural  networks  were  trained  using  the  full  data  sets  with  the  given  number  of  hidden 
neurons.  
 
4.5.2 Prediction of allosteric mGluR5 modulators 
For prospective virtual screening we used the database of the commercial molecule-supplier 
Enamine [Enamine], which consisted of 1,022,483 molecules. For each neural network the 
molecules were processed like the training data: the same variables were selected as for the 
training data. When necessary, autoscaling and PCA were applied using the means, standard 
deviations and transformation matrices from the training data sets. Consensus scores were 
obtained  by  calculation  of  the  average  values  of  the  ten  ANNs  for  the  actives-inactives 
classification and for the two ANNs for the actives-side-actives classification. A histogram of 
the two distributions of the score values is shown in Figure 4.16. Interestingly the scores for 
the actives/inactives classification did not exceed a value of 0.89 for the Enamine dataset. 
This was an effect of the ensemble neural network average score that was applied for the 
prediction.  One  of  the  trained  ANNs  (M5vsCO5)  did  not  predict  any  of  the  Enamine 
molecules as active, despite the fact that this network performed best in training. This might 
be  an  indicator  that  the  Enamine  dataset  might  not  be  appropriate  for  the  screening  for 
mGluR5 allosteric antagonists. An alternative to average scores to find a decision based on 
ensembles of neural networks is the jury decision: a compound is considered as active if the 
majority of neural networks consider the compound as active. In this work a more stringent 
criterion was used: a unanimous decision was needed to result in a maximum score of 1. This 
strategy  was  applied  due  to  the  fact  that  a  large  fraction  of  the  Enamine  dataset  was 
considered as active, by most of the networks (Figure 4.16).  
Figure 4.16 shows the effect of the consensus scoring by average score values. The 
number of peaks found in the scores reflects the number of individual score-values used for 
the average score. For the actives/side-actives classification three peaks were found: a first 
large peak of many molecules where both nets agree that the molecules are more likely side-
actives than actives, a small peak at 0.5 where the two nets do not agree, and another small Chapter 4  100 
peak  where  both  nets  agree  that  the  molecules  belong  to  the  actives  class.  For  the 
actives/inactives  classification  there  should  be  eleven  peaks,  but  since  one  ANN  did  not 
predict any molecule as active, only ten peaks were found.  
From the actives/inactives prediction we selected all molecules with an average score 
larger than 0.885. This value was found to be a reasonable compromise between the presumed 
diversity of the hits and the number of obtained hits. We assumed to find structurally more 
diverse molecules by this strategy in comparison to using the top scoring molecules alone. 
This resulted in a selection of 41,663 molecules. From the actives/side-active classification 
we selected all molecules with an average score above 0.99, which resulted in an additional 
32,099  molecules.  The  union  of  these  sets  gave  a  set  of  8,403  molecules  which  were 
considered as our focused library for mGluR5 allosteric antagonists. 
 
4.5.3 Selection of a representative subset by SOMs 
The obtained focused library was further analyzed by self organizing maps (SOM). SOMs 
provide a topology-preserving projection of data from a high-dimensional space into a low 
dimensional  space.  The  resulting  maps  also  define  clusters  in  the  data  and  provide 
representative and diverse subsets of the original data. Two different SOMs were trained: one 
SOM based on the CATS3D descriptor and one SOM based on MACCS keys. In this way we 
wanted to analyze our focused library by two different objectives. One objective was to get an 
overview over the distribution of diverse sets of scaffolds (based on the MACCS keys) and 
the other objective was to get an overview over the different pharmacophores in the library 
(based on CATS3D). CATS3D representations of molecules consist of a comparably large 
number of dimensions (420) in relation to the two-dimensional SOM projection. To facilitate 
SOM training the discrepancy between the two variable spaces was reduced by the scaled 
Shannon entropy. Only CATS3D-dimensions with a scaled Shannon entropy above 0.3 were 
used for SOM training. To estimate the overlap of the library with the chemical space covered 
by the known mGluR5 allosteric antagonists, all mGluR5 actives from the training set were 
included in the SOM training. Two SOMs with 5 x 5 neurons were trained. The resulting 
SOMs are shown in Figure 4.17. 
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Figure 4.17. Self organizing maps (SOMs) of the best predicted Enamine molecules. SOMs 
were calculated using MACCS keys and CATS3D descriptors. Shown are the distribution of 
the  mGluR  training  set,  the  mGluR1  training  set  and  the  frequency  of  the  predicted  hit 
molecules, projected on the trained SOM. 
 
 
In the MACCS SOM 13 of 25 neurons and in the CATS3D SOM 15 of 25 neurons 
contained known actives. This indicates that the predicted molecules broadly covered the 
chemical  space  of  the  known  mGluR5  allosteric  antagonists.  All  neurons  without  active 
molecules  from  the  training  set  were  directly  neighboring  a  neuron  containing  active 
molecules  within  its  receptive  field.  In  the  MACCS  SOM  the  neurons  containing  active 
molecules from the training set built a cluster with a single neuron containing most of the Chapter 4  102 
molecules. In contrast, in the CATS3D SOM the neurons containing active molecules were 
loosely distributed over the map with more neurons containing a larger fraction of active 
molecules. The results from these two projections indicate that the ANN approach was able to 
predict  novel  scaffolds  and  chemotypes  which  were  similarly  distributed  between  the 
CATS3D  representations,  but  are  found  outside  of  the  cluster  of  known  actives  in  the 
MACCS SOM. A projection of the side-actives onto the trained map revealed that these 
molecules were distributed broadly over the map. In the CATS3D SOM 16 neurons were 
activated  by  mGluR1  antagonists  including  10  neurons  that  also  contained  mGluR5 
antagonists.  For  the  MACCS  SOM  18  neurons  were  found  with  mGluR1  antagonists 
overlapping with 10 neurons with mGluR5 antagonists. The SOMs were not able to define a 
full separation of actives and side-actives on the basis of unsupervised learning. This might be 
grounded on the selection of inappropriate descriptors for that task and on the similarity of the 
two classes of ligands (Figure 4.17). The relative frequency of the selected library is shown in 
Figure 4.17. According to the MACCS keys, the library was broadly distributed over the map. 
With CATS3D most of the library compounds were found in a small set of two neighboring 
neurons.  Interestingly  both  of  these  neurons  did  not  contain  any  known  active  reference. 
These results indicate the presence of large sets of analogues in the Enamine dataset which 
introduced a bias in the molecules selection. By selection of representative compounds for the 
biochemical  verification  of  the  compounds  this  bias  was  circumvented.  For  experimental 
screening for new allosteric modulators of mGluR5, all molecules which were nearest to the 
neuron  centroids  were  selected.  The  respective  molecules  are  shown  in  Figure  4.18  and 
Figure  4.19.  The  representative  molecules  from  both  SOMs  show  a  similar  topology  in 
comparison  to  known  mGluR5  allosteric  antagonists  (see  Section  4.4).  Most  molecules 
consist  of  two  ring  systems  connected  by  a  linker  of  3  or  more  bonds  length.  These 
characteristics  were  found  in  molecules  from  neurons  with  and  without  known  active 
references and in the representative molecules of both SOMs. Some of the selected molecules 
included charged groups like the nitro group. Charged groups were not accounted for in the 
CATS3D descriptor after the variable selection procedure. Especially in the MACCS SOM 
these  molecules  were  found  mostly  outside  of  the  neurons  containing  the  known  active 
molecules.  
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Figure 4.18. Representative molecules selected from the CATS3D SOM. Grey dots indicate 
molecules that were tested in the binding assay. 
 
 
Figure 4.19. Representative molecules selected from the MACCS SOM. Grey dots indicate 
molecules that were tested in the binding assay. 
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4.5.4 Binding assay results 
The  molecules  selected  by  the  SOMs,  that  were  available  (32  of  50  molecules)  were 
purchased from Enamine [Enamine] and tested in an mGluR5 binding assay. The hits and 
some  of  the  inactive  molecules  from  the  mGluR5  assay  were  also  tested  in  an  mGluR1 
binding assay to assess the selectivity of the molecules. The results of the assay are shown in 
Table 4.15. Three of the 16 tested molecules from the CATS3D SOM and two of the 16 
molecules tested from the MACCS SOM showed mGluR5 binding.  
The best binding ligand for mGluR5 was found with the CATS3D SOM in neuron e3: 
4.5.23 with a Ki of 21 µM. This ligand is structurally similar to ligand 4.4.24 (Ki = 12 µM) 
found  with  CATS3D  similarity  searching  in  Section  4.4,  though  the  mGluR5  hits  from 
Section 4.4 were not included in the training data. The Ki values from Section 4.4 were 
determined  considering  the  fraction  of  solvated  ligand  under  the  assay  conditions.  This 
parameter was not determined in this section. For 4.4.24 60 % of the molecule was found in 
solution. Assuming a comparable solubility for 4.5.23 than for 4.4.24, similar Ki values were 
found for the two molecules. The best hit from the MACCS SOM was found in neuron b3: 
4.5.33 with a Ki of 33 µM, which is also similar to 4.5.23 and 4.4.24. One apparent difference 
of 4.5.33 to 4.5.23 and 4.4.24 is the lack of a hydroxyl-group substituent that is present in the 
other two molecules at the benzene ring distant to the linker oxygen. Regarding the lower Ki 
of 4.5.33 in comparison to 4.5.23 and 4.4.24, the hydroxyl group might provide a favorable 
interaction  with  the  receptor.  A  part  of  the  effect  of  the  hydroxyl-group  might  also  be 
addressed to a lower solubility of 4.5.33. 
The selectivity of the molecules for mGluR5 over mGluR1 was low: nine of the 12 
molecules tested from the CATS3D SOM and one of the molecules tested from the MACCS 
SOM were also found to bind to the mGluR1. Thus more molecules were found binding to 
mGluR1 than to mGluR5. The molecule with the highest binding affinity was also found for 
mGluR1 (4.5.13 with a Ki of 8 µM for mGluR1 and a Ki of 38 µM for MgluR5). Similar 
results were observed in Section 4.4 where additional potent ligands for mGluR1 were found 
with  CATS3D  similarity  searching  using  specific  mGluR5  allosteric  antagonists  as  query 
molecules. This might reveal that the employed molecular representation with CATS3D was 
not appropriate for this particular task. While CATS3D was designed for scaffold hopping, 
and accordingly fuzzy representation of the molecules the selectivity between mGluR5 and 
mGluR1 seems to require subtle differences in the ligands, due to the high similarity of the 
binding pockets [Pagano et al., 2000].  Main Section  105 
Many of the molecules that were active on at least one of the receptors mGluR1 or 
mGluR5 were found to have amide groups (4.5.24, 4.5.35, 4.5.49) or ester groups (4.5.5, 
4.5.7, 4.5.10, 4.5.13) as linkers. These linkers were not found in the training data and might 
be considered as alternative chemotypes for the linker part of the molecules.  
One of the most challenging goals of virtual screening is to retrieve novel scaffolds 
and chemotypes with the desired biological activity. In this approach all molecules predicted 
as active were clustered by SOMs. Retrieving active molecules from clusters of molecules 
that did not contain active training samples is a way to find molecules different from the 
training chemotypes. In the SOMs different clusters are represented by different neurons. 
With our approach we were able to find novel active chemotypes from SOM neurons that did 
not  contain  any  of  the  known  reference  molecules.  This  was  found  for  mGluR5  and  for 
mGluR1, using both molecular descriptors MACCS and CATS3D for the SOM calculation. 
For the molecules tested from the MACCS SOM all molecules that were active on mGluR5 
were found in neurons that did not contain any known mGluR5 antagonist and the molecule 
that was active on mGluR1 was found in a neuron that did not contain any of the mGluR1 
training molecules. For the CATS3D SOM molecules were found to be active that were from 
neurons not containing reference molecules from the training set (M5: 4.5.7, M1: 4.5.16, 
4.5.19, 4.5.23). However the most active molecules were found in neurons with reference 
molecules: the best identified mGluR5 antagonist 4.5.23 was found in the neuron containing 
the second largest number of reference molecules and the best mGluR1 antagonist 4.5.13 was 
found in the neuron with the most mGluR1 references. These results are in agreement with the 
findings  of  Sheridan  et  al.  [Sheridan  et  al.,  2004],  that  best  predictions  are  obtained  for 
molecules similar to the training data. In contrast to their findings we also found actives with 
lower activities in neurons not containing training molecules. This ability might have resulted 
from the strategy of training a global model for mGluR5 instead of a set of local models. 
However the task of mGluR5/mGluR1 selectivity might have been better represented using a 
set of local models.  
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Table 4.15. Results from the mGluR5 and mGluR1 binding assays. 
Molecule (neuron)  Ki mGluR5 (µM)  Ki mGluR1 (µM)  Selectivity  
(IC50 mGluR1 / IC50 mGluR5) 
CATS3D-SOM       
4.5.2 (a2)  > 100     
4.5.4 (a4)  > 100  73  < 0.7 
4.5.5 (a5)  > 100  46  < 0.5 
4.5.6 (b1)  > 100  > 100  1 
4.5.7 (b2)  44  51  1.2 
4.5.9 (b4)  > 100     
4.5.10 (b5)  > 100  69  < 0.7 
4.5.11 (c1)  > 100  > 100  1 
4.5.13 (c3)  38  8  0.2 
4.5.15 (c5)  > 100     
4.5.16 (d1)  > 100  45  < 0.5 
4.5.18 (d3)  > 100     
4.5.19 (d4)  > 100  55  < 0.6 
4.5.23 (e3)  21  64  3.1 
4.5.24 (e4)  > 100  56  < 0.6 
4.5.25 (e5)  > 100  > 100  1 
MACCS-SOM       
4.5.30 (a5)  > 100     
4.5.31 (b1)  > 100     
4.5.33 (b3)  33  > 100  > 3.0 
4.5.34 (b4)  > 100  69  < 0.7 
4.5.35 (b5)  > 100     
4.5.36 (c1)  > 100     
4.5.37 (c2)  > 100     
4.5.39 (c4)  > 100  > 100  1 
4.5.40 (c5)  > 100  > 100  1 
4.5.41 (d1)  > 100     
4.5.42 (d2)  > 100     
4.5.45 (d5)  > 100     
4.5.46 (e1)  > 100     
4.5.47 (e2)  > 100     
4.5.48 (e3)  > 100     
4.5.49 (e4)  59  > 100  > 1.7 Main Section  107 
4.5.5 Conclusions 
Using  an  artificial  neural  network  approach  we  retrieved  novel  chemotypes  for  allosteric 
modulators of mGluR5. We used a combination of feedforward neural networks trained on 
the  separation  of  mGluR5  allosteric  antagonists  from  molecules  without  that  activity  and 
trained on the separation of allosteric antagonists of mGluR5 and mGluR1. A representative 
set  of  molecules  for  biochemical  testing  was  compiled  using  unsupervised  SOMs.  Novel 
mGluR5 antagonists with a best Ki value of 21 were found. We were able to retrieve new 
active molecules from regions in the SOMs that contained molecules from the training set and 
from regions that did not contain these molecules. Thus our method was able to correctly 
predict molecules as active that were not similar to the reference molecules. This ability might 
have resulted from the training of a set of global model based on all molecules from the 
heterogeneous training set of mGluR5 antagonists instead of a set of local models. Prediction 
of  the  selectivity  of  ligands  was  not  successful.  This  property  might  have  been  better 
predicted  with  a  set  of  local  models  using  less  general  molecular  descriptors.  Thus  the 
combination of the CATS3D descriptor with neural networks might be best suited for the 
purpose of scaffold hopping, but not for the purpose of ligand optimization.  
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4.6 Retrospective  evaluation  of  SQUID  fuzzy 
pharmacophore models 
Conventional similarity searching (like with the CATS family methods) employs a single 
query molecule for each virtual screening run. In contrast, ensemble-based pharmacophore 
searching [Güner, 2000] (for three-dimensional substructures, e.g. like with Catalyst [Greene 
et al., 1994]) incorporates information from multiple active molecules. Using information 
from multiple reference molecules has also been shown to improve alignment-free descriptor 
vector  based  virtual  screening  [Xu  et  al.,  2001;  Hert  et  al.,  2004a;  Hert  et  al.,  2004b]. 
However there is the limitation that conserved features in the alignment-free descriptor space 
are not necessarily conserved in a three-dimensional alignment of ligands. 
Traditional pharmacophore searching approaches define a query as a substructure. For 
regions in molecules not covered by the substructure no preference is assigned. This can lead 
to the effect that many hits contain large or undesired structural elements in the undefined 
regions.  Excluded  volumes  can  compensate  for  a  part  of  the  problem  by  preventing  the 
selection of molecules that are too large for the binding pocket [Güner, 2000]. 
Using  pairs,  triplets,  or  even  quartets  of  atoms  as  PPPs  is  one  possibility  for  the 
construction of a CV descriptor. An extension to this approach is to use pairs of larger and 
more general objects, which might result in a more generalized and abstract description of the 
molecule.  
The  SQUID  (Sophisticated  Quantification  of  Interaction  Distributions)  fuzzy 
pharmacophore is an approach that was designed to tackle the above mentioned topics. In 
SQUID pairs of Gaussian probability densities are used for the descriptor calculation. The 
Gaussians represent clusters of atoms comprising the same pharmacophoric feature within an 
alignment of several active reference molecules. The incorporation of multiple aligned ligands 
within  the  SQUID  approach  resembles  conceptual  similarity  to  the  traditional  idea  of  a 
pharmacophore model [Güner, 2000]. Based on an alignment of active molecules, tolerances 
for  the  features  are  usually  estimated  to  compensate  for  ligand  and  receptor  flexibility. 
Pharmacophoric features that are present in many of the reference molecules result in a high 
probability,  and  features  which  are  sparse  in  the  underlying  molecules  result  in  a  low 
probability. In this way all features of the reference molecules are included in the model and 
not just the most conserved substructure. Tolerances of the features, which are considered by 
this approach, might be better represented by Gaussian densities than by rigid spheres. For the 
resulting fuzzy pharmacophore models different degrees of fuzziness can be defined, e.g. the Main Section  109 
model can be very generalizing or more restricted to the underlying distribution of atoms from 
the  alignment.  The  fuzziness  can  be  affected  by  the  cluster  radius,  a  variable  which 
determines the radius within which atoms are clustered into PPPs.  
For virtual screening the three-dimensional spatial distribution of Gaussian densities is 
transformed  into  a  two-point  correlation  vector  representation  which  describes  the  same 
probability  density  for  the  presence  of  atom  pairs,  comprising  defined  pharmacophoric 
features. This representation is independent from translation and rotation which makes rapid 
database screening possible without the necessity to explicitly align the molecules, which can 
be a limiting step for the screening of large databases. This renders the fuzzy pharmacophore 
CV useful for ranking 3D pharmacophore-based CV representations of molecules, namely 
CATS3D descriptors of molecules. Consequently SQUID can be characterized as a hybrid 
approach  between  conventional  pharmacophore  searching,  similarity  searching  and  fuzzy 
modeling. 
The  goal  of  this  study  was  to  evaluate  the  pharmacophore  model  perception  and 
virtual screening ability of the SQUID fuzzy pharmacophore models. The ability of SQUID 
pharmacophore models to find important interaction points was tested for known reference 
pharmacophore models from literature. The effectiveness in virtual screening was compared 
with  CATS3D  similarity  searching  and  traditional  pharmacophore  searching  with  MOE 
[Chemical  Computing  Group].  An  optimization  procedure  of  feature-type  weight  was 
necessary in model calculation. The robustness of this optimization was evaluated, too.  
For the evaluation study we selected pharmacophore models for cyclooxygenase 2 
(COX-2) and thrombin from literature [Palomer et al., 2002; Patel et al., 2002]. Both targets 
are  well  characterized  in  the  literature  and  crystal  structures  of  the  receptors  with  bound 
inhibitors  are  available.  This  was  important  since  our  method  depends  on  a  meaningful 
alignment of ligands. Large sets of ligands for both targets are known, which is essential for 
statistical significant results. Ligands from both activities differ largely in size and molecular 
interactions. COX-2 inhibitors are known to be a class of lower diversity (see section scaffold 
hopping) while thrombin inhibitors show a higher diversity in chemotypes and scaffolds (see 
section scaffolds). Using these two references ligand classes the scaffold hopping capability 
of SQUID could also be assessed.  
For retrospective screening we used the COBRA database [Schneider & Schneider, 
2003] (version 2.1). Two versions were calculated: one database with single conformations 
was calculated with CORINA [Sadowski et al., 1994] and one database of up to 50 energy 
minimized  conformations  was  calculated  with  MOE  [Chemical  Computing  Group].  For Chapter 4  110 
retrospective screening molecule that were used for pharmacophore model generation were 
removed from the datasets. The resulting datasets consisted of 92 active molecules and 4611 
inactive molecules for COX-2, and 188 actives and 4517 inactive compounds for thrombin. 
 
4.6.1 Pharmacophore model of COX-2 ligands 
Palomer et al. [Palomer et al., 2002] derived a pharmacophore model for COX-2 inhibitors on 
the basis of five specific inhibitors SC-558 (4.6.1), rofecoxib (4.6.2), DFU, celecoxib, and a 
molecule which they termed “molecule 5” (M5, 4.6.3). For calculation of a 3D structural 
alignment of these ligands they used a template alignment of all COX-2 ligands, for which 
there was a crystal structure of the ligand-receptor complex available. Crystal structures were 
at  hand  for  SC-558  (1CX2)  and  the  two  unspecific  inhibitors  flurbiprofen  (3PGH)  and 
indomethacin (4COX). The alignment of these molecules was performed by superposition of 
their protein structures. The remaining ligands were aligned to the template alignment with 
the program Catalyst [Greene et al., 1994]. This approach was taken as a reference for the 
development of a pharmacophore model with our own program SQUID. The molecules DFU 
and celecoxib were not included in the SQUID pharmacophore model, because they are close 
analogs of rofecoxib and SC-558. The 2D structures of the remaining molecules are shown in 
Figure 4.20. Crystal structures 1CX2, 3PGH and 4COX were aligned with the homology 
alignment tool of MOE [Chemical Computing Group]. Rofecoxib and M5 were aligned to this 
template alignment with the flexible alignment tool of MOE. First, rofecoxib was aligned to 
the fixed template alignment. Then, M5 was aligned to the fixed alignment resulted from the 
previous step. For the final alignment the unspecific inhibitors were removed. The resulting 
alignment of COX-2 inhibitors is shown in Figure 4.21. In accordance with the model of 
Palomer et al. the crucial pharmacophore features of these molecules are the sulfonyl group 
and the two aromatic six-membered rings [Palomer et al., 2002]. The aromatic rings close to 
the sulfonyl group, further referred to as “ring A”, are nearly parallel to each other in the 
model. The angles between the planes of the distant aromatic rings, further referred to as “ring 
B”, seem to be less constrained. The least conserved region of the model is the linker region 
between the two aromatic ring centers. 
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Figure  4.20.  Reference  COX-2  inhibitors  used  for  the  calculation  of  the  SQUID 
pharmacophore model. 
 
 
SQUID pharmacophore models were calculated with cluster radii from 0.5 Å to 3.5 Å 
in steps of 0.1 Å. A sample set of these pharmacophore models is shown in Figure 4.22. The 
models  consisted  of  only  three  generalized  interaction  types:  hydrogen-bond  donors, 
hydrogen-bond acceptors, and hydrophobic interactions. The model resulting from 1 Å cluster 
radius is the most detailed one. Here atoms in close proximity are combined to PPPs, which 
results in a low abstraction from the chemical scaffolds. In contrast to all other models shown, 
the preferred angle between the two aromatic rings A and B are preserved in this model. The 
models resulting from 1.5 and 2.0 Å exhibit a higher degree of generalization from molecular 
structure.  Many  atoms,  especially  in  the  regions  of  the  aromatic  rings  A  and  B,  were 
combined to form large PPPs, covering several atoms from each of the molecules. Up to 2.0 
Å only hydrophobic atoms were combined. The models from the cluster radii 2.5 Å and 3.0 Å 
still represent the overall shape of the molecular alignment with three hydrophobic PPPs, but 
in the 3.5 Å model the shape of the alignment is only marginally visible. In all models with a 
cluster  radius  up  to  2.0  Å  the  sulfonyl  group  is  represented  by  two  highly  conserved 
hydrogen-bond donor PPPs, one hydrogen-bond donor PPP, and one hydrophobic PPP. In the 
models resulting from cluster radii greater than 2.0 Å all oxygen atoms of the sulfonyl group 
are represented by a single large PPP. Moreover, the hydrophobic PPP vanished since the 
methyl group was assigned to the PPP of ring A. 
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Figure 4.21. Three-dimensional alignment of the COX-2 inhibitors. Rofecoxib and M5 were 
aligned  to  the  crystal  structure  conformation  of  SC-558  bound  to  COX-2.  Essential 
interactions for specific COX-2 inhibitors are the aromatic rings A and B and the sulfonyl 
group. 
 
 
4.6.2 Retrospective screening for COX-2 inhibitors 
As the results of retrospective screening were sensitive to the feature-type weights (data not 
shown), a restrained exhaustive search for the optimization of these weights is part of the 
model creation procedure. For every calculated model, each of the feature-type weights for 
features present in the pharmacophore model was varied from 0.1 to 0.5 in steps of 0.1, which 
resulted in 125 different weighting schemes for the COX-2 pharmacophore models. Each of 
the resulting descriptors was evaluated by retrospective screening. To obtain statistically more 
significant results, five different subsets of the COBRA database were created. For each of the 
subsets 50% of actives and 50% of inactives were randomly chosen from the original database 
for retrospective screening.  
 
 Main Section  113 
 
 
Figure  4.22.  SQUID  fuzzy  pharmacophore  models  for  COX-2  calculated  from  different 
cluster radii. The Gaussian PPPs of SQUID are represented by spheres. The radius of a sphere 
denotes  the  standard  deviation  of  the  PPP  and  the  intensity  of  the  color  illustrates  the 
conservation weight of  the PPP. Yellow = hydrophobic, cyan = hydrogen-bond acceptor, 
magenta = hydrogen-bond donor. 
 
 
The results of the optimization procedure are shown in Figure 4.23. For each model 
calculated with a different cluster radius the average enrichment factors for the first 1% and 
5% of the 5 ranked databases obtained with the best found weighting scheme are shown. The 
highest average enrichment factor of 39 for the first 1% of the database was obtained with the 
model calculated with a cluster radius of 1.4 Å and feature-type weights of 0.1 for hydrogen-
bond donors, 0.4 for hydrogen-bond acceptors and 0.3 for hydrophobic interactions.  
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Figure 4.23. Enrichment factors for the first 1% and 5% from retrospective screening with 
COX-2 pharmacophore models with cluster radii from 0.5 Å to 3.5 Å. For each cluster radius 
the result from the best found feature type weights from the optimization procedure is shown. 
The shown enrichment factors are average values from screening of five randomly selected 
subsets of the COBRA database.  
 
 
As it could be anticipated, the standard deviations of the enrichment factors were the 
highest  for  the  first  1%  and  decreased  for  the  first  5%.  Nevertheless  according  to  their 
standard deviations the enrichment factors for the first 1% of the database still seem to be 
appropriate for an evaluation of our pharmacophore models. Both curves exhibit the same 
general characteristics for different cluster radii, although the differences between the models 
vanish more and more considering the enrichment of the first 5% of the database (Figure 
4.23).  
Considering the performance of the models for the enrichment in the first 1% of the 
database, large enrichment factors could be obtained for all models with a cluster radius from 
0.5 Å to 2.4 Å. As can be seen in Figure 4.22 these models only differ in the description of the 
hydrophobic interactions, while models with 2.5 Å and greater cluster radii differ from the 
other models in the description of the oxygen atoms of the sulfonyl group. The models with a 
large cluster radius use a single PPP for the description of these atoms while the models with 
small cluster radius use two PPPs. It seems that a single PPP for the description of these 
oxygen  atoms  is  not  sufficient  for  a  reasonably  performing  pharmacophore  model.  The 
models from 0.5 Å to 2.4 Å can be divided into 4 groups. The pharmacophore models of the 
first group from 0.5 Å to 0.9 Å with enrichment factors of roughly 27 consist only of PPPs 
merging atoms from different molecules within close spatial proximity, e.g., all aromatic rings 
are described by six PPPs. From 1.0 Å to 1.2 Å a minimum in the performance of the models 
was observed. In these models ring A is represented by six PPPs, and ring B is represented by Main Section  115 
four or five PPPs, which might not be an adequate number for the description of an aromatic 
six-ring. 
The three best performing models were obtained with cluster radii of 1.3 Å to 1.5 Å. 
Both models from 1.4 Å and 1.5 Å describe ring A with a single PPP and ring B with three 
and two PPPs respectively. Like within the poorly performing models employing cluster radii 
from 1.0 Å to 1.2 Å, in the model obtained with a cluster radius of 1.3 Å ring B is represented 
by four PPPs, but ring A is represented by three PPPs. The larger tolerances of the three PPPs 
of ring A might have compensated the unfavorable description of ring B. Within the models 
from 1.6 Å to 2.4 Å the hydrophobic interactions are represented by a decreasing number of 
five to three hydrophobic PPPs. 
For comparison, a pharmacophore model was calculated including the two additional 
COX-2 inhibitors DFU and celecoxib from the model of Palomer et al. [Palomer et al., 2002]. 
A slightly better ef for the first 1% of the database (ef = 40) was obtained with a model 
calculated with a cluster radius of 1.5 Å and feature-type weights of 0.2 for hydrogen-bond 
donors,  0.5  for  hydrogen-bond  acceptors  and  0.5  for  hydrophobic  interactions  (data  not 
shown). 
To test if our approach for the optimization of feature-type weights is also valid in 
situations  with  significantly  fewer  reference  molecules  we  repeated  the  optimization 
procedure with only the molecules from the pharmacophore model as reference molecules for 
assessment of the enrichment capabilities of the SQUID models. For all models with cluster 
radii from 0.5 Å to 2.4 Å several weighting schemes were found that ranked two of the three 
reference molecules into the first percent of the database. In no case all three molecules were 
found in the first percent. Ranking of all models according to Eq. 2.7 resulted in four similarly 
top  scoring  1.4  Å  models  with  different  weighting  schemes.  Among  these  models  the 
previously  found  best  working  model  was  found,  with  feature-type  weights  of  0.1  for 
hydrogen-bond donors, 0.4 for hydrogen-bond acceptors and 0.3 for hydrophobic interactions. 
The worst of the other three models still resulted in an ef of 34 screening the database with the 
92 COX-2 inhibitors.  
For comparison the maximum ef value for COX-2 (all 47 molecules of the first 1% are 
COX-2 inhibitors) would be 51. Accordingly at least 34 times more molecules were found 
than expected from a random selection of molecules and at least two-thirds of the COX-2 
inhibitors which could be found at all in the first 1% were retrieved with the SQUID fuzzy 
pharmacophore models. However one has to take care that the actual values of the ef cannot 
be compared between different sets of molecules because the ef depends on the total number Chapter 4  116 
of active molecules in the virtual screening database and thus on the a priory probability to 
find a hit. A low a priori probability for actives results in a larger increase in the ef value for 
each retrieved active molecule than a high a priori probability.  
To compare our method with another established method we performed retrospective 
screenings with the molecules from which the pharmacophore models were calculated. For 
this approach we encoded these molecules with the CATS3D descriptor, but without scaling 
the descriptor to a maximum of 1. The database molecules were scored by the Euclidean 
distance  to  the  query  molecule  and  the  database  was  sorted  according  to  the  calculated 
distances to the query molecule. A comparison of the results of the similarity search with the 
results obtained from the best SQUID model is shown in Figure 4.24. Rofecoxib performed 
best in comparison to the other two COX-2 inhibitors. This might be a consequence of its 
comparably small size. The pharmacophore model performed better than rofecoxib for the 
first 15% of the database. With the SQUID approach 75% of the active COX-2 inhibitors 
were ranked into the first 6% of the database. In comparison, rofecoxib retrieved 75% of the 
actives among the top  16% of the ranked database.  Interestingly, the  performance of the 
pharmacophore model decreased significantly for the last 25% of the active molecules in 
comparison to the COX-2 inhibitors.  
 
 
 
Figure 4.24. Comparison of the enrichment curves of the best COX-2 SQUID model with 
CATS3D similarity searching using the COX-2 inhibitors from model calculation. 
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4.6.3 Pharmacophore model of thrombin ligands 
A diverse set of seven non-covalent, non-peptidic thrombin inhibitors was adopted from Patel 
et al. [Patel et al., 2002]. The 2D structures of these molecules are shown in Figure 4.25. All 
ligands were aligned by superposition of the protein structures with the homology alignment 
tool of MOE. The resulting alignment of the thrombin inhibitors is shown in Figure 4.26. 
According to Patel and coworkers the major interactions are B, H1, H2 and H3, where B is a 
basic interaction which interacts with the carboxylic group of Asp189. H1, H2 and H3 are 
hydrophobic  interactions.  Less  conserved  interactions  are  D1  and  A1,  where  D1  is  a 
hydrogen-bond donor and A1 is a hydrogen-bond acceptor. SQUID pharmacophore models 
were calculated from the 3D alignment with cluster radii from 0.5 Å to 3.5 Å within steps of 
0.1 Å.  
 
 
 
Figure  4.25.  Reference  thrombin  inhibitors  used  for  the  calculation  of  the  SQUID 
pharmacophore model. The names beneath the molecules are the pdb identifiers of the protein 
structures from which the conformations of these molecules were extracted. 
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A  sample  set  of  the  resulting  models  is  shown  in  Figure  4.27.  Four  generalized 
interaction  types  were  found  in  the  ligands  based  on  the  ph4_aType  function  of  MOE: 
hydrogen-bond  acceptor,  hydrogen-bond  donor,  polar  and  hydrophobic.  Since  all  ligands 
were presented in neutralized state, interaction B was not identified as cationic feature, instead 
it  was  represented  by  hydrogen-bond  donor  and  polar  interactions  and  an  additional 
hydrogen-bond  acceptor.  In  the  1.0  Å  and  1.5  Å  models  the  description  of  the  three 
hydrophobic interactions H1, H2 and H3 is very detailed using a large number of PPPs. With 
a cluster radius of 2.0 Å only four PPPs are left. In the models with cluster radii of 2.5 Å, 3.0 
Å and 3.5 Å these hydrophobic interactions are represented by only three PPPs. Both A1 and 
D1  are  structurally  conserved  features  in  the  alignment.  All  appropriate  atoms  from  the 
different molecules lie in near proximity to each other. A1 is represented by a small conserved 
PPP  in  all  models  except  for  the  3.5  Å  model,  where  it  is  represented  by  a  large  PPP, 
including other hydrogen-bond acceptors. D1 is also represented by a small conserved PPP 
except for the models with 3.0 Å and 3.5 Å cluster radius. 
 
 
 
Figure  4.26.  Three-dimensional  alignment  of  thrombin  inhibitors.  The  molecules  were 
aligned by superposition of their appropriate protein structures. Essential interactions with the 
receptor are: B is a basic interaction, H1, H2, and H3 are hydrophobic interactions, A1 is a 
hydrogen-bond acceptor and D1 is a hydrogen-bond donor. 
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4.6.4 Retrospective screening for thrombin inhibitors 
For  retrospective  screening  with  the  SQUID  pharmacophore  models  obtained  from  the 
alignment of thrombin inhibitors the same procedure for feature-type weight optimization was 
applied  as  for  the  screening  for  COX-2  inhibitors.  For  the  thrombin  optimization  625 
weighting schemes had to be evaluated per model. 
The results of the optimization procedure are shown in Figure 4.28. The best average 
enrichment  factor  of  18  for  the  first  1%  of  the  database  was  obtained  with  the  model 
calculated with a cluster radius of 2.0 Å and feature-type weights of 0.4 for polar, 0.5 for 
hydrogen-bond donors, 0.3 for hydrogen-bond acceptors and 0.5 for hydrophobic interactions.  
 
 
 
Figure 4.27. SQUID fuzzy pharmacophore models for thrombin calculated from different 
cluster radii. The Gaussian PPPs of SQUID are represented by spheres. The radius of a sphere 
denotes  the  standard  deviation  of  the  PPP  and  the  intensity  of  the  color  illustrates  the 
conservation weight of  the PPP. Yellow = hydrophobic, cyan = hydrogen-bond acceptor, 
magenta = hydrogen-bond donor, green = polar. 
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Figure 4.28. Enrichment factors for the first 1% and 5% from retrospective screening with 
thrombin pharmacophore models with cluster radii from 0.5 Å to 3.5 Å. For each cluster 
radius the result from the best found feature type weights from the optimization procedure is 
shown. The shown enrichment factors are average values from screening of five randomly 
selected subsets of the COBRA database.  
 
 
We detected two peaks for each of the enrichment factors, one for models with a high 
degree of generalization with cluster radii from 2.0 Å to 2.2 Å, and one for models with a 
lower degree of generalization with cluster radii of 1.0 Å and 1.1 Å. Interestingly, models 
with cluster radii greater than 2.8 Å performed very well, too. As can be seen in Figure 4.27, 
the model with a cluster radius of 1.0 Å from the first peak mainly clustered atoms within 
near proximity into PPPs, while already favoring conserved atoms. The model with a cluster 
radius of 2.0 Å from the second peak represents the features with a drastically diminished 
overall number of PPPs. In particular the three hydrophobic interactions are represented by 
four PPPs, in contrast to all other models with a smaller cluster radius. The models resulting 
from cluster radii larger than 2.8 Å consist mostly of PPPs with large tolerances, but unlike 
for COX-2, these PPPs represent the shape of the molecular alignment very well. 
Like for COX-2 the optimization procedure was repeated with only the molecules 
from the pharmacophore model as reference molecules. For many models weighting schemes 
were  found  which  ranked  two  of  the  seven  reference  molecules  into  the  first  1%  of  the 
database.  In  no  case  more  molecules  were  found  in  the  first  1%.  Ranking  of  all  models 
according to Eq. 2.7 resulted in the previously found best working 2.0 Å model with feature-
type weights of 0.4 for polar interactions, 0.5 for hydrogen-bond donors, 0.4 for hydrogen-
bond acceptors and 0.5 for hydrophobic interactions. Main Section  121 
The result of the 2.0 Å SQUID model was compared with results from retrospective 
screening with CATS3D descriptors calculated from the molecules used for the calculation of 
the pharmacophore model. Enrichment curves are shown in Figure 4.29. Major differences 
were observed in the performance of the individual thrombin inhibitors. The inhibitors from 
the crystal structures 1FPC and 1DWD performed best. The three inhibitors from structures 
1D4P,  1D9I,  and  1TOM  performed  even  worse  than  a  random  distribution  of  active 
molecules within some regions of the ranked database. The SQUID pharmacophore model 
performed better than the most successful similarity search for the first 40% of the database. 
50%  of  the  active  molecules  were  ranked  into  the  first  6%  of  the  database  by  the 
pharmacophore  model  in  comparison  to  the  best  thrombin  inhibitor  from  1DWD,  which 
ranked 50% of the active molecules into the first 13% of the database. 
 
 
 
Figure 4.29. Comparison of the enrichment curves of the best thrombin SQUID model with 
CATS3D similarity searching using the thrombin inhibitors from the model calculation. 
 
 
4.6.5 Method performance 
For  an  additional  comparison  of  the  SQUID  pharmacophore  model  with  an  established 
method  we  calculated  pharmacophore  models  from  the  two  alignments  of  COX-2  and 
thrombin reference compounds with the pharmacophore tool of MOE [Chemical Computing 
Group]. For both models we used the atom-type scheme PCH_ALL which consists of atom-
types  for  cationic,  anionic,  hydrogen-bond  donor,  hydrogen-bond  acceptor,  aromatic  ring Chapter 4  122 
centers and hydrophobic interactions. In contrast to SQUID, one PPP in MOE can describe 
multiple atom-types, which can be combined by logic operators. As a starting point for the 
alignments  pharmacophore  models  were  calculated  automatically  with  the  consensus 
pharmacophore function using MOE default parameters. This function clusters features into 
PPPs which are more conserved than a threshold value. For the threshold 50 % conservation 
was used. Retrospective screening with these first pharmacophore models was very slow and 
the program even failed to screen the whole database due to limitations of the software. As a 
consequence, we modified the models manually by removing PPPs which were not among the 
key features of the pharmacophore models published by Palomer et al. [Palomer et al., 2002] 
or Patel et al. [Patel et al., 2002] respectively (Figure 4.21, Figure 4.26). For the thrombin 
model the radii and the positions of the PPPs for H1, H2 and D1 were manually adjusted for a 
more accurate representation of the underlying ring structures and the cluster of hydrogen-
bond donors. Additional multiple features of the PPPs were also removed. The resulting MOE 
pharmacophore  models  are  shown  in  Figure  4.30.  Both  models  were  evaluated  by 
retrospective screening of the COBRA database.  
With the MOE COX-2  model (Figure 4.30a) we retrieved 84 matching molecules 
among which we found 49 (58 %) of the known COX-2 inhibitors. In comparison, the COX-2 
SQUID model found 47 (56 %) active molecules in the first 84 compounds from the ranked 
database. Reinsertion of a PPP from the first MOE model, which represents the central five-
ring of the COX-2 inhibitors by an acceptor, aromatic or hydrophobic interaction, resulted in 
48 actives (91 %) out of 53 matches. Within the first 53 molecules of the ranked database the 
SQUID pharmacophore model retrieved only 38 (72 %) active compounds. A comparison of 
the actives found by MOE and SQUID showed that the overlap was only 25 molecules, i.e., 
that both methods complement each other. SQUID retrieved additional 13 actives which were 
missed by the refined MOE model. 
With the MOE thrombin model (Figure 4.30b) we retrieved 5 actives (31 %) among 
16 matches, in comparison to the SQUID model which retrieved 13 actives (81 %) among the 
first  16  molecules  of  the  sorted  database.  Retrospective  screening  with  the  partial  match 
option of the MOE pharmacophore search function requiring only six of the seven PPPs as 
matching criterion resulted in 489 matches including 87 (18 %) thrombin inhibitors. With 
SQUID 119 actives (24 %) were found among the first 489 molecules of the ranked database. 
The two sets of actives have 64 molecules in common. Again, we conclude that the two 
pharmacophore searching approaches complement each other. 
 Main Section  123 
 
 
Figure 4.30. MOE Pharmacophore models for COX-2 (a) and thrombin (b). In the COX-2 
pharmacophore model the rings A and B are represented by two aromatic ring center PPPs, 
and the sulfonyl group is represented by a PPP for a donor or hydrophobic interaction. In the 
thrombin pharmacophore model the hydrophobic interactions H1 and H2 are represented by 
hydrophobic PPPs while H3 is represented by an aromatic PPP. For A1 a hydrogen-bond 
acceptor PPP and for D1 a hydrogen-bond donor PPP was found. The basic interaction B was 
represented by two PPPs, one for hydrogen-bond acceptor or hydrogen-bond donor and one 
for hydrogen-bond acceptor and hydrogen-bond donor. 
 
 
To gain further confidence in our approach we took a look at the two top-scoring non-
active  molecules  from  each  of  the  best  pharmacophore  models  for  COX-2  and  thrombin 
(Figure 4.31). Molecules 4.6.11 [Woo et al., 1998] and 4.6.12 [Supuran et al., 2003] were 
found with the COX-2 pharmacophore model with 1.4 Å cluster radius, and molecules 4.6.13 
[Marlowe  et  al.,  2000]  and  4.6.14  [Rudolf  et  al.,  1994]  were  found  with  the  thrombin 
pharmacophore model with 2.0 Å cluster radius. Ethoxzolamide (4.6.12) is an inhibitor of 
carbonic anhydrase. Also, it has been shown recently that celecoxib is a nanomolar inhibitor 
of  carbonic  anhydrase  [Weber  et  al.,  2004].  EMATE  (4.6.11)  is  an  inhibitor  of  estrone 
sulfatase, and a nanomolar inhibitory effect of EMATE on carbonic anhydrase activity has 
been  reported  [Ho  et  al.,  2003].  This  indicates  that  both  “non-active”  molecules  share 
common features with the COX-2 inhibitors from the pharmacophore model.  
Molecule  4.6.13  (BOC-D-Arg-Pro-Arg)  is  an  inhibitor  of  Factor  Xa  for  which 
nanomolar inhibition of thrombin has been reported [Ho et al., 2003]. It thus represents a real 
hit. BIBP3226 (4.6.14) is an antagonist of the neuropeptide Y1 receptor. To our knowledge 
thrombin activity has not been tested for this molecule.  
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Figure 4.31. Best scoring false-positive hits found with the SQUID fuzzy pharmacophore 
models. Compounds 4.6.11 and 4.6.12 were found with the COX-2 pharmacophore model 
with 1.4 Å cluster radius. Compounds 4.6.13 and 4.6.14 were found with the thrombin model 
derived form 2.0 Å cluster radius. 
 
 
4.6.6 Conclusion 
We  challenged  our  SQUID  approach  using  inhibitors  of  COX-2  and  thrombin.  For  both 
classes COX-2 and thrombin SQUID pharmacophore models were able to find an appropriate 
representation  of  important  pharmacophoric  interactions.  The  optimization  procedure  was 
found to be robust in cross-validation using five different randomly sampled subsets of 50 % 
of  the  COBRA  database.  Using  only  the  molecules  from  the  pharmacophore  model  as 
references for the optimization resulted in identical (COX-2) or near identical (thrombin) 
results as for using all active molecules as references. The best retrospective screening results 
for COX-2 were obtained with the model resulting from a cluster radius of 1.4 Å, yielding an 
enrichment factor of 39 for the first 1% of the ranked database. For thrombin, the best results 
for the enrichment in the first 1% of the database were obtained with the model resulting from 
a cluster radius of 2.0 Å, yielding ef = 18. For both targets, the best models outperformed 
retrospective  screening  by  CATS3D  similarity  searching.  This  showed  that  -  independent 
from the overall enrichment and thus independent of the explicit selection of active molecules 
- the pharmacophore model outperformed conventional similarity searching. In comparison to 
conventional pharmacophore searching with MOE, SQUID identified additional actives and 
thus complements existing methods. We demonstrated that the SQUID pharmacophore model Main Section  125 
approach provides a potentially useful new method for virtual screening. The inherent fuzzy 
description of the molecules should support the goal of ‘scaffold hopping’, especially with 
higher degrees of fuzziness.  
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4.7 Prospective  screening  for  inhibitors  of  the  Tat-TAR 
RNA  interaction  with  a  SQUID  fuzzy  pharmacophore 
model and CATS3D 
RNA  is  a  relatively  new  target  to  be  tackled  deliberately  in  drug  discovery  projects. 
Molecules inhibiting the interaction between the TAR RNA and the Tat protein might be 
useful to defeat HIV. The first inhibitor found was argininamide (4.7.1), a derivative of the 
arginine which is responsible for specific binding of Tat to TAR [Tao & Frankel, 1992]. So 
far, only structure-based virtual screening has been reported for TAR, where an automated 
docking approach including a scoring function optimized for RNA led to the identification of 
acetylpromazine (4.7.2) and chlorpromazine (4.7.3) [Lind et al., 2002]. 
An  alternative  for  structure-based  virtual  screening  are  ligand-based  approaches 
[Schneider  &  Böhm,  2002].  Especially  methods  including  the  active-analog  idea  of 
pharmacophores have been shown to be suited for scaffold-hopping [Schneider et al., 1999]. 
Pharmacophore based similarity searching which was originally developed to identify protein-
ligands might be robust enough to identify new RNA ligands without altering the definitions 
of the pharmacophoric interactions towards RNA specific interactions.  
The  goal  of  this  study  was  to  enhance  the  evaluation  CATS3D  and  SQUID  with 
prospective  virtual  screening  experiments.  Further  the  applicability  of  our  alignment-free 
pharmacophore based virtual screening approaches should be tested for RNA targets. The 
SPECS  compound  set  [SPECS]  containing  229,658  screening  compounds  was  virtually 
screened for potential inhibitors of the Tat-TAR interaction. Virtual screening consisted of 
three  steps:  i)  calculation  of  a  “drug-likeness”  score  by  an  artificial  neural  network  as  a 
prescreening  step,  ii)  CATS3D  pharmacophore  similarity  searching,  and  iii)  SQUID 
pharmacophore  similarity  searching  based  on  the  flexible  alignment  of  known  active 
reference molecules. Steps ii) and iii) were performed independently for the 20,000 most 
“druglike” compounds. Main Section  127 
 
 
Figure 4.32. NMR structures of TAR RNA. a) TAR with bulge binders: 1anr (free TAR), 
1qd3  (TAR  complexed  with  neomycin),  1arj  (arginine),  1aju  (argininamide),  1lvj 
(acetylpromazine). ). The bulge nucleotides are represented in space filling: U23 (blue), C24 
(green),  and  U25  (red).  All  structures  are  from  HIV-1  TAR  except  1aju  (HIV-2,  C24  is 
missing). b) Binding pockets of the TAR ligands. Surface representation of the binding sites, 
mapped by electrostatic partial charges (red = negative partial charge, blue = positive partial 
charge). 
 
 
Figure  4.33.  TAR-Tat  interaction  inhibitors.  Argininamide  4.7.1,  acetylpromazine  4.7.2, 
chlorpromazine 4.7.3, CGP40336A 4.7.4. Chapter 4  128 
 
 
 
Figure 4.34. Modification of ligand 4.7.4 for the alignment. 
 
 
4.7.1 Calculation of an alignment of reference compounds 
Several  NMR  structures  of  the  TAR-RNA  with  bound  inhibitors  are  publicly  available 
(Figure  4.32).  Different  ligands  address  different  binding-sites  and  stabilize  different 
conformations  of  the  bulge  (Figure  4.32a).  Acetylpromazine  (4.7.2)  is  bound  in  a  deep 
binding-site mediated by  a combination of stacking and charged interactions whereas the 
other ligands are bound in shallow binding-sites dominated by charged interactions (Figure 
4.32b). Because of the seemingly more druglike relation of ligand-receptor interactions in the 
acetylpromazine binding-site in comparison to the other sites we decided to design ligands for 
the former binding-site. Acetylpromazine (4.7.2) [Lind et al., 2002] and CGP40336A (4.7.4) 
[Hamy  et  al.,  1998]  (Figure  4.33)  were  chosen  as  reference  ligands  from  literature  with 
reported  nanomolar  IC50  values.  For  both  molecules  binding  to  the  bulge  had  been 
experimentally verified, however detailed structural data was not available for 4.7.4. As 4.7.4 
contains a ring system -- which might be involved in stacking interactions like in 4.7.2 -- and 
a charged flexible part -- which might interact similar to a potential charge-p interaction of 
4.7.2 with C24 [Du et al., 2002] --, we assumed that 4.7.4 could have a comparable binding 
mode as 4.7.2. For calculation of a SQUID model the two ligands had to be aligned to each 
other. One possibility would be to dock the reference ligands into the TAR binding pocket; 
the other possibility is to perform a flexible ligand-based alignment. Since we were not able to 
reproduce the experimentally determined TAR-bound conformation of acetylpromazine 4.7.2 
within the binding pocket using either MOE [Chemical Computing Group] docking or the 
AUTODOCK  approach  [Morris  et  al.,  1998]  (results  not  shown),  we  decided  to  align 
CGP40336A 4.7.4 to the NMR conformation of 4.7.2 by help of the flexible alignment tool of 
MOE. Interestingly, fruitless attempts to reproduce the NMR structure of 4.7.2 complexed to Main Section  129 
TAR RNA was also reported by Detering and Varani who successfully reproduced many 
other  RNA-ligand  complexes  using  AUTODOCK,  but  failed  to  reproduce  the 
acetylpromazine binding mode with an RMSD value below 2 Å [Detering & Varani, 2004]. 
Their study supports our decision to follow the ligand-based alignment approach. For the 
alignment calculation we used the first NMR model of the Protein Database entry (PDB code: 
1LVJ) [Du et al., 2002]. Since it was not possible to predict reasonable conformations of the 
aliphatic amino groups of 4.7.4 based on flexible alignment alone, we decided to cut off these 
groups and use molecule 4.7.5 instead (Figure 4.34) for the alignment and virtual screening. 
The top scoring solutions of the flexible alignment were visually inspected, and we selected 
the  conformation  where  the  ligand  appeared  to  fit  best  into  the  receptor  (Figure  4.35). 
Stacking  and  polar  interactions  of  4.7.4  occupy  the  same  parts  of  the  binding  pocket  as 
acetylpromazine 4.7.2, so we think that a reasonable starting solution was found.  
 
 
 
Figure 4.35. Alignment of 4.7.5 to the NMR conformation of 4.7.2 (a) (PDB-code: 1LVJ). 
The alignment shown in the binding pocket of TAR (b) with 4.7.2 in red and 4.7.5 in green. Chapter 4  130 
4.7.2 Calculation of pharmacophores and virtual screening 
For  virtual  screening  with  CATS3D  we  calculated  the  CATS3D  descriptor  from  those 
conformations  of  the  reference  molecules  that  resulted  from  the  flexible  alignment.  For 
screening with the SQUID pharmacophore model the best resolution of the model, i.e. the 
optimal  PPP  cluster  radius,  and  the  best  weights  for  the  different  features  had  to  be 
determined. The performance of the different parameter sets was determined by their ability 
to rank the two molecules from the pharmacophore model to top positions in comparison to 
molecules from the COBRA reference dataset [Schneider & Schneider, 2003] (version 3.12) 
of bioactive molecules, as described earlier in Section 4.6.  
For the optimization cluster radii from 0.5 to 3.0 Å in steps of 0.1 Å were applied. 
Feature  type  weights  were  applied  from  0.1  to  0.5  in  steps  of  0.1  for  hydrogen-bond 
acceptors,  hydrogen-bond  donors  and  hydrophobic  interactions.  This  resulted  in  125 
combinations of feature type weights explored for each of the 26 cluster-radii. For all cluster 
radii models were found which ranked at least one of the query compounds into the first 1% 
of the hit-list. Equal best results were obtained with cluster-radii of 1.4, 1.5, and 1.6 Å: the 
same eight combinations of feature type weights were found for each model ranking both 
query compounds into the first 1% of the database. The eight combinations were: {(0.1 for 
hydrogen-bond donors, 0.2 for hydrogen-bond acceptors, 0.3 for hydrophobes), (0.1, 0.3, 0.3), 
(0.1, 0.3, 0.4), (0.1, 0.4, 0.4), (0.1, 0.4, 0.5), (0.1, 0.5, 0.5), (0.2, 0.4, 0.5), (0.2, 0.5, 0.5)}. For 
virtual screening we chose the intermediate model with cluster radius = 1.5 Å and weights of 
(0.1, 0.3, 0.4). The selected pharmacophore model is shown in Figure 4.36.  
 
 
 
Figure 4.36. SQUID fuzzy pharmacophore model derived from 4.7.2 and 4.7.5 in top-view 
(a) and side-view (b). The spheres represent the Gaussian PPPs of SQUID. The radius of a 
sphere denotes the standard deviation of the PPP and the intensity of the color illustrates the 
conservation weight of  the PPP. Yellow = hydrophobic, cyan = hydrogen-bond acceptor, 
magenta = hydrogen-bond donor. Main Section  131 
 
Three virtual screening experiments were performed with different queries: i) + ii) the 
two CATS3D CVs which were calculated from molecules 4.7.2 and 4.7.5, and iii) the CV 
from the optimized SQUID pharmacophore model. From the results the top scoring database 
molecules were visually inspected, and a set of 19 molecules (10 molecules from SQUID and 
10 molecules from CATS3D, one molecule overlap) was selected for experimental testing 
(Figure 4.37). To estimate the degree of “scaffold-hopping” of the retrieved molecules the 
average  MACCS  Tanimoto  similarity  of  the  hits  to  the  respective  most  similar  reference 
molecules was calculated. For SQUID this similarity was found to be 0.52 ± 0.13 and for 
CATS3D 0.53 ± 0.11. For comparison the MACCS Tanimoto similarity between the two 
reference  molecules  was  found  to  be  0.61.  According  to  this  criterion  the  chemotypes 
retrieved were more dissimilar to the reference chemotypes than the references to themselves.  
 
4.7.3 FRET determination of the inhibition constants 
All  19  molecules  were  tested  for  their  potency  in  a  Tat-TAR  inhibition  assay  (These 
experiments were performed by Verena Ludwig and Ute Scheffer in collaboration with the 
group of Prof. Göbel, Frankfurt). As reference we determined the IC50 values of argininamide, 
acetylpromazine  and  chlorpromazine  --  three  inhibitors  from  the  literature  with  reported 
values  of  Ki  ~  1  mM  for  argininamide  [Tao  &  Frankel,  1992],  and  IC50  <  1  µM  for 
acetylpromazine and chlorpromazine . IC50 values in our assay were 1.4 mM for argininamide 
and  500  µM  for  acetylpromazine  and  chlorpromazine  [Lind  et  al.,  2002].  The  strong 
discrepancy in the IC50 for acetylpromazine and chlorpromazine compared to the reported 
values is in accordance with a recently published article which reported a discrepancy in the 
same order of magnitude for acetylpromazine (KD = 270 µM compared to IC50 ~ 1 µM, as 
previously stated) [Mayer & James, 2004]. As a first prescreening of the compounds we 
performed  single-point  measurements  of  the  inhibition  potency  using  three  fixed 
concentrations of 10, 100 and 1000 µM of the candidate molecule. Molecules 4.7.14 (hit form 
SQUID) [Tugusheva et al., 1998] and 4.7.21 (hit from CATS3D with reference molecule 
4.7.5) [Shanazarov et al., 1989] (Figure 4.37) showed a stronger inhibition than argininamide 
in the single point measurements. Multipoint measurements yielded IC50 values of 46 µM and 
500 µM for 4.7.14 and 4.7.21, respectively.  
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Figure 4.37. Molecules selected from SQUID and CATS3D virtual screening.  
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Figure  4.38.  Flexible  alignment  of  4.7.14  (a)  and  4.7.21  (b)  to  the  aligned  reference 
molecules 4.7.2 (red) and 4.7.5 (green). 
 
 
The  two  ligand-based  pharmacophore  methods  were  able  to  perform  “scaffold-
hopping”, retrieving isofunctional but slightly different molecular scaffolds from the SPECS 
catalogue.  Both  new  ligands  contain  a  central  structure  consisting  of  three  rings  with  an 
aliphatic  amide  side-chain,  like  the  reference  compounds.  An  additional  aromatic  ring  is 
present at different positions in both molecules, extending the original ring systems to four 
concatenated  rings.  Flexible  alignments  of  4.7.14  and  4.7.21  (Figure  4.38)  revealed  that 
4.7.14 fits better to the reference alignment than 4.7.21. Also, the aliphatic amide side-chain 
of 4.7.14 was closer aligned to the corresponding side-chains of the references. The nitrogen 
of the additional pyridine ring of 4.7.14 was positioned directly above the potential hydrogen-
bond acceptors of the reference molecules. In both 4.7.14 and 4.7.21 the additional ring might 
be used for more favorable stacking interactions with the receptor. In 4.7.21 this potentially 
favorable  effect  might  have  been  compensated  by  steric  stress  due  to  an  unfavorable 
orientation  of  the  ring  or  the  amide  side-chain.  Still  the  IC50  value  is  comparable  to 
acetylpromazine and chlorpromazine.  
 
4.7.4 Conclusions 
In this study we presented the application of two ligand-based virtual screening approaches 
for the compilation of a small focused library containing potential TAR RNA ligands. Among 
the 19 molecules tested we found two molecules which were able to inhibit the Tat-TAR 
interaction in a FRET assay. The SQUID fuzzy pharmacophore approach yielded the most Chapter 4  134 
potent  molecule  with  an  improved  activity  of  one  order  of  magnitude  compared  to 
acetylpromazine  4.7.2  or  chlorpromazine  4.7.3.  This  could  be  an  effect  of  incorporating 
information from multiple active reference molecules into the pharmacophore-based search 
for new TAR ligands.  
Ligand-based approaches provide a complementary concept to structure based design, 
which might be hampered by the large inherent flexibility of RNA targets. Though it has been 
shown that specific parameterization of scoring functions is not essential for ligand docking to 
RNA it is still significantly slower than a ligand-based approach [Detering & Varani, 2004]. It 
has been demonstrated that ligand-based pharmacophore approaches are capable of finding 
new RNA ligands. Although the best molecule resulted in a moderate IC50 of only 46 µM in 
the  FRET  assay  this  molecule  might  provide  a  starting  point  for  further  optimization. 
Certainly, other assay types will be needed to confirm and further scrutinize these findings. 
The  new  inhibitors  might  not  represent  ideal  candidates  for  starting  a  lead  optimization 
project. Additional experiments will have to be performed addressing the question which role 
the  additional  ring  system  actually  plays  for  RNA  recognition  and  binding  affinity. 
Furthermore, structures 4.7.14 and 4.7.21 might be intercalating agents and exhibit unspecific 
binding to both RNA and DNA targets due to the planar ring systems and relatively high 
lipophilicity. Such issues could also be addressed in a different setting of the virtual screening 
approach.  For  example,  to  obtain  selectivity  towards  RNA,  known  DNA-binders  and 
intercalators  might  be  used  as  negative  examples  for  similarity  searching.  This  tactic  is 
currently pursued in our laboratory. 
Irrespective of the outcome of such analyses, both ligand-based methods have proved 
to  be  useful  for  finding  new  molecules  within  the  activity  range  of  known  reference 
compounds. Notably both approaches were originally developed for protein ligands, but they 
also seem to be applicable to virtual screening for RNA ligands. To our knowledge this study 
presents  the  first  inhibitors  of  an  RNA-protein  complex  found  by  ligand-based  virtual 
screening. 
 
 
 
 Main Section  135 
 
4.8 Prospective  screening  for  taspase1  inhibitors  with  a 
receptor-derived pharmacophore model 
 
When  no  ligand  and  no  receptor  structure  information  are  available  for  virtual  screening 
alternative approaches have to be applied. One possibility is to predict the protein structure 
with a homology model and utilize the predicted structure for virtual screening [Hillisch et al., 
2004; Bissantz et al., 2003; Grüneberg, 2005;  Evers  & Klebe, 2004;  Evers  & Klabunde, 
2005]. Homology models are better described as a good approximation of the real protein 
structure than as a high accuracy replicate. Hence, high-throughput docking studies can be 
misleading,  when  based  on  homology  models  alone.  An  alternative  to  this  approach  are 
receptor-derived pharmacophore models [Wolber & Langer, 2005; Pirard et al., 2005]. Such 
an  approach  was  used  to  search  for  a  first  inhibitor  of  human  taspase1.  Taspase1  is  a 
threonine protease [Hsieh et al., 2003] and hence the problem of finding an inhibitor for 
taspase1 involves the problem of scaffold-hopping form a peptide substrate to a drug-like 
molecule  inhibitor.  This  is  a  comparably  complex  task  for  ligand-based  pharmacophore-
descriptor  approaches  like  the  CATS  descriptor  that  are  often  hampered  by  the  many 
potentially  interacting  groups  in  peptides  [Sheridan  et  al.,  2001].  Thus  a  pharmacophore 
model focusing on small numbers of relevant interactions might be favorable for this task. 
The sequence of the human taspase1 from the swiss-prot entry Q9H6P5 was used for a 
BLAST [Altschul et al., 1997] search for related protein structures from the PDB database 
[Berman et al., 2000]. Protein structures were selected with a significant similarity in both 
subunits of taspase1. Mutant proteins were discarded. An overview of the PDB structures 
which were finally selected is given in Table 4.16.  
1T3M [Prahl et al., 2004] is an isoaspartyl peptidase with an additional L-asparaginase 
activity [Hejazi et al., 2002; Borek et al., 2004] (Figure 4.39). 2GAW [Guo et al., 1998] and 
1APZ [Oinonen et al., 1995] have a glycosylasparaginase activity and also an L-asparaginase 
activity [Noronoski et al., 1997, Tarentino & Plummer, 1993] (Figure 4.39). All activities 
include the hydrolysis of a beta-N amide linking an aspartate and varying substituents. In 
taspase1 there is also an amide bond hydrolyzed (Figure 4.39): the peptide bond between 
aspartate and glycin. Though the glycin is not bound to the beta amide of an asparagine, the 
sidechain carboxyl group of this aspartate might interact similarly to the free carboxyl group 
of  the  asparagine  of  the  other  enzymes.  For  all  enzymes,  isoaspartyl  peptidase, 
glycosylasparaginases  and  taspase1  is  has  been  demonstrated  that  they  undergo Chapter 4  136 
autoproteolysis as an activation step, which is mediated by the same reaction centre as used 
for the enzymatic activity [Xu et al., 1999, Hsieh et al., 2003]. Accordingly all actives sites 
have a proteolytic activity.  
 
 
Table  4.16.  Selected  reference  protein  structures  for  homology  modeling  of  taspase1. 
Identities were determined according to the BLAST alignment. (NT = N-terminal subunit; CT 
= C-terminal subunit). 
 
PBD code    1T3M  2GAW  1APZ 
% sequence 
identity 
NT: 
CT: 
42 / 151 (27%) 
35 / 70 (50%) 
29 / 87 (33%) 
22 / 68 (32%) 
22 / 48 (45%) 
29 / 98 (29%) 
e-value  NT: 
CT: 
4e
-9 
7e
-12 
4e
-5 
4e
-6 
3e
-5 
2e
-5 
crystal structure 
resolution 
  1.65 Å  2.2 Å  2.3 Å 
enzymatic 
function 
  isoaspartyl 
peptidase / L-
asparaginase 
glycosyl-
asparaginase 
glycosyl-
asparaginase 
organism    Eschrichia coli  Flavobacterium 
meningosepticum 
Human 
 
 
The structure 1APZ is a co-crystal structure of glycosylasparaginase with the reaction 
product aspartate. Mutagenesis experiments of residues near to the bound aspartate identified 
a set of eight amino-acids essential for the catalytic activity [Liu et al., 1998]. An overview of 
the spatial orientation of these sidechains with respect to the bound aspartate is given in 
Figure  4.40.  T152  is  the  key  functionality  providing  the  nucleophile  for  the  hydrolase 
reaction.  The  hydroxyl  of  T170  contributes  to  the  reaction  rate.  D183  and  R180  bind  to 
aspartate via hydrogen or ionic bonds to the alpha amino- and the alpha carboxy-group. W11 
is involved in the regulation of the enzyme reaction rate. S50, D66 and T203 were also shown 
to be important for the enzymatic activity. A ninth important residue is revealed by the crystal 
structure  1APZ:  G203  which  shows  a  hydrogen  bonding  interaction  with  the  aspartate 
mediated via the back-bone oxygen of the glycine. 
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Figure 4.39. Reactions catalyzed by the isoaspartyl peptidase (PDB code 1T3M) and the 
glycosylasparaginases (PDB code 2GAW and 1APZ) in comparison to taspase1. 
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Figure 4.40. Aspartate bound in the active site of 1APZ. Essential residues in the binding 
pocket are indicated.  
 
 
To construct a template for the calculation of a homology model of taspase1 all three 
crystal structures were aligned based on the structure of the enzymes with the homology align 
tool in MOE [Chemical Computing Group]. This structural alignment was used as a template 
to align the taspase1 sequence. The resulting alignment is shown in Figure 4.41. All residues 
considered essential for the enzymatic activity in 1APZ [Liu et al., 1998], except for W11, 
were  fully conserved  (D66, T152, R180, G204) or replaced by isofunctional amino-acids 
(S50A,  T170S,  D183Q,  T203S).  The  full  conservation  of  the  reaction  center  T152,  the 
carboxyl interaction partner R180, the hydrogen-bond acceptor interaction of G204, and D66 
reflects the similar reaction of the enzymes and underlines the possibility of a similar binding 
mode of the ligands. 
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N-terminus 
                                           W11 
                                            | 
>1APZ.A         ------------------SPLPLVVNT-WPF---KNATEAAW-RALASGGSALDAVESGC 
>1T3M.A         ----GKAVIAIHGGAGAISRAQMSLQQELRYIEALSAIVETGQKMLEAGESALDVVTEAV 
>2GAW.A         -------------------NKPIVLST-WNF--GLHANVEAW-KVLSKGGKALDAVEKGV 
>Taspase_N      (39)RGGFVLVHAGAG--YHSESKAKE-YKHV-CKRACQKAI-EKLQAGALATDAVTAAL 
Consensus/100%  ......thlhlHtGAG........hpp.b.al.sbpA...sh.c.L..G..AhDsVp.th 
 
                         S50             D66 
                          |               | 
>1APZ.A         AMCEREQCDGSVGFGGSPDELGETTLDAMIMDGTTMDVGAVGDLRRIKNAIGVA-RKVLE 
>1T3M.A         RLLEECPLFNA-GIGAVFTRDETHELDACVMDGNTLKAGAVAGVSHLRNPVLAA-RLVME 
>2GAW.A         RLVEDDPTERSVGYGGRPDRDGRVTLDACIMDEN-YNIGSVACMEHIKNPISVA-RAVME 
>Taspase_N      VELEDSPFTNA-GMGSNLNLLGEIECDASIMDGKSLNFGAVGALSGIKNPVSVANRLLCE 
Consensus/100%  .bhEcp.h..tVGbGt..sb..phphDA.lMD.p*bphGtVtshp.l+Nsl.sA.R.lhE 
 
>1APZ.A         ---------HTTHTLLVGESATTFAQSMGFINEDLSTSASQALHSDWLARNCQPNYWRNV 
>1T3M.A         ---------QSPHVMMIGEGAENFAFARGMERVSPEIFSTSLRYEQLLAAR--------- 
>2GAW.A         ---------KTPHVMLVGDGALEFALSQGFKKENLLTAESEKEWKEWLKT---------- 
>Taspase_N      GQKGKLSAGRIPPCFLVGEGAYRWAVDHGIPSCPPNIMTTRFSLAAFKRNKRKLELAERV 
Consensus/100%  .........p.s.sbblG-tA.paA.sbGb.p.s..h..*p..b..bb..ppp.pbhcpV 
 
>1APZ.A         IPDPSKYCGPYKPP---- 
>1T3M.A         ------------------ 
>2GAW.A         ------------------ 
>Taspase_N      DTDFMQLKKRRQSS(10) 
Consensus/100%  .sD..pbp..bpss.... 
 
C-terminus  
               T152              T170     R180 D183                  T203  G204  
                |                 |         |  |                         \/ 
>1APZ.B         TIGMVVIHKTGHIAAGTSTNGIKFKIHGRVGDSPIPGAGAYADDT------AGAAAATGN 
>1T3M.B         TVGAVALDLDGNLAAATSTGGMTNKLPGRVGDSPLVGAGCYANNA------SVAVSCTGT 
>2GAW.B         TIGMIALDAQGNLSGACTTSGMAYKMHGRVGDSPIIGAGLFVDNE------IGAATATGH 
>Taspase_C      TVGAVVVDHEGNVAAAVSSGGLALKHPGRVGQAALYGCGCWAENTGAHNPYSTAVSTSGC 
Consensus/100%  TlGhlslc.pGplttts**sGb..Kb.GRVGptsl.GsGhasps.......sAsss*Gp 
 
>1APZ.B         GDILMRFLPSYQAVEYMR-RGEDPTIACQKVI-SRIQKHFP-------EFFGAVICANV- 
>1T3M.B         GEVFIRALAAYDIAALMDYGGLSLAEACERVVMEKLPALG---------GSGGLIAIDH- 
>2GAW.B         GEEVIRTVGTHLVVELMN-QGRTPQQACKEAV-ERIVKIVNRRGKNLKDIQVGFIALNK- 
>Taspase_C      GEHLVRTILARECSHAL--QAEDAHQALLETMQNKFISSPFLASED--GVLGGVIVLRSC 
Consensus/100%  G-.hhRhl.sb.hs.hbp..tbs..bAhbcshbp+b.....b.tcs...h.sthIshp.. 
 
>1APZ.B         --TGSYGAACNKLSTFTQFSFMVYNSEKNQPTEEKVDCI---- 
>1T3M.B         --EGNVALPFN----TEGMYRAWGYAG-DTPTTGIYR------ 
>2GAW.B         --KGEYGAYCIQ----DGFNFAVHDQ-K-GNRLETP------- 
>Taspase_C      RCSAEPDSSQNK--QTLLVEFLWSHTT-ESMCVGYMSAQ(35) 
Consensus/100%  ..ptp.s....p..ph..h.bhh....Kp..p....psb.... 
 
Figure  4.41.  Alignment  of  the  C-terminal  and  the  N-terminal  taspase1  sequences  to  the 
structural  alignment  of  1T3M,  1APZ  and  2GAW.  Consensus  symbols  other  than  residue 
letters are: - = negative, * = ser/thr, | = aliphatic, + = positive, t = tiny, a = aromatic, c = 
charged, s = small, p = polar, b  = big, h  = hydrophobic. Essential residues for  catalytic 
activity in glycosylasparaginase are marked according to the numbering of [Liu et al., 1998]. 
Amino acid symbols at alignment positions that are 100% conserved over proteins that have a 
residue at the respective positions were colored. Conservation was first considered on the 
level of residue identity. For non-identical residues conservation was further considered on 
the level of similar biochemical properties:  red = negative,  cyan  = S/T, grey  highlighted 
yellow = aliphatic, dark blue = positive, light green = tiny, dark blue highlighted yellow = 
aromatic, pink = charged, dark green = small, light blue = polar, light blue highlighted yellow 
= big, black highlighted yellow = hydrophobic.  Chapter 4  140 
 
Figure 4.42. Evaluation of the taspase1 homology model. a) Binding pocket of taspase1 with 
essential residues. Y52 was the only binding-site residue flagged in the MOE protein report to 
have  unusual  backbone  torsion  angles.  b)  Structure  alignment  of  the  taspase1  homology 
model with the reference structures 1T3M, 2GAW and 1APZ. Comparison of the protein 
structures. c) Comparison of the active site residues (black. essential residues in 1APZ, blue: 
aligned residues in taspase1). d) Comparison of the loops after helix one. Large differences in 
the protein structures are found in this region.  Main Section  141 
A homology model was calculated for taspase1 with MOE using the alignment from 
Figure 4.41. The Cartesian average of ten homology models was used for further experiments. 
The  model  was  minimized  including  solvatation  terms  and  chiral  constraints  with  the 
MMFF94xx forcefield. The protein structure quality of the model was controlled with the 
protein report function in MOE (see Appendix 6.2). Dihedral torsion deviations were mostly 
observed in loop regions distant from the binding site. Most relevant for the model might be 
an omega torsion angle deviation of Y52, which is directed into the binding pocket (Figure 
4.41a). Since this deviation only affected the back-bone it might have no effect on the binding 
site geometry. It was left unchanged. 
To assess the similarity of the taspase1 homology model to the template structures, the 
calculated structure was aligned with the reference structures with the homology alignment 
tool  of  MOE.  The  calculated  structure  of  taspase1  fitted  well  to  the  reference  structures 
(Figure 4.41b): according to our model, the protein core with the beta-sheet and the flanking 
alpha-helices was structurally conserved over the enzymes. Differences were found in the 
loop connecting the secondary structure elements. All essential residues, except for W11, 
were found to be aligned (Figure 4.41c). After the new structural alignment including the 
taspase1 model the S50 position of the glycosylasparaginases was aligned to glutamine in 
taspase1 and isoaspartyl peptidase, which seems more reasonable than the former alignment 
to  the  directly  neighboring  alanines:  serine  and  glutamine  are  both  capable  to  perform 
hydrogen-bonding interactions while alanine is not able to do so. For the W11 position no 
structural alignment was found. A reason for this can be seen in Figure 4.41d. Both in the 
isoaspartyl peptidase and in taspase1 the loop where W11 is located was found displaced due 
to an extended alpha helix, connected to the loop. Both, the former “aligned” leucin from 
isoaspartyl peptidase and the tyrosine from taspase1 did not fit to the tryptophanes (Figure 
4.41d).  The  extended  helix  and  the  connected  loop  of  taspase1  also  fitted  poorly  to  the 
respective structural element of 1T3M. Accordingly this region of the model seems to be the 
least reliable with respect to the binding site. However the remaining part of the binding site 
covering the essential residues except W11 was conserved between the enzymes and thus 
provided a reliable structural basis for the understanding of the taspase1 activity and virtual 
screening for inhibitors.  
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Figure  4.42. Docking solution for the peptide QLDGVDD in the taspase1 active site. a) 
Surface representation of the active site, colored according to the electrostatic potential. b) 
Potential interacting residues of taspase1 with the peptide. 
 
 
To test whether the cleaved sequence of the MLL protein can bind in a comparable 
manner to the substrates of the reference proteins we applied a docking approach. For the 
docking we used the peptide QLDGVDD. To avoid unwanted charged interactions the C-
terminus of the peptide was amidated for the docking experiments. The N-terminal alpha-
nitrogen of threonin was set positively charged. The best docking solution is shown in Figure 
4.42. As expected the peptide bond between aspartate and glycine was directly situated above 
the reactive T234. The sidechain carboxylate of the peptide aspartate was found to interact 
with R262. The absence of an amino group beside this carboxy-group was compensated by 
the  mutation  of  aspartate  to  glutamine  at  position  265.  A  hydrogen  bonding  interaction Main Section  143 
between G311 and the backbone nitrogen of the cleaved aspartate in the peptide was also 
found.  
The interpretations of the docking solution have to be taken with care: it is comparably 
more difficult to retrieve the correct receptor bound conformation of a peptide than for small 
molecules by docking calculations [Liu et al., 2004]. Peptides are much more flexible than 
drug-like molecules and thus provide a much larger set of possible docking solutions that 
have to be ranked by a scoring function. The scoring of the docking solutions is already a 
non-trivial  task  for  drug-like  molecules  [Kitchen  et  al.,  2004]  and  might  be  even  more 
complicated for peptides. Given that the position of the peptide bond to be cleaved was placed 
directly above the nucleophile and the carboxylic group of the aspartate at the cleavage-site 
was found to interact with R262, the found docking solution seems to provide a reasonable 
starting hypothesis for the ligand binding-mode. 
 
 
 
Figure 4.43. Pharmacophore hypothesis derived from the docked peptide and interactions 
with the receptor. The hydrogen-bond acceptor (Acc) interaction with T234 and the hydrogen-
bond  acceptor  AND  anion  (Acc  &  Ani)  interaction  were  defined  essential  for  virtual 
screening. Hyd = hydrophobe, Don = hydrogen-bond donor.  
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Using the bound peptide and the receptor structure a pharmacophore model (Figure 
4.43) was created for virtual screening for ligands inhibiting the taspase1 reaction. Three 
interactions were defined as essential, i.e. interactions which had to be satisfied by a molecule 
to be considered as hit. Essential interactions were: a hydrogen-bond acceptor function within 
a radius of 3 Å around the N-terminal nitrogen of T234 and two (hydrogen-bond acceptor 
AND anion) functions within a radius of 0.8 Å around the two oxygens form the aspartate 
carboxyl-group interacting with R262. Other hydrogen bonding interactions were defined at 
the positions of the two substrate interaction partners of G311 and G313. Two hydrophobic 
interactions were defined within a radius of 1.2 Å around the beta and gamma carbon atom of 
the hydrophobic sidechains of valine and leucine of the substrate, respectively. All protein 
atoms were defined as excluded spheres. To be considered as a hit, a molecule had to satisfy 
at least four of the pharmacophore points. 
 
We  screened  the  SPECS  database  of  compounds  (june  2003  version).  For  the  virtual 
screening experiment the database was preprocessed in the following way with MOE: 
1)  Acids and bases were set charged. 
2)  All molecules were discarded with: > 500 Da, logP > 5, > 5 hydrogen-bond donors, > 
10 hydrogen-bond acceptors, > 10 rotatable bonds. 
3)  Molecules lacking acidic groups were removed.  
4)  Molecules with Br, I, B, P, S- and nitro groups and sulfate as only single acidic group 
were removed. 
For  the  remaining  8,018  molecules  initial  conformations  were  calculated  with  CORINA 
[Sadowski et al., 1994] and up to 20 low energy conformations were calculated with MOE.  
 
376 drug-like and non-peptidic molecules satisfied the pharmacophore. This list was manually 
reduced to 85 compounds removing too similar molecules or molecules with unreasonably 
appearance. These molecules were purchased for experimental testing. Unfortunately at the 
time of finishing this thesis no results from the assays about the potency of the selected 
potential ligands were available. 
 
4.8.1 Conclusions  
A  pharmacophore  model  derived  from  a  receptor  homology  model  and  a  binding  mode 
hypothesis were used to virtually screen for the first inhibitors for human taspase1. Yet with 
the assay system still in development one can already state that our approach was successful Main Section  145 
in  retrieving  85  diverse  drug-like  and  non-peptidic  molecules,  that  satisfied  the 
pharmacophore  and  looked  reasonable  to  exhibit  at  least  slight  activity  according  to  the 
medicinal chemistry experience of the authors. While this does not tell much about the actual 
activity of the compounds one can already resume that the approach seemed to produce in 
principle meaningful results and thus represents an alternative to entirely ligands based or 
structure-based approaches. The approach seems to be attractive for scaffold hopping from 
peptides to drug-like molecules and in combination with homology model approximations of 
the receptor structure.  
 
 
 
 
 
 5 Summary 
 
5.1 Summary  
The  goal  of  this  thesis  was  the  development,  evaluation  and  application  of  novel  virtual 
screening approaches for the rational compilation of high quality pharmacological screening 
libraries. The criteria for a high quality were a high probability of the selected molecules to be 
active compared to randomly selected molecules and diversity in the retrieved chemotypes of 
the selected molecules to be prepared for the attrition of single lead structures. For the latter 
criterion  the  virtual  screening  approach  had  to  perform  “scaffold  hopping”.  The  first 
molecular  descriptor  that  was  explicitly  reported  for  that  purpose  was  the  topological 
pharmacophore  CATS  descriptor,  representing  a  correlation  vector  (CV)  of  all 
pharmacophore points in a molecule. The representation is alignment-free and thus renders 
fast screening of large databases feasible. 
In a first series of experiments the CATS descriptor was conceptually extended to the 
three-dimensional pharmacophore-pair CATS3D descriptor and the molecular surface based 
SURFCATS descriptor. The scaling of the CATS3D descriptor, the combination of CATS3D 
with different similarity metrics and the dependence of the CATS3D descriptor on the three-
dimensional conformations of the molecules in the virtual screening database were evaluated 
in retrospective screening experiments. The “scaffold hopping” capabilities of CATS3D and 
SURFCATS  were  compared  to  CATS  and  the  substructure  fingerprint  MACCS  keys. 
Prospective virtual screening with CATS3D similarity searching was applied for the TAR 
RNA and the metabotropic glutamate receptor 5 (mGlur5). A combination of supervised and 
unsupervised neural networks trained on CATS3D descriptors was applied prospectively to 
compile  a  focused  but  still  diverse  library  of  mGluR5  modulators.  In  a  second  series  of 
experiments the SQUID fuzzy pharmacophore model method was developed, that was aimed 
to provide a more general query for virtual screening than the CATS family descriptors. A 
prospective application of the fuzzy pharmacophore models was performed for TAR RNA 
ligands. In a last experiment a structure-/ligand-based pharmacophore model was developed 
for  taspase1  based  on  a  homology  model  of  the  enzyme.  This  model  was  applied 
prospectively for the screening for the first inhibitors of taspase1. Main Section  147 
The effect of different similarity metrics (Euc: Euclidean distance, Manh: Manhattan 
distance and Tani: Tanimoto similarity) and different scaling methods (unscaled, scaling1: 
scaling by the number of atoms, and scaling2: scaling by the added incidences of potential 
pharmacophore  points  of  atom  pairs)  on  CATS3D  similarity  searching  was  evaluated  in 
retrospective  virtual  screening  experiments.  12  target  classes  of  the  COBRA  database  of 
annotated ligands from recent scientific literature were used for that purpose. Scaling2, a new 
development  for  the  CATS3D  descriptor,  was  shown  to  perform  best  on  average  in 
combination with all three similarity metrics (enrichment factor ef (1%): Manh = 11.8 ± 4.3, 
Euc = 11.9 ± 4.6, Tani = 12.8 ± 5.1). The Tanimoto coefficient was found to perform best 
with  the  new  scaling  method.  Using  the  other  scaling  methods  the  Manhattan  distance 
performed best (ef (1%): unscaled: Manh = 9.6 ± 4.0, Euc = 8.1 ± 3.5, Tani = 8.3 ± 3.8; 
scaling1: Manh = 10.3 ± 4.1, Euc = 8.8 ± 3.6, Tani = 9.1 ± 3.8). 
Since  CATS3D  is  independent  of  an  alignment,  the  dependence  of  a  “receptor 
relevant” conformation might also be weaker compared to other methods like docking. Using 
such methods might be a possibility to overcome problems like protein flexibility or the 
computational expensive calculation of many conformers. To test this hypothesis, co-crystal 
structures of 11 target classes served as queries for virtual screening of the COBRA database. 
Different numbers of conformations were calculated for the COBRA database. Using only a 
single conformation already resulted in a significant enrichment of isofunctional molecules on 
average (ef (1%) = 6.0 ± 6.5). This observation was also made for ligand classes with many 
rotatable bonds (e.g. HIV-protease: 19.3 ± 6.2 rotatable bonds in COBRA, ef (1%) = 12.2 ± 
11.8). On average only an improvement from using the maximum number of conformations 
(on  average  37  conformations  /  molecule)  to  using  single  conformations  of  1.1  fold  was 
found. It was found that using more conformations actives and inactives equally became more 
similar to the reference compounds according to the CATS3D representations. Applying the 
same parameters as before to calculate conformations for the crystal structure ligands resulted 
in  an  average  Cartesian  RMSD  of  the  single  conformations  to  the  crystal  structure 
conformations  of  1.7  ±  0.7  Å.  For  the  maximum  number  of  conformations,  the  RMSD 
decreased to 1.0 ± 0.5 Å (1.8 fold improvement on average).  
To  assess  the  virtual  screening  performance  and  the  scaffold  hopping  potential  of 
CATS3D and SURFACATS, these descriptors were compared to CATS and the MACCS 
keys,  a  fingerprint  based  on  exact  chemical  substructures.  Retrospective  screening  of  ten 
classes of the COBRA database was performed. According to the average enrichment factors 
the  MACCS  keys  performed  best  (ef  (1%):  MACCS  =  17.4  ±  6.4,  CATS  =  14.6  ±  5.4, Chapter 4  148 
CATS3D = 13.9 ± 4.9, SURFCATS = 12.2 ± 5.5). The classes, where MACCS performed 
best, consisted of a lower average fraction of different scaffolds relative to the number of 
molecules  (0.44  ±  0.13),  than  the  classes,  where  CATS  performed  best  (0.65  ±  0.13). 
CATS3D was the best performing method for only a single target class with an intermediate 
fraction of scaffolds (0.55). SURFCATS was not found to perform best for a single class. 
These results indicate that CATS and the CATS3D descriptors might be better suited to find 
novel scaffolds than the MACCS keys. All methods were also shown to complement each 
other by retrieving scaffolds that were not found by the other methods.  
A prospective evaluation of CATS3D similarity searching was done for metabotropic 
glutamate receptor 5 (mGluR5) allosteric modulators. Seven known antagonists of mGluR5 
with sub-micromolar IC50 were used as reference ligands for virtual screening of the 20,000 
most drug-like compounds – as predicted by an artificial neural network approach – of the 
Asinex vendor database (194,563 compounds). Eight of 29 virtual screening hits were found 
with a Ki below 50 µM in a binding assay. Most of the ligands were only moderately specific 
for  mGluR5  (maximum  of  >  4.2  fold  selectivity)  relative  to  mGluR1,  the  most  similar 
receptor to mGluR5. One ligand exhibited even a better Ki for mGluR1 than for mGluR5 
(mGluR5: Ki > 100 µM, mGluR1: Ki = 14 µM). All hits had different scaffolds than the 
reference molecules. It was demonstrated that the compiled library contained molecules that 
were  different  from  the  reference  structures  –  as  estimated  by  MACCS  substructure 
fingerprints  –  but  were  still  considered  isofunctional  by  both  CATS  and  CATS3D 
pharmacophore approaches.  
Artificial  neural  networks  (ANN)  provide  an  alternative  to  similarity  searching  in 
virtual  screening,  with  the  advantage  that  they  incorporate  knowledge  from  a  learning 
procedure. A combination of artificial neural networks for the compilation of a focused but 
still  structurally  diverse  screening  library  was  employed  prospectively  for  mGluR5. 
Ensembles of neural networks were trained on CATS3D representations of the training data 
for the prediction of “mGluR5-likeness” and for “mGluR5/mGluR1 selectivity”, the most 
similar receptor to mGluR5, yielding Matthews cc between 0.88 and 0.92 as well as 0.88 and 
0.91 respectively. The best 8,403 hits (the focused library: the intersection of the best hits 
from  both  prediction  tasks)  from  virtually  ranking  the  Enamine  vendor  database  (ca. 
1,000,000 molecules), were further analyzed by two self-organizing maps (SOMs), trained on 
CATS3D descriptors and on MACCS substructure fingerprints. A diverse and representative 
subset of the hits was obtained by selecting the most similar molecules to each SOM neuron. 
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the molecules from the CATS3D SOM and two of the molecules from the MACCS SOM 
showed mGluR5 binding. The best hit with a Ki of 21 µM was found in the CATS3D SOM. 
The selectivity of the  compounds for mGluR5 over mGluR1 was low. Since the binding 
pockets in the two receptors are similar the general CATS3D representation might not have 
been appropriate for the prediction of selectivity. In both SOMs new active molecules were 
found in neurons that did not contain molecules from the training set, i. e. the approach was 
able  to  enter  new  areas  of  chemical  space  with  respect  to  mGluR5.  The  combination  of 
supervised  and  unsupervised  neural  networks  and  CATS3D  seemed  to  be  suited  for  the 
retrieval of dissimilar molecules with the same class of biological activity, rather than for the 
optimization of molecules with respect to activity or selectivity.  
A  new  virtual  screening  approach  was  developed  with  the  SQUID  (Sophisticated 
Quantification of Interaction Distributions) fuzzy pharmacophore method. In SQUID pairs of 
Gaussian probability densities are used for the construction of a CV descriptor. The Gaussians 
represent clusters of atoms comprising the same pharmacophoric feature within an alignment 
of  several  active  reference  molecules.  The  fuzzy  representation  of  the  molecules  should 
enhance the performance in scaffold hopping. Pharmacophore models with different degrees 
of fuzziness (resolution) can be defined which might be an appropriate means to compensate 
for  ligand  and  receptor  flexibility.  For  virtual  screening  the  3D  distribution  of  Gaussian 
densities is transformed into a two-point correlation vector representation which describes the 
probability  density  for  the  presence  of  atom-pairs,  comprising  defined  pharmacophoric 
features.  The  fuzzy  pharmacophore  CV  was  used  to  rank  CATS3D  representations  of 
molecules.  The  approach  was  validated  by  retrospective  screening  for  cyclooxygenase  2 
(COX-2) and thrombin ligands. A variety of models with different degrees of fuzziness were 
calculated  and  tested  for  both  classes  of  molecules.  Best  performance  was  obtained  with 
pharmacophore  models  reflecting  an  intermediate  degree  of  fuzziness.  Appropriately 
weighted  fuzzy  pharmacophore  models  performed  better  in  retrospective  screening  than 
CATS3D similarity searching using single query molecules, for both COX-2 and thrombin (ef 
(1%): COX-2: SQUID = 39.2., best CATS3D result = 26.6; Thrombin: SQUID = 18.0, best 
CATS3D result = 16.7). The new pharmacophore method was shown to complement MOE 
pharmacophore models. 
SQUID  fuzzy  pharmacophore  and  CATS3D  virtual  screening  were  applied 
prospectively to retrieve novel scaffolds of RNA binding molecules, inhibiting the Tat-TAR 
interaction. A pharmacophore model was built up from one ligand (acetylpromazine, IC50 = 
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with a comparable binding mode as acetylpromazine. The fragment was flexible aligned to 
the  TAR  bound  NMR  conformation  of  acetylpromazine.  Using  an  optimized  SQUID 
pharmacophore  model  the  20,000  most  druglike  molecules  from  the  SPECS  database 
(229,658 compounds) were screened for Tat-TAR ligands. Both reference inhibitors were also 
applied  for  CATS3D  similarity  searching.  A  set  of  19  molecules  from  the  SQUID  and 
CATS3D results was selected for experimental testing. In a fluorescence resonance energy 
transfer (FRET) assay the best SQUID hit showed an IC50 value of 46 µM, which represents 
an approximately tenfold improvement over the reference acetylpromazine. The best hit from 
CATS3D similarity searching showed an IC50 comparable to acetylpromazine (IC50 = 500 
µM). Both hits contained different molecular scaffolds than the reference molecules.  
Structure-based pharmacophores provide an alternative to ligand-based approaches, 
with the advantage that no ligands have to be known in advance and no topological bias is 
introduced. The latter is e.g. favorable for hopping from peptide-like substrates to drug-like 
molecules. A homology model of the threonine aspartase taspase1 was calculated based on 
the crystal structures of a homologous isoaspartyl peptidase. Docking studies of the substrate 
with GOLD identified a binding mode where the cleaved bond was situated directly above the 
reactive N-terminal threonine. The predicted enzyme-substrate complex was used to derive a 
pharmacophore model for virtual screening for novel taspase1 inhibitors. 85 molecules were 
identified  from  virtual  screening  with  the  pharmacophore  model  as  potential  taspase1-
inhibitors, however biochemical data was not available before the end of this thesis. 
In summary this thesis demonstrated the successful development, improvement and 
application  of  pharmacophore-based  virtual  screening  methods  for  the  compilation  of 
molecule-libraries for early phase drug development. The highest potential of such methods 
seemed to be in scaffold hopping, the non-trivial task of finding different molecules with the 
same biological activity. 
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5.2 Zusammenfassung 
Ziel dieser Arbeit war die Entwicklung, Untersuchung und Anwendung von neuen virtuellen 
Screening-Verfahren für den rationalen Entwurf hoch-qualitativer Molekül-Datenbanken für 
das  pharmakologische  Screening.  Anforderung  für  eine  hohe  Qualität  waren  eine  hohe  a 
priori Wahrscheinlichkeit für das Vorhandensein aktiver Moleküle im Vergleich zu zufällig 
zusammengestellten Bibliotheken, sowie das Vorhandensein einer Vielfalt unterschiedlicher 
Grundstrukturen  unter  den  selektierten  Molekülen,  um  gegen  den  Ausfall  einzelner 
Leitstrukturen in der weiteren Entwicklung abgesichert zu sein. Notwendig für die letztere 
Eigenschaft  ist  die  Fähigkeit  eines  Verfahrens  zum  „Grundgerüst-Springen“.  Der  erste 
Molekül-Deskriptor, der explizit für das „Grundgerüst-Springen“ eingesetzt wurde war der 
CATS Deskriptor – ein topologischer Korrelations-Vektor („correlation vector“, CV) über 
alle Pharmakophor-Punkte eines Moleküls. Der Vergleich von Molekülen über den CATS 
Deskriptor  geschieht  ohne  eine  Überlagerung  der  Moleküle,  was  den  effizienten  Einsatz 
solcher Verfahren für sehr große Molekül-Datenbanken ermöglicht. 
In einer ersten Serie von Versuchen wurde der CATS Deskriptor erweitert zu dem 
dreidimensionalen  CATS3D  Deskriptor  und  dem  auf  der  Molekül-Oberfläche  basierten 
SURFCATS Deskriptor. In retrospektiven Studien wurde für diese Deskriptoren der Einfluss 
verschiedener Skalierungs-Methoden, die Kombination mit unterschiedlichen Ähnlichkeits-
Metriken und die Auswirkung verschiedener dreidimensionaler Konformationen untersucht. 
Weiter wurden das Potential der entwickelten Deskriptoren CATS3D und SURFCATS im 
„Grundgerüst-Springen“  mit  CATS  und  dem  Substruktur-Fingerprint  MACCS  keys 
verglichen. Prospektive Anwendungen der CATS3D Ähnlichkeitssuche wurden für die TAR-
RNA und den metabotropen Glutamat Rezeptor 5 (mGluR5) durchgeführt. Eine Kombination 
von  überwachten  und  unüberwachten  neuronalen  Netzen  wurde  prospektiv  für  die 
Zusammenstellung  einer  fokussierten  aber  dennoch  diversen  Bibliothek  von  mGluR5 
Modulatoren  eingesetzt.  In  einer  zweiten  Reihe  von  Versuchen  wurde  der  SQUID  Fuzzy 
Pharmakophor  Ansatz  entwickelt,  mit  dem  Ziel  zu  einer  noch  generelleren  Molekül-
Beschreibung als mit den Deskriptoren aus der CATS Familie zu gelangen. Eine prospektive 
Anwendung der „Fuzzy Pharmakophor“ Methode wurde für die TAR-RNA durchgeführt. In 
einem letzten Versuch wurde für Taspase1 ein Struktur-/Liganden-basiertes Pharmakophor-
Modell auf der Grundlage eines Homologie-Modells des Enzyms entwickelt. Dieses wurde 
für das prospektive Screening nach Taspase1-Inhibitoren eingesetzt. 
Der Einfluss verschiedener Ähnlichkeits-Metriken (Euk: Euklidische Distanz, Manh: 
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(Ohne-Skalierung, Skalierung1: Skalierung aller Werte nach der Anzahl Atome, Skalierung2: 
Skalierung der Werte eines Paares von Pharmakophor-Punkten entsprechend der Summe aller 
Pharmakophor-Punkte mit denselben Pharmakophor-Typen) auf die Ähnlichkeits-Suche mit 
CATS3D wurde in retrospektiven virtuellen Screening Experimenten untersucht. Für diesen 
Zweck  wurden  12  verschiedene  Klassen  von  Rezeptoren  und  Enzymen  aus  der  COBRA 
Datenbank von annotierten Liganden aus der jüngeren wissenschaftlichen Literatur eingesetzt. 
Skalierung2,  eine  neue  Entwicklung  für  CATS3D,  zeigte  im  Durchschnitt  die  beste 
Performanz in Kombination mit allen drei Ähnlichkeits-Metriken (Anreicherungs-Faktor ef 
(1%): Manh = 11,8 ± 4,3; Euk = 11,9 ± 4,6; Tani = 12,8 ± 5,1). Die  Kombination von 
Skalierung2 mit dem Tanimoto Ähnlichkeits-Koeffizienten lieferte die besten Ergebnisse. In 
Kombination  mit  den  anderen  Skalierungen  brachte  die  Manhattan  Distanz  die  besten 
Ergebnisse (ef (1%): Ohne-Skalierung: Manh = 9,6 ± 4,0; Euk = 8,1 ± 3,5; Tani = 8,3 ± 3,8; 
Skalierung1: Manh = 10,3 ± 4,1; Euk = 8,8 ± 3,6; Tani = 9,1 ± 3,8). 
Da  die  CATS3D  Ähnlichkeits-Suche  unabhängig  von  der  Überlagerung  einzelner 
Moleküle  ist,  könnte  ebenfalls  eine  gewisse  Unabhängigkeit  von  der  vorhandenen  3D 
Konformation bestehen. Eine solche Unabhängigkeit wäre interessant um die zeitaufwendige 
Berechnung  multipler  Konformationen  zu  umgehen.  Um  diese  Hypothese  zu  untersuchen 
wurden Co-Kristalle von Liganden aus 11 Klassen von Rezeptoren und Enzymen ausgewählt, 
um als Anfrage-Strukturen im virtuellen Screening in der COBRA Datenbank zu dienen. 
Verschiedene  Versionen  der  COBRA  Datenbank  mit  unterschiedlicher  Anzahl 
Konformationen  wurden  berechnet.  Bereits  mit einer  einzigen  Konformation  pro  Molekül 
konnte im Mittel eine deutliche Anreicherung an aktiven Molekülen beobachte werden (ef 
(1%) = 6,0 ± 6,5). Diese Beobachtung beinhaltete auch Klassen von Molekülen mit vielen 
rotierbaren Bindungen. (z.B. HIV-Protease: 19,3 ± 6,2 rotierbare Bindungen in COBRA, ef 
(1%)  =  12,2  ±  11,8).  Im  Mittel  konnten  dazu  bei  Verwendung  der  maximalen  Anzahl 
Konformationen (durchschnittlich 37 Konformationen / Molekül) nur eine Verbesserung von 
1.1 festgestellt werden. Nach der CATS3D Ähnlichkeit wurden die inaktiven Moleküle im 
gleichen Maß ähnlicher zu den Referenzen als die aktiven Moleküle. Zum Vergleich konnte 
durch Verwendung multipler statt einzelner Konformationen eine 1,8-fache Verbesserung des 
RMSD zu den Konformationen aus den Kristall-Struktur Konformationen erreicht werden 
(einzelne Konformationen: 1,7 ± 0,7 Å; max. Konformationen: 1,0 ± 0,5 Å).  
Um die Leistungsfähigkeit von CATS3D und SURFCATS im virtuellen Screening 
und im Grundgerüst-Springen zu beurteilen, wurden diese Deskriptoren mit CATS und den 
MACCS  keys,  einem  Fingerprint  basierend  auf  exakten  chemischen  Substrukturen, Main Section  153 
verglichen. Für die retrospektive Analyse wurden 10 Klassen von Rezeptoren und Enzymen 
aus der COBRA Datenbank ausgewählt. Nach den mittleren Anreicherungs-Faktoren ergaben 
sich für MACCS die besten Resultate (ef (1%): MACCS = 17,4 ± 6,4; CATS = 14,6 ± 5,4; 
CATS3D = 13,9 ± 4,9; SURFCATS = 12,2 ± 5,5). Es zeigte sich, dass die Klassen, in denen 
MACCS  die  besten  Ergebnisse  erzielen  konnte,  einen  geringen  gemittelten  Anteil  von 
verschiedenen Grundgerüsten aufwiesen im Verhältnis zu der Anzahl an Molekülen (0,44 ± 
0,13) als die Klassen, in denen CATS am besten war (0,65 ± 0,13). CATS3D war nur in einer 
Klasse mit einem mittleren Anteil von Grundgerüsten (0,55) die beste Methode. SURFCATS 
war für keine Klasse besser als alle anderen Methoden. Diese Ergebnisse deuten darauf hin, 
dass Methoden wie CATS und CATS3D besser geeignet sind, um neue Grundgerüste zu 
finden. Es konnte weiter gezeigt werden, dass sich die Methoden einander ergänzen, dass also 
mit  jeder  Methode  Grundgerüste  gefunden  werden  konnten,  die  mit  keiner  der  anderen 
Methoden gefunden werden konnten. 
Eine  prospektive  Anwendung  wurde  für  CATS3D  in  der  Suche  nach  neuen 
allosterischen Modulatoren des metabotropen Glutamat Rezeptors 5 (mGluR5) durchgeführt. 
Sieben  bekannte  allosterische  mGluR5  Antagonisten  mit  sub-mikromolaren  IC50  Werten 
wurde als Referenzen eingesetzt. Das virtuelle Screening wurde auf den 20.000 von einem 
künstlichen neuronalen Netz als am wirkstoff-artigsten vorhergesagten Molekülen der Asinex 
Datenbank (194.563 Moleküle) durchgeführt. Acht der 29 gefundenen Hits aus dem virtuellen 
Screening  zeigten  Ki  Werte  unter  50  µM  in  einem  Bindungs-Assay.  Die  Mehrheit  der 
Liganden zeigte nur eine geringe Selektivität (Maximum > 4,2-fach) gegenüber mGluR1, dem 
ähnlichsten Rezeptor zu mGluR5. Einer der Liganden zeigte einen besseren Ki für mGluR1 
als für mGluR5 (mGluR5: Ki > 100 µM, mGluR1: Ki = 14 µM). Alle gefundenen Moleküle 
zeigten verschiedene Grundgerüste als die Referenz Moleküle. Es konnte gezeigt werden, 
dass  die  zusammengestellte  Bibliothek  von  den  MACCS  keys  als  unterschiedlich  zu  den 
Referenz Strukturen betrachtet wurden, von CATS und CATS3D aber noch als isofunktional 
betracht wurden. 
Künstliche neuronal Netze („artificial neural net“, ANN) bieten eine Alternative zur 
Ähnlichkeits-Suche im virtuellen Screening mit dem Vorteil, dass in einer Serie von Liganden 
enthaltenes implizites Wissen über eine Lernprozedur in ein Modell integrierte werden kann. 
Eine  Kombination  von  ANNs  für  die  Zusammenstellung  einer  fokussierten  aber  dennoch 
diversen  Molekül-Bibliothek  wurde  prospektiv  für  die  Suche  nach  mGluR5  Antagonisten 
eingesetzt. Gruppen von ANNs wurden auf den Basis von CATS3D Repräsentationen für die 
Vorhersage  von  „mGluR5-artigkeit“  und  „mGluR5/mGluR1  Selektivität“  trainiert.  Dabei Chapter 4  154 
ergaben sich Matthews cc zwischen 0,88 und 0,92 sowie zwischen 0,88 und 0,91. Die besten 
8.403 Hits (die Schnittmenge der besten Hits aus beiden Vorhersagen) aus einem virtuellen 
Screening der Enamine Datenbank (ca. 1.000.000 Moleküle) ergab die fokussierte Bibliothek. 
Diese wurde weiter mit Selbstorganisierten Karten („self organizing maps“, SOM) analysiert, 
die  auf  CATS3D  und  MACCS  key  Repräsentationen  trainiert  wurden.  Eine  diverse  und 
repräsentative  Untermenge  der  Moleküle  wurde  gewonnen,  indem  die  jeweils  nächsten 
Moleküle  zu  jedem  der  Neuronen  der  Karten  ausgewählt  wurden.  Bindungsstudien  der 
selektierten Moleküle (16 von jeder der Karten) ergaben, dass drei Moleküle aus der CATS3D 
SOM und zwei der Moleküle aus der MACCS SOM mGluR5 Bindung zeigten. Der beste Hit 
mit  einem  Ki  von  21  µM  wurde  über  die  CATS3D  SOM  gefunden.  Die  Selektivität  der 
gefundenen Moleküle gegenüber mGluR1 war wiederum gering. Da sich die Bindungstaschen 
der  beiden  Rezeptoren  sehr  ähnlich  sind,  könnte  die  verallgemeinernde  Beschreibung  der 
Moleküle mit CATS3D nicht geeignet für eine solche Vorhersage gewesen sein. In beiden 
SOMs  wurden  neue  aktive  Moleküle  in  Neuronen  gefunden,  in  denen  sich  keine  der 
bekannten Inhibitoren befanden, d.h. es wurden mit diesem Ansatz neue chemische Bereiche 
auf der SOM für mGluR5 beschrieben. Die Verbindung von überwachten und unüberwachten 
neuronalen  Netzen  mit  CATS3D  scheint  am  besten  geeignet  zu  sein,  um  Moleküle  mit 
unterschiedlicher Struktur, aber gleicher Aktivitätsklasse aufzufinden. Die Optimierung auf 
höhere Aktivität oder Selektivität schien weniger geeignet zu sein. 
Mit  dem  SQUID  (Sophisticated  Quantification  of  Interaction  Distributions)  Fuzzy 
Pharmakophor  Modell  wurde  ein  neuer  Ansatz  für  das  virtuelle  Screening  entwickelt.  In 
SQUID  werden  Paare  von  Gauß-Wahrscheinlichkeits-Dichten  für  die  Konstruktion  eines 
Korrelations-Vektors  eingesetzt.  Die  Gauß-Dichten  repräsentieren  Gruppen  von  Atomen 
desselben Pharmakophor-Typs in einer Überlagerung mehrerer aktiver Referenz-Moleküle. 
Die  unscharfe  Repräsentation  der  Moleküle  sollte  das  Springen  zwischen  Grundgerüsten 
erleichtern. Der Ansatz ermöglicht die Definition von Pharmakophor-Modellen verschiedener 
Unschärfe  oder  Auflösung,  was  eventuell  eine  Möglichkeit  darstellt,  die  Flexibilität  von 
Ligand  und  Rezeptor  zu  berücksichtigen.  Für  das  virtuelle  Screening  wird  die 
dreidimensionale Verteilung der Gauß-Dichten in einen 2-Punkt CV transformiert, der die 
Wahrscheinlichkeit für die Anwesendheit von Paaren von Pharmakophor-Punkten beschreibt. 
Der Fuzzy Pharmakophor CV wurde eingesetzt um CATS3D Repräsentationen zu bewerten. 
Evaluiert  wurde  die  Methode  durch  retrospektives  Screening  nach  COX-2  und  Thrombin 
Inhibitoren.  Eine  Serie  von  Modellen  mit  verschiedener  Auflösung  wurde  für  beide 
Molekülklassen getestet. Die besten Ergebnisse wurden in beiden Fallen mit Modellen mit Main Section  155 
mittlerer  Auflösung  erzielt.  Geeignet  gewichtete  Pharmakophor-Modelle  erzielten  bessere 
Resultate  als  CATS3D  Ähnlichkeits-Suche  mit  den  einzelnen  Molekülen  aus  den 
Pharmakophor-Modellen (ef (1%): COX-2: SQUID = 39,2; bestes CATS3D Resultat = 26,6; 
Thrombin:  SQUID  =  18,0;  bestes  CATS3D  Resultat  =  16,7).  Es  konnte  weiter  gezeigt 
werden, dass die neue Methode MOE Pharmakophor Modelle in den gefundenen Molekülen 
ergänzt. 
Der  SQUID  Fuzzy  Pharmakophor  Ansatz  sowie  CATS3D  wurden  prospektiv 
eingesetzt für die Suche nach neuen Grundgerüsten für RNA bindendende Inhibitoren der 
Tat-TAR  Interaktion.  Ein  SQUID  Modell  wurde  auf  der  Grundlage  von  einem  Liganden 
(Acetylpromazin, IC50 = 500 µM) und dem Fragment eines weiteren bekannten Liganden 
(CGP40336A) berechnet, von dem ein zum Acetylpromazin vergleichbarer Bindungsmodus 
angenommen  wurde.  Das  Fragment  wurde  flexibel  an  die  TAR-RNA  gebundene  NMR 
Konformation des Acetylpromazins aligned. Mit einem optimierten SQUID Modell wurden 
die 20.000 wirkstoffartigsten Moleküle der SPECS Datenbank (229.658 Moleküle) virtuell 
nach  TAR-RNA  Liganden  durchsucht.  Mit  beiden  Referenz  Inhibitoren  wurden  zum 
Vergleich auch CATS3D Suchen durchgeführt. 19 Moleküle aus den Hits von SQUID und 
CATS3D wurden für einen FRET Assay ausgewählt. Der beste Hit von SQUID zeigte einen 
IC50 Wert von 46 µM, was eine ca. 10-fache Verbesserung im Verhältnis zu Acetylpromazin 
darstellt. Der beste CATS3D Hit war vergleichbar mit Acetylpromazin (IC50 = 500 µM). 
Beide  gefundenen  Moleküle  zeigten  unterschiedliche  Grundgerüste  im  Verhältnis  zu  den 
Referenz Molekülen. 
Struktur-basierte  Pharmakophor  Modelle  stellen  eine  Alternative  zu  Liganden-
basierten Ansätzen dar, mit dem Vorteil, dass keine bekannten Liganden benötigt werden und 
somit keine Beeinflussung hin zu bekannten Strukturen in das Modell hineingebracht wird. 
Die letztere Eigenschaft sollte günstig für das Grundgerüst Springen sein. Ein Homologie 
Modell  der  Threonin  Aspartase  Taspase1,  eine  Protease,  wurde  auf  der  Grundlage  der 
Kristallstruktur einer homologen Isoaspartyl-Peptidase berechnet. Über Docking Studien mit 
dem Programm GOLD wurde ein Bindungsmodus des natürlichen Substrats identifiziert, in 
dem  die  gespaltene  Peptidbindung  direkt  über  dem  reaktiven  N-terminalen  Threonin 
angeordnet lag. Der vorhergesagte Enzym-Substrat-Komplex wurde herangezogen, um ein 
Pharmakophor-Modell zu für das virtuelle Screening nach neuen Taspase1  Inhibitoren zu 
entwickeln.  85  Moleküle  wurden  aus  der  SPECS  Datenbank  als  potentielle  Inhibitoren 
identifiziert, jedoch fehlten bei Fertigstellung dieser Arbeit noch gesicherte experimentelle 
Daten über die pharmakologischen Eigenschaften der gefundenen Moleküle. Chapter 4  156 
Zusammenfassend wurde in dieser Arbeit die erfolgreiche Entwicklung, Verbesserung 
und Anwendung von Pharmakophor-basierten virtuellen Screening Methoden für den Entwurf 
von Molekül-Bibliotheken für die frühe Wirkstoff-Entwicklung gezeigt. Das Potential dieser 
Methoden schien besonders im Grundgerüst-Springen zu liegen, also in der nicht-trivialen 
Identifikation von unterschiedlichen Molekülen mit gleicher biologischer Aktivität. 
 
 
 
 
 6 Appendix 
 
6.1 Enrichment factors of activity classes from Section 4.3 
 
Enrichment  factors  of  different  molecular  representations  (“Molecules”,  “Scaffolds”, 
“Reduced Scaffolds”) over the activity classes. ef values are given for the first 1% and 5% of 
the hit-lists. The Manhattan distance was applied as similarity metric. 
 
  Molecules 
% DB  MACCS  CATS  CATS3D  SURFCATS 
ACE         
1  25 (12)  27 (17)  16 (11)  18 (13) 
5  10 (4)  10 ( 5)   6 ( 3)   6 ( 3) 
COX2         
1  30 (16)  16 (10)  21 (12)  19 (11) 
5  13 (5)   6 ( 3)   8 ( 4)   8 ( 4) 
CRF         
1  25 (14)  14 ( 9)  22 (10)  16 ( 9) 
5  11 (4)   7 ( 3)  10 ( 3)   8 ( 3) 
DPP         
1  21 (14)  14 (11)  16 (11)  13 (10) 
5   7 (3)   5 ( 3)   5 ( 3)   4 ( 2) 
HIVP         
1  13 ( 7)  21 (11)  12 ( 8)  15 (10) 
5   5 (2)   9 ( 4)   5 ( 3)   6 ( 4) 
MMP         
1  13 ( 8)  12 ( 7)  10 ( 7)  12 ( 9) 
5   5 (3)   5 ( 2)   4 ( 2)   5 ( 3) 
NK         
1   9 ( 6)   9 ( 4)  11 ( 7)   7 ( 5) 
5   5 (2)   5 ( 2)   5 ( 3)   4 ( 2) 
PPAR         
1  18 (15)  19 (12)   8 ( 7)   9 ( 8) 
5   6 (4)   7 ( 3)   3 ( 2)   3 ( 2) 
BACE         
1  14 (11)  12 (10)  12 (10)   7 ( 5) 
5   6 (4)   4 ( 3)   3 ( 2)   2 ( 2) 
THR         
1  12 ( 6)  14 ( 7)   7 ( 5)   7 ( 5) 
5   6 (2)   8 ( 4)   3 ( 2)   4 ( 3) 
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    Scaffolds    Reduced Scaffolds 
% DB    MACCS  CATS  CATS3D  SURFCATS    MACCS  CATS  CATS3D  SURFCATS 
ACE                     
1    25 (12)  30 (16)  15 (10)  16 ( 9)    29 (13)  33 (14)  18 (10)  19 ( 9) 
5    11 (4)  11 ( 4)   6 ( 2)   6 ( 2)    11 (3)  11 ( 4)   6 ( 2)   6 ( 2) 
COX2                     
1    28 (12)  17 ( 8)  21 ( 8)  19 ( 9)    33 (12)  22 (10)  26 (10)  24 (11) 
5    11 (4)   6 ( 2)   8 ( 2)   8 ( 3)    12 (3)   7 ( 2)   9 ( 2)   9 ( 3) 
CRF                     
1    24 (12)  18 (11)  23 (10)  17 (10)    28 (13)  20 (11)  25 (10)  18 (11) 
5    10 (4)   8 ( 3)  10 ( 3)   8 ( 3)    11 (4)   8 ( 3)  10 ( 3)   8 ( 3) 
DPP-IV                     
1    22 (13)  15 (10)  17 (10)  15 (11)    25 (12)  22 (14)  23 (14)  21 (16) 
5     8 (3)   6 ( 3)   5 ( 2)   4 ( 2)     9 (5)   7 ( 3)   6 ( 3)   6 ( 3) 
HIVP                     
1    14 ( 8)  23 (12)  14 ( 9)  17 (11)    19 (12)  31 (15)  18 (12)  23 (15) 
5     6 (3)  10 ( 4)   5 ( 3)   7 ( 4)     7 (3)  11 ( 4)   7 ( 4)   8 ( 4) 
MMP                     
1    16 (11)  15 ( 9)  13 (10)  16 (12)    23 (12)  23 (12)  21 (13)  22 (14) 
5     6 (3)   6 ( 3)   4 ( 3)   6 ( 4)     8 (3)   8 ( 3)   6 ( 4)   7 ( 4) 
NK                     
1    10 ( 6)  10 ( 4)  12 ( 7)   8 ( 5)    11 ( 6)  11 ( 5)  13 ( 7)   9 ( 6) 
5     5 (2)   5 ( 2)   5 ( 3)   4 ( 2)     5 (2)   6 ( 2)   5 ( 3)   5 ( 2) 
PPAR                     
1    16 (13)  19 (11)   9 ( 7)  10 ( 9)    20 (15)  24 (14)  11 ( 8)  13 (11) 
5     5 (3)   7 ( 3)   3 ( 2)   3 ( 2)     7 (4)   8 ( 4)   4 ( 2)   4 ( 3) 
BACE                     
1    14 (10)  12 ( 8)  11 ( 6)   8 ( 5)    15 (11)  14 ( 9)  12 ( 7)   9 ( 5) 
5     4 (2)   4 ( 2)   3 ( 2)   3 ( 2)     5 (3)   4 ( 2)   3 ( 2)   3 ( 2) 
THR                     
1    14 ( 6)  18 (10)   9 ( 6)  10 ( 7)    18 ( 8)  27 (13)  14 ( 8)  17 ( 9) 
5     6 (2)   8 ( 4)   4 ( 3)   5 ( 3)     8 (3)  10 ( 4)   5 ( 3)   6 ( 3) 
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Enrichment  factors  of  different  molecular  representations  (“Molecules”,  “Scaffolds”, 
“Reduced Scaffolds”) over the activity classes. ef values are given for the first 1% and 5% of 
the hit-lists. The Euclidean distance was applied as similarity metric. 
 
  Molecules 
% DB  MACCS  CATS  CATS3D  SURFCATS 
ACE         
1  25 (12)  22 (12)  17 (11)  20 (14) 
5  10 (4)  10 ( 5)   6 ( 4)   7 ( 4) 
COX2         
1  30 (16)  14 ( 9)  20 (13)  18 (11) 
5  13 (5)   5 ( 3)   8 ( 4)   8 ( 4) 
CRF         
1  25 (14)  12 ( 8)  20 (10)  16 (10) 
5  11 (4)   7 ( 3)  10 ( 3)   8 ( 3) 
DPP         
1  21 (14)  13 (10)  16 (12)  13 (11) 
5   7 (3)   4 ( 3)   5 ( 3)   4 ( 2) 
HIVP         
1  13 ( 7)  22 (11)  15 ( 9)  17 (11) 
5   5 (2)  10 ( 3)   7 ( 4)   7 ( 4) 
MMP         
1  13 ( 8)  11 ( 6)  11 ( 7)  11 ( 9) 
5   5 (3)   5 ( 2)   4 ( 2)   5 ( 3) 
NK         
1   9 ( 6)   8 ( 4)  12 ( 8)   8 ( 5) 
5   5 (2)   5 ( 2)   6 ( 3)   5 ( 3) 
PPAR         
1  18 (15)  18 (12)   9 ( 8)  10 ( 7) 
5   6 (4)   7 ( 3)   3 ( 2)   3 ( 2) 
BACE         
1  14 (11)  12 (10)  12 (10)   6 ( 5) 
5   6 (4)   4 ( 3)   3 ( 3)   3 ( 2) 
THR         
1  12 ( 6)  14 ( 7)   8 ( 5)   7 ( 5) 
5   6 (2)   8 ( 4)   4 ( 2)   4 ( 3) 
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    Scaffolds    Reduced Scaffolds 
% DB    MACCS  CATS  CATS3D  SURFCATS    MACCS  CATS  CATS3D  SURFCATS 
ACE                     
1    25 (12)  24 (13)  17 (10)  19 (10)    29 (13)  27 (13)  20 (10)  21 ( 8) 
5    11 (4)  11 ( 4)   6 ( 3)   7 ( 3)    11 (3)  11 ( 3)   7 ( 3)   8 ( 2) 
COX2                     
1    28 (12)  16 ( 9)  21 ( 9)  20 ( 9)    33 (12)  20 (10)  25 (10)  26 (11) 
5    11 (4)   5 ( 2)   8 ( 3)   8 ( 3)    12 (3)   6 ( 2)   9 ( 2)   9 ( 3) 
CRF                     
1    24 (12)  15 (10)  21 (10)  17 (10)    28 (13)  18 (10)  22 ( 9)  18 (11) 
5    10 (4)   7 ( 4)  10 ( 3)   8 ( 3)    11 (4)   7 ( 3)   9 ( 3)   8 ( 3) 
DPP-IV                     
1    22 (13)  13 (10)  18 (11)  14 (12)    25 (12)  18 (12)  24 (14)  20 (17) 
5     8 (3)   5 ( 4)   5 ( 3)   4 ( 2)     9 (5)   6 ( 4)   6 ( 3)   5 ( 3) 
HIVP                     
1    14 ( 8)  24 (12)  16 (10)  20 (13)    19 (12)  31 (15)  22 (13)  27 (17) 
5     6 (3)  10 ( 4)   7 ( 4)   8 ( 4)     7 (3)  12 ( 4)   8 ( 4)  10 ( 4) 
MMP                     
1    16 (11)  15 ( 8)  14 (10)  15 (12)    23 (12)  23 (11)  21 (13)  22 (13) 
5     6 (3)   6 ( 2)   5 ( 3)   6 ( 4)     8 (3)   8 ( 3)   6 ( 3)   8 ( 3) 
NK                     
1    10 ( 6)   9 ( 4)  13 ( 8)   9 ( 6)    11 ( 6)  11 ( 5)  14 ( 8)  10 ( 6) 
5     5 (2)   5 ( 2)   6 ( 3)   5 ( 3)     5 (2)   6 ( 2)   6 ( 3)   5 ( 3) 
PPAR                     
1    16 (13)  18 (11)   9 ( 8)  10 ( 8)    20 (15)  24 (14)  11 ( 9)  13 (10) 
5     5 (3)   6 ( 3)   3 ( 2)   3 ( 2)     7 (4)   8 ( 4)   4 ( 2)   4 ( 2) 
BACE                     
1    14 (10)  14 ( 9)  11 ( 6)   8 ( 5)    15 (11)  16 (10)  11 ( 7)   8 ( 5) 
5     4 (2)   4 ( 2)   3 ( 2)   3 ( 1)     5 (3)   4 ( 2)   3 ( 2)   3 ( 2) 
THR                     
1    14 ( 6)  18 ( 9)   9 ( 6)  10 ( 6)    18 ( 8)  27 (12)  15 ( 8)  16 ( 8) 
5     6 (2)   9 ( 4)   4 ( 3)   5 ( 3)     8 (3)  10 ( 4)   6 ( 3)   6 ( 3) 
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6.2 Protein  report  from  MOE  for  the  taspase1  homology 
model from Section 4.8 
 
 
 
Protein Report 
Wed Jan 05 14:22:19 2005 (MOE 2004.03, MOE-ProEval 2002.01) 
 
Options: 
-------- 
 
Z-Score Threshold               : 5  
VDW Contact Threshold           : 70  
Write Outliers Only             : TRUE  
Contacts Within Chains Only     : TRUE  
 
Topics: 
-------- 
 
Dihedrals                       : TRUE  
Bond Angles                     : TRUE  
Bond Lengths                    : TRUE  
Contacts                        : TRUE  
 
Protein Report: Dihedrals 
Chain/Residue       phi     psi    omega   chi1    chi2     zeta 
---------------------------------------------------------------------------
----- 
>1  TaspaseASN49     106.7<  -48.3< -176.1  -158.5    12.3    26.5     
>1  TaspaseGLU103    106.8<  -53.7<  114.2< -179.9   179.0    31.2     
>1  TaspaseASP104    -77.4   132.9  -115.2< -138.5   -30.0    29.8     
>1  TaspaseLEU107   -158.8   146.7  -145.3<   10.3  -172.3    39.4     
>1  TaspaseGLY108   -120.7   171.2   137.3<   -       -       -        
>1  TaspaseARG117     99.3< -126.4<  175.4   -65.8   -90.0    24.5     
>1  TaspaseLYS128   -107.2    99.7  -143.0<   53.1  -109.5    27.9     
>2  TaspaseTYR52     143.7   167.6   150.1<  -86.4    19.8    21.1     
>2  TaspaseHIS53    -123.3  -101.4  -146.9< -170.8    80.5    32.5     
>2  TaspaseSER54      42.5   -24.2  -151.0< -154.0    -       27.7     
>2  TaspaseGLU55     176.3    31.2  -121.4<  159.8  -178.7    34.7     
>2  TaspaseILE73  T -139.0    62.0   -23.0<  -94.9   -71.2    29.7    cis 
>2  TaspaseGLY150   -123.9   138.5   149.5<   -       -       -        
>2  TaspaseGLN151    -82.2   116.6   104.5<  -89.6    50.8    31.8     
>2  TaspaseLYS152    -78.7   120.4    63.2<   43.9   163.2    32.5    cis 
>2  TaspaseLYS154   -164.1< -106.8< -157.2   -24.4    75.2    33.9     
>2  TaspaseLEU155     18.2   -75.0   143.7< -143.7    76.7    29.0     
>2  TaspaseALA157    -89.5    61.3   149.7<   -       -       32.9     
>2  TaspaseARG159    146.3<  -37.7<   59.3< -167.0    47.2    60.2<   cis 
>2  TaspasePRO162    -66.2   113.3   135.5<   22.6   -33.8    38.5     
>2  TaspaseCYS163     72.0<  -51.4<   15.3<  -83.3    -       27.4    cis 
>2  TaspasePHE164    175.7   107.7  -148.2<  177.0   -67.5    34.8     
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Protein Report: Bond Angles 
Chain/Residue     C-N-CA  N-CA-C N-CA-CB CB-CA-C  CA-C-N  CA-C-O   O-C-N 
--------------------------------------------------------------------------- 
>1  TaspaseGLN126  120.3   127.6<  118.6    93.0   112.3   122.8   124.9  
>1  TaspaseASN127  108.0   142.0<  105.8   103.4   115.5   121.0   123.4  
>2  TaspaseILE73   172.1<  109.2   106.2   121.4   110.8   124.3   124.5  
>2  TaspaseGLN151  119.3    92.2<  116.0   113.8   117.7   120.5   120.5  
>2  TaspaseARG159  117.7   137.5<   99.9    89.4<  117.7   118.1   122.3  
>2  TaspaseILE160  110.9    94.8   129.8<  118.4   120.9   117.8   121.2  
>2  TaspaseCYS163  137.1<  111.1   120.8   108.7   113.0   121.1   124.7  
 
Protein Report: Bond Lengths 
Chain/Residue           N-CA   CA-CB    CA-C    C-O     C-N 
--------------------------------------------------------------------------- 
>1  TaspaseTYR36       1.460   1.236<  1.528   1.227   1.387  
>1  TaspaseALA120      1.452   1.385<  1.522   1.229   1.386  
>1  TaspasePHE135      1.462   1.662<  1.528   1.223   1.400  
>1  TaspaseLEU136      1.463   1.689<  1.545   1.226   1.398  
>2  TaspaseALA50       1.456   1.288<  1.524   1.226   1.389  
>2  TaspaseHIS63       1.457   1.706<  1.534   1.226   1.388  
>2  TaspaseGLN70       1.467   1.356<  1.529   1.224   1.391  
>2  TaspaseGLY153      1.421     -     1.531   1.229   1.424< 
>2  TaspaseLYS154      1.479   1.507   1.551   1.228   1.423< 
>2  TaspaseILE160      1.438   1.582   1.494   1.222   1.430< 
 
Protein Report: Contacts 
Chain/Residue       Atom  Distance  Chain/Residue        Atom 
--------------------------------------------------------------------------- 
No Items to Report 
 
Protein Report: Summary 
 
% residues in CORE   :  78.47 
 
Parameter                        Observed                 Expected 
                             mean         s.d.        mean         s.d. 
 
trans omega         :       170.7         10.6       180.0          5.8 
C-alpha chirality   :        33.4          3.2        33.8          4.2 
chi1 - gauche minus :       -66.0         25.1       -66.7         15.0 
chi1 - gauche plus  :        56.4         19.2        64.1         15.7 
chi1 - trans        :       195.3         18.1       183.6         16.8 
helix phi           :       -78.3         21.0       -65.3         11.9 
helix psi           :       -27.1         15.6       -39.4         11.3 
chi1 - pooled s.d.  :          -          19.2          -          15.7 
proline phi         :       -69.3          7.7       -65.4         11.2 
 
 
 7 References 
D. Agrafiotis, V. S. Lobanov, F. R. Salemme. Combinatorial informatics in the post-genomics 
era. Nat. Rev. Drug. Discov. 2002, 1, 337-346. 
 
A. Ajay, W. P. Walters, M. A. Murcko, Can we learn to distinguish between "drug-like" and 
"nondrug-like" molecules? J. Med. Chem. 1998, 41, 3314-3324. 
 
S. F. Altschul, T. L. Madden, A. A. Schäffer, J. Zhang, Z. Zhang, W. Miller, D. J. Lipman, 
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. 
Nuc. Ac. Res. 1997, 25, 3389-3402. 
 
J. J. Anderson, M. J. Bradbury, D. R. Giracello, D. F. Chapman, G. Holtz, J. Roppe, C. King, 
N. D. Cosford, M. A. Varney, In vivo receptor occupancy of mGlu5 receptor antagonists 
using  the  novel  radioligand  [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine).  Eur.  J. 
Pharmacol. 2003, 473, 1, 35-40. 
 
A. Andreeva, D. Howorth, S. E. Brenner, T. J. P. Hubbard, C. Cothia, A. G. Murzin, SCOP 
database in 2004: refinements integrate structure and sequence family data, Nuc. Ac. Res. 
2004, 32, D226-D229. 
 
S. Anzali. J. Gasteiger, U. Holzgrabe, J. Polanski, A. Teckentrup, M. Wagener, The use of 
self-organizing neural networks in drug design. Persp. Drug Disc. Design 1998, 9-11, 273-
299. 
 
ASINEX Ltd., Moscow, Russia. (http://www.asinex.com) 
 
J.  Bajorath,  Integration  of  virtual  and  high-throughput  screening.  Nat. Rev.  Drug  Discov. 
2002, 1, 882-894.  
 
J. M. Barnard, Substructure Searching Methods: Old and New. J. Chem. Inf. Comput. Sci. 
1993, 33, 532-538. 
 
G. W. Bemis, M. A. Murcko, The properties of known drugs. 1. Molecular frameworks. J. 
Med. Chem. 1996, 39, 2887-2893. 
 
A. Bender, R. C. Glen, Molecular similarity: a key technique in molecular informatics. Org. 
Biomol. Chem. 2004, 2, 3204-3218. 
 
H. .M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov, 
P. E. Bourne, The Protein Data Bank. Nuc. Ac. Res. 2000, 28, 235-242. 
 
C. Bissantz, P. Bernard, M. Hilbert, D. Rognan, Protein-based virtual screening of chemical 
databases.  II.  Are  homology  models  of  G-protein  coupled  receptors  suitable  targets?. 
PROTEINS: Struct. Funct. Genet. 2003, 50, 5-25. 
 
K. H. Bleicher, H.-J. Böhm, K. Müller, A. I. Alanine, Hit and lead generation: beyond high-
throughput screening. Nat. Rev. Drug Discov. 2003, 2, 369-378.   164 
 
J. Bockaert, J. P. Pin, Molecular tinkering of G protein-coupled receptors: an evolutionary 
success. EMBO J. 1999, 18, 1723-1729.  
 
H.-J. Böhm, G. Schneider (Eds.), Virtual screening for bioactive molecules, Wiley-VCH: 
Weinheim, 2000 
 
H.-J. Böhm, A. Flohr, M. Stahl. Scaffold hopping. Drug Discov. Today: Technologies 2004, 
1, 217-224. 
 
H.-J. Böhm, D. Banner, S. Bendels, M. Kansey, B. Kuhn, K. Müller, U. Obst-Sander, M. 
Stahl, Fluorine in medicinal chemistry. ChemBioChem 2004, 5, 637-543. 
 
D.  Borek,  K.  Michalska,  K.  Brzezinski,  A.  Kisiel,  J.  Podkowinski,  D.  T.  Bonthron,  D. 
Krowarsch,  J.  Otlewski,  M.  Jaskolski.  Expression,  purification  and  catalytic  activity  of 
Lupinus  luteus  asparagine  beta-amidohydrolase  and  its  Escherichia  coli  homolog.  Eur  J 
Biochem. 2004, 271, 3215-26. 
 
J. Boström, P.-O. Norrby,  T.  Liljefors, Conformational energy penalties of protein-bound 
ligands. J. Comput. Aided Mol. Des. 1998, 12, 383-396. 
 
J. Boström, Reproducing the Conformation of Protein-Bound Ligands: A Critical Evaluation 
of Several Popular Conformational Searching Tools. J. Comput.-Aided Mol. Des. 2002, 15, 
1137-1152. 
 
R.  D.  Brown,  Y.  C.  Martin,  Use  of  Structure-Activity  Data  to  Compare  Structure-Based 
Clustering Methods and Descriptors for Use in Compound Selection, J. Chem. Inf. Comput. 
Sci. 1996, 36, 572-584. 
 
F. K. Brown, Chemoinformatics: what is it and how does it impact drug discovery. Ann. Rep. 
Med. Chem. 1998, 33, 375. 
 
B. L. Bush, R. P. Sheridan, PATTY: A programmable atom-typer and language for automatic 
classification of atoms in molecular databases, J. Chem. Inf. Comput. Sci. 1993, 33, 756-762. 
 
E. Byvatov, U. Fechner, J, Sadowski, G. Schneider, Comparison of Support Vector Machine 
and  Artificial  Neural  Network  Systems  for  Drug/Nondrug  Classification.  J.  Chem.  Inf. 
Comput. Sci. 2003, 43, 1882-1889. 
 
R.  E.  Carhart,  D.  H.  Smith,  R.  Venkataraghavan,  Atom  pairs  as  molecular  features  in 
structure-activity studies: Definitions and applications. J. Chem. Inf. Comput. Sci. 1985, 25, 
64-73. 
 
H. A. Carlson, K. M. Masukawa, K. Rubins, F. D. Bushman, W. L. Jorgensen, R. D. Lins, J. 
M.  Briggs,  J.  A.  McCammon,  Developing  a  dynamic  pharmacophore  model  for  HIV-1 
integrase. J. Med. Chem. 2000, 43, 2100-2114. 
 
Chemical Computing Group, Montreal, Canada (http://www.chemcomp.com) 
 References  165 
C.  Cheng,  W.  H.  Prussoff,  Relationship  between  the  inhibition  constant  (Ki)  and  the 
concentration  of  inhibitor  which  causes  50  per  cent  inhibition  (IC50)  of  an  enzymatic 
reaction. Biochem. Pharmacol. 1973, 22, 3099–3108. 
 
C. Chiamulera, M. P. Epping-Jordan, A. Zocchi, C. Marcon, C. Cottiny, S. Tacconi, M. Corsi, 
F. Orzi, F. Conquet, Reinforcing and locomotor stimulant effects of cocaine are absent in 
mGluR5 null mutant mice. Nat. Neurosci. 2001, 4, 873-874 
 
C. Chothia, A. M. Lesk, The relation between the divergence of sequence and structure in 
proteins, EMBO J. 1986, 5, 823-826. 
 
T.  Clark,  Does  quantum  chemistry  have  a  place  in  Cheminformatics?  In  Molecular 
informatics confronting complexity. M. G. Hicks, C. Kettner, Eds., Logos Verlag: Berlin, 
2003, pp.193-207. 
 
T. Clark, QSAR and QSPR based solely on surface properties?, J. Mol. Graph. Model. 2004, 
22, 519-525. 
 
P. J. Conn, J.-P. Pin, Pharmacology  and  Functions  of  Metabotropic  Glutamate  Receptors 
Annu. Rev. Pharmacol. Toxicol. 1997, 37, 205-237. 
 
N. D. Cosford, L. Tehrani, J. Roppe, E. Schweiger, N. D. Smith, J. Anderson, L. Bristow, J. 
Brodkin, X. Jiang, I. McDonald, S. Rao, M. Washburn, M. A. Varney, 3-[(2-Methyl-1,3-
thiazol-4-yl)ethynyl]-pyridine:  A  Potent  and  Highly  Selective  Metabotropic  Glutamate 
Subtype 5 Receptor Antagonist with Anxiolytic Activity. J. Med. Chem. 2003, 46, 204-206.  
 
R.  D.  Cramer,  III,  D.  E.  Patterson,  J.  D.  Bunce,  Comparative  molecular  field  analysis 
(CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 
1988, 110, 5959-5967. 
 
A.  M.  Davis,  S.  J.  Teague,  G.  J.  Kleywegt,  Application  and  limitations  of  X-ray 
crystallographic data in structure-based ligand and drug design. Angew. Chem. Int. Ed. Engl. 
2003, 42, 2718-2736. 
 
Daylight  Chemical  Information  Systems,  Inc.:  Los  Altos,  CA,  USA. 
(http://www.daylight.com) 
 
Z. Du, K.E. Lind, T.L. James, Structure of TAR RNA complexed with a Tat-TAR interaction 
nanomolar inhibitor that was identified by computational screening. Chem. Biol. 2002, 9, 707-
712. 
 
R.  Durbin,  S.  Eddy,  A.  Krogh,  G.  Mitchinson,  Biological  sequence  analysis.  Cambridge 
University Press: Cambridge, 1998. 
 
I. J. DeEsch, J. E. Mills, T. D. Perkins, G. Romeo, M. Hoffmann, K. Wieland, R. Leurs, W. 
M. Menge, P. H. Nederkorn, P. M. Dean, H. Timmerman. Development of a pharmacophore 
model for histamine H3 receptor antagonists, using the newly developed molecular modeling 
program SLATE. J. Med. Chem. 2001, 44, 1666-1647. 
 
C.  Detering,  G.  Varani,  Validation  of  Automated  Docking  Programs  for  Docking  and 
Database Screening against RNA Drug Targets. J. Med. Chem. 2004, 47, 4188-4201.   166 
 
M. .J. Drysdale, G. Lentzen, N. Matassova, A. I. H. Murchie, F. Aboul-ela, M. Afshar, RNA 
as a drug target. Prog. Med. Chem. 2002, 39, 73-119. 
 
D. M. Dykxhoorn, C. D. Novina, P. A. Sharp, Killing the messenger: short RNAs that silence 
gene expression. Nat. Rev. Mol. Cell Biol. 2003, 4, 457-467. 
 
M. D. Eldridge, C. W. Murray, T. R. Auton, G. V. Paolini R. P. Mee, Empirical scoring 
functions: I. The development of a fast empirical scoring function to estimate the binding 
affinity of ligands in receptor complexes., J Comput. Aided Mol. Des. 1997, 11, 425-445. 
 
Enamine Ltd., Kiev, Ukraine. (http://www.enamine.net) 
 
O. Engkvist, P. Wrede, High-throughput, in silico prediction of aqueous solubility based on 
one- and two-dimensional descriptors. J. Chem. Inf. Comput. Sci. 2002, 42, 1247-1249. 
 
L.  Eriksson,  E.  Johansson,  N.  Kettaneh-Wold,  S.  Wold,  Multi-  and  Megavariate  Data 
Analysis: Principles and Applications, Umetrics Academy: Umeå, 2001. 
 
A. Evers, H. Gohlke, G. Klebe, Ligand-supported homology modeling of protein binding-
sites using knowledge-based potentials. J. Mol. Biol. 2003, 334, 327-345. 
 
A.  Evers,  G.  Klebe,  Successful  virtual  screening  for  a  submicromolar  antagonist  of  the 
neurokinin-1 receptor based on a ligand-supported homology model. J. Med. Chem. 2004, 47, 
5381-5392. 
 
A. Evers, T. Klabunde, Structure-based drug discovery using GPCR homology modeling: 
Successful  virtual  screening  for  antagonists  of  the  alpha  1A  adrenergic  receptor.  J.  Med. 
Chem. 2005, 48, 1088-1097. 
 
U. Fechner, L. Franke, S. Renner, P. Schneider, G. Schneider, Comparison of correlation 
vector methods for ligand-based similarity searching. J. Comput. Aided Mol. Des. 2003, 17, 
687-698. 
 
A. V. Filikov, V. Mohan, T. A. Vickers, R. H. Griffey, P. D. Cook, R. A. Abagyan, T. L. 
James, Identification of ligands for RNA targets via structure-based virtual screening: HIV-1 
TAR. J. Comput. Aided Mol. Des. 2000, 14, 593-610. 
 
R.  Fredriksson,  M.  C.  Lagerström,  L.-G.  Lundin,  H.  B.  Schiöth,  The  G-protein-coupled 
receptors in the human genome form five main families. Phylogenetic analysis, paralogon 
groups, and fingerprints. Mol. Pharmacol. 2003, 63, 1256-1272. 
 
M.  Froeyen,  P.  Herdewijn,  RNA  as  a  target  for  drug  design,  the  example  of  Tat-TAR 
interaction. Curr. Top. Med. Chem. 2002, 2, 1123-1145. 
 
J.  Gallego,  G.  Varani,  Targeting  rna  with  small-molecule  drugs:  therapeutic  promise  and 
chemical challenges. Acc. Chem. Res. 2001, 34, 836-843. 
 
F. Gasparini, K. Lingenhöhl, N. Stoehr, P. J. Flor, M. Heinrich, I. Vranesic, M. Biollaz, H. 
Allgeier, R. Heckendorn, S. Urwyler, M. A. Varney, E. C. Johnson, S. D. Hess, S. P. Rao, A. 
I.  Sacaan,  E.  M.  Santori,  G.  Veliçelebi,  R.  Kuhn,  2-Methyl-6-(phenylethynyl)-pyridine References  167 
(MPEP),  a  potent,  selective  and  systemically  active  mGlu5  receptor  antagonist. 
Neuropharmacology 1999, 38, 1493-1503. 
 
F. Gasparini, Y. Auberson, S. Ofner, WO03/047581 2003.  
 
V. J. Gillet, W. Khatib, P. Willett, P. J. Fleming, D. V. S. Green, Compbinatorial library 
design using a multiobjective genetic algorithm. J. Chem. Inf. Comput. Sci. 2002, 42, 375-
385. 
 
G. Gini, M. V. Craciun, C. König, E. Benfenati, Combining unsupervised and supervised 
artificial neural networks to predict aquatic toxicity. J. Chem. Inf. Comput. Sci. 2004, 44, 
1897-1902. 
 
J.  Godden,  J.  Bajorath,  An  Information-Theoretic  Approach  to  Descriptor  Selection  for 
Database Profiling and QSAR Modeling. QSAR Comb. Sci. 2003, 22, 487-479. 
 
A.  C.  Good,  J.  S.  Mason.  Three-dimensional  structure  database  searches.  In  Reviews  in 
Computational Chemistry, Vol. 7. K. B. Lipkowitz, D. B. Boyd, Eds., VCH Publishers, 1996, 
pp 67-117. 
 
A. C. Good, I. D. Kuntz, Investigating the extension of pairwise distance pharmacophore 
measures to triplet-based descriptors. J Comput Aided Mol Des 1995, 4, 373. 
 
P. J. Goodford, A computational procedure for determining energetically favorable binding 
sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 849-857. 
 
L. Goodstadt, C. P. Ponting, CHROMA: consensus-based colouring of multiple alignments 
for publications. Bioinformatics 2001, 17, 845-846. 
 
O.  Güner  (Ed.),  Pharmacophore  perception,  development,  and  use  in  drug  design, 
International University Line: La Jolly CA, 2000. 
 
C. Goudet, F. Gaven, J. Kniazeff, C. Vol, J. Liu, M. Cohen-Gonsaud, F. Acher, L. Prézeau, J. 
P. Pin, Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like 
receptors. Proc. Natl. Acad. Sci. U S A 2004 , 101, 378-383. 
 
J. Greene, S. Kahn, H. Savoj, P. Sprague, S. Teig, Chemical function queries for 3D database 
search. J. Chem. Inf. Comput. Sci. 1994, 34, 1297-1308. 
 
S.  Grüneberg,  A  QSAR  model  derived  from  a  homology  model:  a  strategy  to  include 
structural information in ligand-based design. QSAR Comb. Sci. 2005, 24, 517-526. 
 
H.-C.  Guo,  Q.  Xu,  D.  Buckley,  C.  Guan,  Crystal  structures  of  Flavobacterium 
glycosylasparaginase.  An  N-terminal  nucleophile  hydrolase  activated  by  intramolecular 
proteolysis. J Biol Chem 1998, 273, 20205-20212. 
 
T. A. Halgren, Merck  molecular  force field .1. Basis,  form, scope, parameterization, and 
performance of MMFF94. J. Comput. Chem. 1996, 5-6, 490-519. 
 
I. Halperin, B. Ma, H. Wolfson, R. Nussinov, Principles of Docking: an overview of search 
algorithms and a guide to scoring functions. Proteins 2002, 47, 409-443.   168 
 
F. Hamy, V. Brondani, A. Florsheimer, W. Stark, M.J. Blommers, T. Klimkait, A New Class 
of HIV-1 Tat Antagonist Acting through Tat-TAR Inhibition. Biochemistry 1998, 37, 5086-
5095. 
 
C. Hansch, A. Leo, D. Hoekman (Eds.), Exploring QSAR – Hydrophobic, electronic, and 
steric constants, American Chemical Society: Washington, 1995. 
 
M. Hejazi, K. Piotukh, J. Mattow, R. Deutzmann, R. Volkmer-Engert, W. Lockau, Isoaspartyl 
dipeptidase activity of plant-type asparaginases. Biochem J. 2002, 364, 129-136. 
 
T.  Hermann,  Chemical  function  and  diversity  of  small  molecule  ligands  for  RNA. 
Biopolymers 2003, 70, 4-18. 
 
T.  Hermann,  Strategies  for  the  Design  of  Drugs  Targeting  RNA  and  RNA-Protein 
Complexes. Angew Chem Int Ed Engl. 2000, 39, 1890-1904. 
 
E. Hermans, R. A. J. Challiss, Structural, signalling and regulatory properties of the group I 
metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors. Biochem. 
J. 2001, 359, 465-484. 
 
J.  Hert,  P.  Willett,  D.  J.  Wilton,  P.  Acklin,  K.  Azzaoui,  E.  Jacoby,  A.  Schuffenhauer, 
Comparison  of  fingerprint-based  methods  for  virtual  screening  using  multiple  bioactive 
reference structures. J. Chem. Inf. Comput. Sci. 2004, 44, 1177-1185. 
 
J.  Hert,  P.  Willett,  D.  J.  Wilton,  P.  Acklin,  K.  Azzaoui,  E.  Jacoby,  A.  Schuffenhauer, 
Comparison of topological descriptors for similarity-based virtual screening using multiple 
bioactive reference structures. Org. Biomol. Chem. 2004, 2, 3256. 
 
A. Hillisch, L. F. Pineda, R. Hilgenfeld, Utility of homology models in the drug discovery 
process. Drug Discov. Today 2004, 9, 659-669. 
 
Y. T. Ho, A. Purohit, N. Vicker, S. P. Newman, J. J. Robinson, M. P. Lease, D. Ganeshapillai, 
L. W. Woo, B. V. Potter, M. J. Reed. Inhibition of carbonic anhydrase II by steroidal and 
nonsteroidal sulphamates. Biochem. Biophys. Res. Commun. 2003, 305, 909-914. 
 
D.  Horvath,  B.  Mao,  R.  Gozalbes,  F.  Barbosa,  S.  Rogalski,  Strength  and  limitations  of 
pharmacophore-based virtual screening. In Chemoinformatics in drug discovery. T. I. Oprea, 
Ed., Wiley-VCH: Weinheim, 2004, pp.117-140. 
 
J. J.  Hsieh,  E.  H.  Cheng,  S.  L.  Korsmeyer,  Taspase1:  a  threonine  aspartase  required  for 
cleavage of MLL and proper HOX gene expression. Cell 2003, 115, 293-303.  
 
J. L. Jenkins, M. Glick, J. W. Davies. A 3D method for scaffold hopping from known drugs 
or natural ligands to new chemotypes. J. Med. Chem. 2004, 47, 6144-6159. 
 
M. A. Johnson, G. M. Maggiora, Concepts and Applications of Molecular Similarity. John 
Wiley & Sons, 1990. 
 References  169 
G. Jones, P. Willett, R. C. Glen, A. R. Leach, R. Taylor, Development and validation of a 
genetic  algorithm  for  flexible  docking.  J.  Mol.  Biol.  1997,  267,  727-748.  GOLD,  CCDC 
Software Limited, Cambridge Crystallographic Data Centre, Cambridge, UK. 
 
J. Karn, Tackling Tat. J. Mol. Biol. 1999, 293, 135-154. 
 
M. Karplus, J. A. McCammon, Molecular dynamics simulation of biomolecules. Nat Struct. 
Biol. 2002, 9, 646-652. 
 
G. W. Kauffman, P. C. Jurs, Prediction of inhibition of the sodium ion-proton antiporter by 
benzoylguaninidine derivatives from molecular structure. J. Chem. Inf. Comput. Sci. 2000, 40, 
753-761. 
 
R. W. Kennard, L. A. Stone, Computer aided design of experiments. Technometrics 1969, 11, 
137-148. 
 
D. B. Kitchen, H. Decornez, J. R. Furr, J. Bajorath, Docking and scoring in virtual screening 
for drug discovery: methods and applications. Nat. Rev. Drug. Discov. 2004, 3, 935-949. 
 
G. Klebe, U. Abraham, T. Mietzner, Molecular similarity indices in a comparative analysis 
(CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 
1994, 37, 4130-4146. 
 
T. Kohonen, Self-organized formation of topologically correct feature maps. Biol. Cybern. 
1982, 43, 59-69. 
 
A. Krebs, V. Ludwig, O. Boden, M.-W. Göbel, Targeting the HIV trans-activation responsive 
region--approaches towards RNA-binding drugs. Chembiochem 2003, 4, 972-978. 
 
K. Kruger, P. J. Grabowski, A. J. Zaug, J. Sands, D. E. Gottschling, T. R. Cech, Self-splicing 
RNA:  autoexcision  and  autocyclization  of  the  ribosomal  RNA  intervening  sequence  of 
Tetrahymena. Cell 1982, 31, 147-157. 
 
H. Kubinyi (Ed.), 3D QSAR in Drug Design, ESCOM: Leiden, 1993. 
 
N. Kunishima, Y. Shimada, Y. Tsuji, T. Sato, M. Yamamoto, T. Kumasaka, S. Nakanishi, H. 
Jingami, K. Morikawa, Structural basis of glutamate recognition by a dimeric metabotropic 
glutamate receptor. Nature 2000, 407, 971-977. 
 
P. Labute, C. Williams, M. Feher, E. Sourial, J. M. Schmidt, Flexible alignment of small 
molecules. J. Med. Chem. 2001, 44, 1483-1490. 
 
A. R. Leach, V. J. Gillet, An introduction to chemoinformatics, Kluwer Academic Publishers: 
Dordrecht, 2003. 
 
N. Leulliot, G. Varani, Current topics in RNA-protein recognition: control of specificity and 
biological function through induced fit and conformational capture. Biochemistry 2001, 40, 
7947-7956. 
   170 
K. E. Lind, Z. Du, K. Fujinaga, B. M. Peterlin, T. L. James, Structure-based computational 
database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA. 
Chem. Biol. 2002, 9, 185-193.  
 
C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, Experimental and computational 
approaches  to  estimate  solubility  and  permeability  in  drug  discovery  and  development 
settings. Adv. Drug Del. Rev. 1997, 23, 3-25. 
 
Y. Liu, C. Guan, N. N. Aronson Jr., Site-directed mutagenesis of essential residues involved 
in the mechanism of bacterial glycosylasparaginases. J. Biol. Chem. 1998, 273, 9688-9694. 
 
Z.  Liu,  B.  N.  Dorniny,  E.  I.  Shakhnovitch,  Structural  Mining:  Self-consistent  design  on 
flexible protein-peptide docking and transferable binding affinity potential. J. Am. Chem. Soc. 
2004, 126, 8515-8528. 
 
D. J. Livingstone, D. T. Manallack, Neural networks in 3D QSAR, QSAR Comb. Sci. 2003, 
22, 510-518. 
 
D.  G.  Lloyd,  C.  L.  Buenemann,  N.  P.  Todorov,  D.  T.  Manallack,  P.  M.  Dean,  Scaffold 
hopping in de novo design. Ligand generation in the absence of receptor information. J. Med. 
Chem. 2004, 47, 493-496. 
 
G. M. Maggiora, V. Shanmugasundaram, M. J. Lajiness, T. N. Doman, M. W- Schultz, A 
practical strategy for directed compound acquisition. In Chemoinformatics in drug discovery. 
T. I. Oprea, Ed., Wiley-VCH: Weinheim, 2004, pp.315-332. 
 
P. Malherbe, N. Kratochwil, M. T. Zenner, J. Piussi, C. Diener, C. Kratzeisen, C. Fischer, R. 
H.  Porter,  Mutational  analysis  and  molecular  modeling  of  the  binding  pocket  of  the 
metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine. 
Mol. Pharmacol. 2003, 64, 823-832. 
 
M. Mandal, R. R. Breaker, Gene regulation by riboswitches. Nat. Rev. Mol. Cell Biol. 2004, 
5, 451-463. 
 
Y. C. Martin, J. L. Kofron, L. M. Traphagen, Do structurally similar molecules have similar 
biological activity. J. Med. Chem. 2002, 45, 4350-4358. 
 
J. S. Mason, I. Morize, P. R. Menard, D. L. Cheney, C. Hulme, R. F. Labaudiniere, New 4-
point pharmacophore method for molecular similarity and diversity applications: overview of 
the  method  and  applications,  including  a  novel  approach  to  the  design  of  combinatorial 
libraries containing privileged substructures.J Med Chem 1999, 42, 3251. 
 
J. S. Mason, A. C. Good, E. J. Martin, 3-D pharmacophores in drug discovery. Curr. Pharm. 
Des. 2001, 7, 567-597. 
 
H.  Matter,  Selecting  optimally  diverse  compounds  from  structure  databases:  A  validation 
study of two-dimensional and three-dimensional molecular descriptors. J. Med. Chem. 1997, 
40, 1219-1229.  
 References  171 
Marlowe, C. K., Sinha, U., Gunn, A. C., Scarborough, R. M. Design, synthesis and structure-
activity relationship of a series of arginine aldehyde factor Xa inhibitors. Part 1: structures 
based on the (D)-Arg-Gly-Arg tripeptide sequence. Bioorg. Med. Chem. Lett. 2000, 10, 13-16. 
 
M. Mayer, T. L. James, NMR-based characterization of phenothiazines as a RNA binding 
scaffold. J. Am. Chem. Soc. 2004, 126, 4453-4460. 
 
MDL Information Systems Inc.: San Leandro, CA, USA. (http://www.mdl.com) 
 
L. Molnar, G. M. Keseru, A neural network based virtual screening of cytochrome P450 3A4 
inhibitors. Bioorg. Med. Chem. 2002, 12, 419-421. 
 
G.  Moreau,  P.  Broto,  The  auto-correlation  of  a  topological  structure  –  a  new  molecular 
descriptor. Nouv. J. Chim. 1980, 4, 359-360. 
 
G.  Moreau,  P.  Broto,  C.  Vandycke,  Molecular  structures  –  perception,  auto-correlation 
descriptor and SAR studies – auto-correlation descriptor. Eur. J. Med. Chem. 1984, 19, 66-70. 
 
H. L. Morgan, The generation of a unique machine description for chemical structures – a 
technique developed at the chemical abstract service. J. Chem. Doc. 1965, 5, 107. 
 
G.M. Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, A.J. Olson, 
Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free 
Energy Function. J. Comput. Chem. 1998, 19, 1639-1662.  
 
V. Mutel, J. U. Peters, J. Wichmann, WO02/46166, 2002. 
 
L. Nærum, L. Nørskov-Lauritsen, P. H. Olesen, Scaffold hopping and optimization towards 
libraries of glycogen synthase kinase-3 inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 1525-
1528. 
 
M. C. Nicklaus, S. Wang, J. S. Driscoll, G. W. Milne, Conformational changes of small 
molecules binding to proteins. Bioorg. Med. Chem. 1995, 3, 411-428. 
 
H- F. Noller, V. Hoffarth, L. Zimniak, Unusual resistance of peptidyl transferase to protein 
extraction procedures. Science 1992, 256, 1416-1419. 
 
T.  Noronoaki,  I.  B.  Stoivea,  D.  D.  Petkov,  I.  Mononen.  Recombinant  human 
glycosylasparaginase catalyued hydrolysis of L-asparagine. FEBS Lett. 1997, 412, 149-152. 
 
J. A. O'Brien, W. Lemaire, T. B. Chen, R. S. Chang, M. A. Jacobson, S. N. Ha, C. W. 
Lindsley, H. J. Schaffhauser, C. Sur, D. J. Pettibone, P. J. Conn, D. L. Williams Jr., A family 
of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. 
Mol. Pharmacol. 2003, 64, 731-740. 
 
C. Oinonen, R. Tikkanen, J. Rouvinen, L. Peltonen, Three-dimensional structure of human 
lysosomal aspartylglucosaminidase. Nat. Struct. Biol. 1995, 2, 1102-1108. 
 
A. Pagano, D. Ruegg, S. Litschig, N. Stoehr, C. Stierlin, M. Heinrich, P. Floersheim, L. 
Prezeau, F. Carroll, J. P. Pin, A. Cambria, I. Vranesic, P. J. Flor, F. Gasparini, R. Kuhn, The 
Non-competitive  Antagonists  2-Methyl-6-  (phenylethynyl)pyridine  and  7-  172 
Hydroxyiminocyclopropan  [b]chromen-1a-carboxylic  Acid  Ethyl  Ester  Interact  with 
Overlapping  Binding  Pockets  in  the  Transmembrane  Region  of  Group  I  Metabotropic 
Glutamate Receptors. J. Biol. Chem. 2000, 275, 33750-33758. 
 
K. Palczewski, T. Kumasaka, T. Hori, C. A. Behnke, H. Motoshima, B. A. Fox, I. Le Trong, 
D. C. Teller, T. Okada, R. E. Stenkamp, M. Yamamoto, M. Miyano, Crystal structure of 
rhodopsin: A G protein-coupled receptor. Science 2000, 289, 739-745. 
 
A. Palomer, F. Cabre, J. Pascual, J. Campos, M. Trujillo, A. Entrena, M. Gallo, L. Garcia, D. 
Mauleon, A. Espinosa, Identification of novel cyclooxygenase-2 selective inhibitors using 
pharmacophore models, J. Med. Chem. 2002, 45, 1402-1411. 
 
Pannanugget Consulting L. L. C., Kalamazoo, MI, USA. (http://www.pannanugget.com) 
 
M. Pastor, G. Cruciani,  I. McLay, S. Pickett, S. Clementi, GRid-INdependent descriptors 
(GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. J. 
Med. Chem. 2000, 43, 3233-3243. 
 
G. A. Patani, E. J. LaVoie, Bioisosterism: A rational approach ni drug design. Chem. Rev. 
1996, 96, 3147-3176. 
 
Y. Patel, V. J. Gillet, G. Bravi, A. R. Leach, Comparison of the pharmacophore identification 
programs: Catalyst, DISCO and GASP. J. Comput. Aided Mol. Des. 2002, 16, 653-681. 
 
D. E. Patterson, R. D. Cramer, A. M. Ferguson, R. D. Clark, L. E. Weinberger, Neighborhood 
behavior: a useful concept for validation of "molecular diversity" descriptors. J. Med. Chem. 
1996, 39, 3049-3059. 
 
E. Perola, P. S. Charifson, Conformational analysis of drug-like molecules bound to proteins: 
an extensive study of ligand reorganization upon binding. J. Med. Chem. 2004, 47, 2499-
2510. 
 
S. Pickett, The biophore concept. In Protein-ligand interactions. H.-J. Böhm, G. Schneider, 
Eds., Wiley-VCH: Weinheim, 2003, pp 73-106. 
 
J.-P. Pin, T. Galvez, L. Prézeau, Evolution, structure, and activation mechanism of family 3/C 
G-protein-coupled receptors. Pharmacol. Ther. 2003, 98, 325-54. 
 
J.-P. Pin, J. Kniazeff, C. Goudet, A.-S. Bessis, J. Liu, T. Galvez, F. Acher, P. Rondard, L. 
Prézeau, The actvation mechanism of class-C G-protein coupled receptors. Biol. Cell 2004, 
96, 335-342. 
 
B. Pirard, J. Brendel, S. Peukert, The discovery of Kv1.5 blockers as a case study for the 
application of virtual screening approaches. J. Chem. Inf. Model. 2005, 45, 477-485.  
 
A.  Prahl,  M.  Pazgier,  M.  Hejazi,  W.  Lockau,  J.  Lubkowski,  Structure  of  the  isoaspartyl 
peptidase  with  L-asparaginase  activity  from  Escherichia  coli.  Acta  Crystallogr  D  Biol 
Crystallogr. 2004, 60, 1173-1176. 
 
L. Prézeau, J. Gomeza, S. Ahern, S. Mary, T. Galvez, J. Bockaert, J.-P. Pin, Changes in the 
carboxyl-terminal  domain  of  metabotropic  glutamate  receptor  1  by  alternative  splicing References  173 
generate receptors with  differing agonist-independent activity. Mol. Pharmacol. 1996, 49, 
422-429. 
 
J. W. Raymond, P. Willett, Maximum common subgraph isomorphism algorithms for the 
matching of chemical structures. J. Comput. Aided Mol. Des. 2002, 16, 521-533. 
 
F. M. Richards, Areas, volumes, packing and protein structure. Ann. Rev. Biophys. Bioeng. 
1977, 6, 151-176. 
 
O. Roche, P. Schneider, J. Zuegge, W. Guba, M. Kansy, A. Alanine, K. Bleicher, F. Danel, 
E.-M.  Gutknecht,  M.  Rogers-Evans,  W.  Neidhart,  H.  Stalder,  M.  Dillon,  E.  Sjögren,  N. 
Fotouhi, P. Gillespie, R. Goodnow, W. Harris, P. Jones, M. Taniguchi, S. Tsujii, W. von der 
Saal,  G.  Zimmermann,  G.  Schneider,  Development  of  a  Virtual  Screening  Method  for 
Identification of “Frequent Hitters” in Compound Libraries. J. Med. Chem. 2002, 45, 137-
142. 
 
O. Roche, G. Trube, J. Zuegge, P. Pflimlin, A. Alanine, G. Schneider, A Virtual Screening 
Method for Prediction of the hERG Potassium Channel Liability of Compound Libraries. 
ChemBioChem 2002, 3, 455-459. 
 
J. Roppe, N. D. Smith, D. Huang, L. Tehrani, B. Wang, J. Anderson, J. Brodkin, J. Chung, X. 
Jiang, C. King,  B. Munoz, M. A. Varney, P. Prasit, N.  D. Cosford, Discovery of  Novel 
Heteroarylazoles  That  Are  Metabotropic  Glutamate  Subtype  5  Receptor  Antagonists  with 
Anxiolytic Activity. J. Med. Chem. 2004, 47, 4645-4648. 
 
Rudolf, K., Eberlein, W., Engel, W., Wieland, H. A., Willim, K. D., Entzeroth, M., Wienen, 
W., Beck-Sickinger, A. G., Doods, H. N. The first highly potent and selective non-peptide 
neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur. J. Pharmacol. 1994, 271, R11-R13. 
 
J. Sadowski, J. Gasteiger, G. Klebe, Comparison of Automatic Three-Dimensional Model 
Builders  Using  639  X-Ray  Structures.  J.  Chem.  Inf.  Comput.  Sci.  1994,  34,  1000-1008. 
CORINA  is  available  from  Molecular  Networks  GmbH,  Erlangen,  Germany 
(http://www.mol-net.com). 
 
J. Sadowski, H. Kubinyi, A soring scheme for discriminating between drugs and nondrugs, J. 
Med. Chem. 1998, 41, 3325-3329. 
 
H.  Sashida,  M.  Kato,  T.  Tsuchiya,  Thermal  rearrangements  of  cyclic  amine  ylides.  VIII 
Intramolecular  cyclization  of  2-ethenylpyridine.  N-ylides  into  indolizines  and 
cycl[3.2.2]azines. Chem. Pharm. Bull. 1988, 36, 3826-3832. 
 
M. Schmucker, A. Givehchi, G. Schneider, Impact of different software implementations on 
the performance of the Maxmin method for diverse subset selection. Mol. Div. 2004, 8, 421-
425. 
 
G. Schneider, P. Wrede, PROFI – a tool for the analysis of protein sequence features using a 
simple artificial neural network. Protein Seq. Data Anal. 1993, 5, 419-421. 
 
G.  Schneider,  W.  Neidhart,  T.  Giller,  G.  Schnmid,  "Scaffold-Hopping"  by  Topological 
Pharmacophore Search: A Contribution to Virtual Screening. Angew. Chem. Int. Ed. Engl. 
1999, 38, 2894-2896.   174 
 
G. Schneider, O. Clément-Chomienne, L. Hilfiger, P. Schneider, S. Kirsch, H.-J. Böhm, W. 
Neidhard, Virtual screening for bioactive molecules by evolutionary de novo design. Angew. 
Chem. Int. Ed. 2000, 39, 4130-4133. 
 
G. Schneider, Neural networks are useful tools for drug design. Neural Netw. 2000, 13, 15-16. 
 
G.  Schneider,  H.-J.  Böhm,  Virtual  screening  and  fast  automated  docking  methods,  Drug 
Discov. Today 2002, 7, 64-70. 
 
G. Schneider, Trends in combinatorial library design, Curr. Med. Chem. 2002, 9, 2095-2101. 
 
G. Schneider, S.-S. So, Adaptive systems in drug design. Eurekah.com / Landes Bioscience: 
Georgetown, USA, 2003. 
 
G. Schneider, M. Nettekoven, Ligand-Based Combinatorial Design of Selective Purinergic 
Receptor (A2A) Antagonists Using Self-Organizing Maps. J. Comb. Chem. 2003, 5, 233-237. 
 
P. Schneider, G. Schneider, Collection of bioactive reference compounds for focused library 
design. QSAR Comb. Sci. 2003, 22, 713-718. 
 
G. Schneider, P. Schneider, Navigation in Chemical Space: Ligand-based Design of Focused 
Compound Libraries. In Chemogenomics in Drug Discovery. H. Kubinyi, G. Müller, Eds., 
Wiley-VCH: Weinheim, 2004. pp 341-376. 
 
G. Schneider, U. Fechner, Computer-based de novo design of drug-like molecules. Nat. Rev. 
Drug Discov. 2005, 4, 649-663. 
 
E. A. Schultes, D. P. Bartel, One sequence, two ribozymes: implications for the emergence of 
new ribozyme folds. Science 2000, 289, 448-452.  
 
R. Schroeder, A. Barta, K. Semrad, Strategies for RNA folding and assembly. Nat. Rev. Mol. 
Cell Biol. 2004, 5, 908-919. 
 
A.  Schuffenhauer,  P.  Floersheim,  P.  Acklin,  E.  Jacoby,  Similarity  metrics  for  ligands 
reflecting the similarity of the target proteins. J. Chem. Inf. Comput. Sci. 2003, 43, 391-405. 
 
C. H. Schwab, Conformational Analysis and Searching. In Handbook of Cheminformatics; J. 
Gasteiger, Ed.; Wiley-VCH: Weinheim, New-York, 2003; pp 262-301. ROTATE is available 
from Molecular Networks GmbH, Erlangen, Germany (http://www.mol-net.com). 
 
A.  K.  Shanazarov,  V.  G.  Granik,  N.  I.  Andreeva,  S.  M.  Golovina,  M.  D.  Mashkovskii, 
Synthesis and pharmacological activity of pyrano[3,2-a]carbazole and pyrido[3,2-a]carbazole 
derivatives. Khimiko-Farmatsevticheskii Zhurnal 1989, 23, 1197-1200. 
 
C. E. Shannon, W. Weaver, The mathematical theory of communication. University of Illinois 
Press: Urbana, USA, 1963. 
 
R.P. Sheridan, S.B. Singh, E.M. Fluder, S.K. Kearsley, Protocols for Bridging the Peptide to 
Nonpeptide Gap in Topological Similarity Searches. J. Chem. Inf. Comput. Sci. 2001, 41, 
1395-1406. References  175 
 
R. P. Sheridan, M. D. Miller, D. J. Underwood, S. K. Kearsley, Chemical similarity using 
geometric atom pair descriptors. J. Chem. Inf. Comput. Sci. 1996, 36, 128-136. 
 
R.  P.  Sheridan,  S.  K.  Kearsley,  Why  do  we  need  so  many  chemical  similarity  search 
methods? Drug Discov. Today 2002, 7, 903-911. 
 
R. P. Sheridan, B. P. Feuston, V. N. Maiorov, S. K. Kearsley, Similarity to molecules in the 
training set is a good discriminator for prediction accuracy in QSAR. J. Chem. Inf. Comput. 
Sci. 2004, 44, 1912-1928. 
 
R.D.  Snyder,  D.  E.  Ewing,  L.  B.  Hendry,  Evaluation  of  DNA  intercalation  potential  of 
pharmaceuticals  and  other  chemicals  by  cell-based  and  three-dimensional  computational 
approaches. Environ. Mol. Mutagen. 2004, 44, 163-173. 
 
Special  journal  issues  on  RNA  as  drug  target:  a)  Biopolymers  2003,  70,  1-119;  b) 
Chembiochem 2003, 4, 913-1106 . 
 
S.-S. So, M. Karplus, Evolutionary optimization in quantitative structure activity relationship: 
an application of genetic neural networks. J. Med. Chem. 1996, 39, 1521-1530. 
 
Specs, Delft, The Netherlands. (http://www.specs.net) 
 
W. P. Spooren, F. Gasparini, T. E. Salt, R. Kuhn, Novel allosteric antagonists shed light on 
mglu(5) receptors and CNS disorders. Trends Pharmacol. Sci. 2001, 295, 1267-1275. 
 
M. Stahl, N. P. Todorov, T. James, H. Mauser, H. J. Böhm, P. M. Dean. A validation study on 
the practical use of automated de novo design. J. Comput. Aided Mol. Des. 2002, 16, 459-478. 
 
F. L. Stahura, J. W. Godden, L. Xue, J. Bajorath, Distinguishing between Natural Products 
and  Synthetic  Molecules  by  Descriptor  Shannon  Entropy  Analysis  and  Binary  QSAR 
Calculations. J. Chem. Inf. Comput. Sci. 2000, 40, 1245-1252. 
 
N. Stiefl, K. Baumann, Mapping property distributions of molecular surfaces: algorithm and 
evaluation of a novel 3D quantitative structure-activity relationship technique. J. Med. Chem. 
2003, 46, 1390-1407. 
 
S. J. Sucheck, C. H. Wong, RNA as a target for small molecules. Curr. Opin. Chem. Biol. 
2000, 4, 678-686. 
 
Supuran, C. T., Scozzafava, A., Casini, A. Carbonic anhydrase inhibitors. Med. Res. Rev. 
2003, 23, 146-189. 
 
C-  J.  Swanson,  M.  Bures,  M.  P.  Johnson,  A.-M.  Linden,  J.  A.  Monn,  D.  D.  Schoepp, 
Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat. Rev. 
Drug Discov. 2005, 4, 131-144. 
 
J. Tao, A. D. Frankel, Specific binding of arginine to TAR RNA. Proc. Natl. Acad. Sci. USA 
1992, 89, 2723-2726.  
   176 
A.  L.  Tarentino,  T.  H.  Plummer  Jr.,  The  first  demonstration  of  a  procariotic 
glycosylasparaginase. Biochem. Biophys. Res. Commun. 1993, 197, 179-186. 
 
S. J. Teague, A. M. Davis, P. D. Leeson, T. I. Oprea, The design of leadlike compbinatorial 
libraries, Angew. Chem. Int. Ed. Engl. 1999, 38, 3743-3748. 
 
S. J. Teague, Implications of protein flexibility for drug discovery. Nat. Rev. Drug Discov. 
2003, 2, 527-542. 
 
A.  Teckentrup,  H.  Briem,  J.  Gasteiger,  Mining  high-throughput  screening  data  of 
combinatorial libraries: development of a filter to distinguish hits from nonhits. J. Chem. Inf. 
Comput. Sci. 2004, 44, 626-634. 
 
L.  Terfloth,  J.  Gasteiger,  Neural  networks  and  genetic  algorithms  in  drug  design.  Drug 
Disovc. Today, 2001, 6, S102-S108. 
 
R. Todeschini, V. Consonni, Handbook of MolecularDescriptors, Wiley-VCH: Weinheim, 
2000. 
 
P.  Tollman,  P.  Guy,  J.  Altshuler,  A.  Flanagan,  M.  Steiner.  A  revolution  in  R&D.  How 
genomics  and  genetics  are  transforming  the  biopharmaceutical  industry.  The  Boston 
Consulting Group. 2001. 
 
N. Z. Tugusheva, S. Y. Ryabova, N. P. Solov’eva, V. G. Granik, Investigation of indolo[2,1-
b]quinolines. Chem. Heterocyc. Comp. 1998, 34, 216-221. 
 
M. Varney, N. D. Cosford, C. Jachec, S. P. Rao, A. I. Sacaan, F. F. Lin, L. Bleicher, E. 
Santori,  P.  J.  Flor,  H.  Allgeier,  F.  Gasparini,  R.  Kuhn,  S.  D.  Hess,  G.  Veliçelebi,  E.  C. 
Johnson, SIB-1757 and SIB-1893: Selective, Noncompetitive Antagonists of Metabotropic 
Glutamate Receptor Type 5. J. Pharmacol. Exp. Ther. 1999, 290, 170-181. 
 
M. Wagener, J. Sadowski, J. Gasteiger, Aurocorrelation of molecular surface properties for 
modeling  corticosteroid  binding  globulin  and  cytosolic  Ah  receptor  activity  by  neural 
networks. J. Am. Chem. Soc. 1995, 117, 7769-7775. 
 
W. P. Walters, M. T. Stahl, M. A. Murcko, Virtual screening – an overview. Drug Discov. 
Today 1998, 3, 160-178. 
 
B. Wang, J. M. Vernier, S. Rao, J. Chung, J. J. Anderson, J. D. Brodkin, X. Jiang, M. F. 
Gardner,  X.  Yang,  B.  Munoz,  Discovery  of  novel  modulators  of  metabotropic  glutamate 
receptor subtype-5. Bioorg. Med. Chem. 2004, 12, 17-21. 
 
R.  Wang,  X.  Fang,  S.  Wang,  The  PDBbind  database:  collection  of  binding  affinities  for 
protein-ligand complexes with known three-dimensional structures. J. Med. Chem. 2004, 37, 
2977-2980. 
 
Weber,  A.,  Casini,  A.,  Heine,  A.,  Kuhn,  D.,  Supuran,  C.  T.,  Scozzafava,  A.,  Klebe,  G. 
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new 
pharmacological opportunities due to related binding site recognition. J. Med. Chem. 2004, 
47, 550-557. 
 References  177 
C. G. Wermuth, C. R. Gannelin, P. Lindberg, L. A. Mitscher, Glossary of terms used in 
medicinal chemistry. Pure & Appl. Chem. 1998, 70, 1129. 
 
P.  Willett,  J.  M.  Barnard,  G.  M.  Downs,  Chemical  Similarity  Searching,  J.  Chem.  Inf. 
Comput. Sci. 1998, 38, 983-996. 
 
J. R. Williamson, Induced fit in RNA-protein recognition. Nat. Struct. Biol. 2000, 7, 834-837. 
 
W. Winkler, A. Nahvi, R. R. Breaker, Thiamine derivatives bind messenger RNAs directly to 
regulate bacterial gene expression. Nature 2002, 419, 952-956. 
 
W. C. Winkler, S. Cohen-Chalamish, R. R. Breaker, An mRNA structure that controls gene 
expression by binding FMN. Proc. Natl. Acad. Sci. USA 2002, 99, 15908-15913. 
 
G. Wolber, T. Langer, LigandScout: 3-D pharmacophores derived from protein-bound ligands 
and their use as virtual screening filters. J. Chem. Inf. Model. 2005, 45, 160-169. 
 
H. Wold, Estimation of principal components and related models by iterative least squares. In 
Multivariate Analysis; P. R. Krishnaiah, Ed.; Academic Press, New York, 1966, pp 391-420. 
 
H.Wold,  Path  models  with  latent  variables:  The  NIPALS  approach.  In  Quantitative 
Sociology: International perspectives on mathematical and statistical model building, H.M. 
Blalock et al., Eds.; Academic Press, New York, 1975, pp 307-357. 
 
Woo, L. W., Howarth, N. M., Purohit, A., Hejaz, H. A., Reed, M. J., Potter, B. V. Steroidal 
and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase. J. Med. Chem. 1998, 41, 
1068-1083. 
 
Q.  Xu,  D.  Buckley,  C.  Guan,  H.-C.  Guo,  Structural  insight  into  the  mechanism  of 
intramolecular proteolysis. Cell 1999, 98, 651-661. 
 
Y.  Xu,  M.  Johnson,  Algorithm  for  naming  molecular  equivalence  classes  represented  by 
labeled pseudographs. J Chem Inf Comput Sci 2001, 41, 181.  
 
Y. J. Xu, M. Johnson, Using molecular equivalence numbers to visually explore structural 
features that distinguish chemical libraries. J Chem Inf Comput Sci 2002, 42, 912.  
 
H. Xu, D. K. Agrafiotis, Retrospect and prospect of virtual screening in drug discovery. Curr. 
Top. Med. Chem. 2002, 2, 1305-1320. 
 
L. Xue, F. L. Stahura, J. W. Godden, J. Bajorath, Fingerprint scaling increases the probability 
of identifying molecules with similar activity in virtual screening calculations. J. Chem. Inf. 
Comput. Sci. 2001, 41, 746-753. 
 
J. R. Zaman, P. J. A. Michiels, C. A. A. van Boeckel, Targeting RNA: new opportunities to 
address drugless targets. Drug Discov. Today 2003, 8, 297-306. 
 
I. Zamora, T. I. Oprea, G. Cruciani, M. Pastor, A. L. Ungell, Surface descriptors for protein-
ligand affinity prediction. J. Med. Chem. 2003, 46, 25-33. 
   178 
J. Zupan, J. Gasteiger, Neural Networks in Chemistry and Drug Design (2nd edn.), Wiley-
VCH: Weinheim, 1999. 
 
 
 
 
 
  
Lebenslauf 
 
Zur Person 
Steffen Renner, geboren am 20.12.1975  
in Freiburg im Breisgau,  
Staatsangehörigkeit: deutsch, 
verheiratet, eine Tochter. 
 
Schulische Ausbildung 
1982 – 1986  Grundschule Umkirch 
1986 - 1995  Wentzinger Gymnasium Freiburg im Breisgau 
07/95  Abitur 
 
Hochschulbildung 
10/97  Studium der Biologie an der Albert-Ludwigs-Universiät, Freiburg im 
Breisgau 
10/99  Vordiplom in Biologie / Hauptstudium mit Fokus auf Biochemie, 
Genetik, Bioinformatik und Informatik 
02/02 – 02/03  Diplomarbeit in der Arbeitsgruppe von Prof. Dr. Wolfgang Haehnel 
Albert-Ludwig-Universität Freiburg im Breisgau 
“Computergestützter Entwurf und Synthese einer kombinatorischen 
Bibliothek von Cytochrom P450 analogen Vier-Helix-Bündel 
Proteinen” 
04/03 – 06/05  Promotion in der Arbeitsgruppe von Prof. Dr. Gisbert Schneider 
Johann Wolfgang Goethe-Universität Frankfurt am Main 
“Development and application of fast pharmacophore-based virtual 
screening methods” 
04/04 – 06/05  Stipendiat von Merz Pharmaceuticals GmbH Frankfurt am Main 
seit 06/05 
 
Postdoktorale Arbeit mit Merz Pharmaceuticals GmbH Frankfurt am 
Main 
 
 